var title_f32_19_33072="Ankle PI";
var content_f32_19_33072=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F83112&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F83112&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 483px\">",
"   <div class=\"ttl\">",
"    Ankle bones",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 463px; height: 577px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The ankle is made up of 3 bones: the tibia (shinbone), fibula (calf bone), and talus (foot bone).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_19_33072=[""].join("\n");
var outline_f32_19_33072=null;
var title_f32_19_33073="Algorithm CF Dx";
var content_f32_19_33073=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F50886&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F50886&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 478px\">",
"   <div class=\"ttl\">",
"    Algorithm for the diagnosis of cystic fibrosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 458px; height: 716px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     IRT: immunoreactive trypsinogen; DNA: genetic screen for CF transmembrane conductance regulator (CFTR) gene mutations.",
"     <br>",
"      * For asymptomatic infants with intermediate sweat chloride results, test should be repeated at 1 to 2 months of age.",
"      <br>",
"       &bull; DNA testing may not be necessary at this stage if newborn screen included DNA testing and identified two CF-causing mutations.",
"       <br>",
"        &Delta; \"CF-related mutations\" denotes mutations in the CFTR gene that are known to cause disease.",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Julie P Katkin, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_19_33073=[""].join("\n");
var outline_f32_19_33073=null;
var title_f32_19_33074="Foot amputations";
var content_f32_19_33074=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F78430&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F78430&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 548px\">",
"   <div class=\"ttl\">",
"    Foot amputations",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 528px; height: 309px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_19_33074=[""].join("\n");
var outline_f32_19_33074=null;
var title_f32_19_33075="Eosinophilic folliculitis histology low power view";
var content_f32_19_33075=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F78005&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F78005&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Eosinophilic folliculitis histology",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 292px; height: 360px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This low-power photomicrograph demonstrates spongiotic change with exocytosis extending from the sebaceous gland and its duct into the follicular epithelium of the infundibulum. For reasons which are not understood, the inflammatory process in HIV-associated eosinophilic folliculitis appears to be focused in these areas of the follicular apparatus.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Whitney High, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_19_33075=[""].join("\n");
var outline_f32_19_33075=null;
var title_f32_19_33076="Chenodeoxycholic acid (chenodiol): Drug information";
var content_f32_19_33076=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"10\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Chenodeoxycholic acid (chenodiol): Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?9/21/9556?source=see_link\">",
"    see \"Chenodeoxycholic acid (chenodiol): Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F10484405\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Chenodal&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F13806079\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Bile Acid",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F10484462\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Cerebrotendinous xanthomatosis (unlabeled use):",
"     </b>",
"     Oral: 750 mg/day in 3 divided doses (Beringer, 1984)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Gallstone dissolution (monotherapy):",
"     </b>",
"     Oral: Initial: 250 mg twice daily for the first 2 weeks and increasing by 250 mg/day each week thereafter until the recommended or maximum tolerated dose is achieved; maintenance: 13-16 mg/kg/day in 2 divided doses.",
"     <b>",
"      Note:",
"     </b>",
"     Dosages &lt;10 mg/kg are usually ineffective and may increase the risk of cholecystectomy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Gallstone dissolution (combination therapy; unlabeled dose):",
"     </b>",
"     Oral: 5-7.5 mg/kg/day once daily at bedtime, in combination with ursodeoxycholic acid, with or without adjuvant lithotripsy (Jazrawi, 1992; Pereira, 1997; Petroni, 2001)",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F10484461\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Cerebrotendinous xanthomatosis (unlabeled use):",
"     </b>",
"     Oral: 15 mg/kg/day in three divided doses (van Heijst, 1998)",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F15682577\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F10484463\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use extreme caution; contraindicated for use in presence of known hepatocyte dysfunction or bile duct abnormalities.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F240027\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Chenodal&trade;: 250 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F240012\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F240028\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral dissolution of radiolucent cholesterol gallstones in selected patients as an alternative to surgery",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F10484406\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Cerebrotendinous xanthomatosis (CTX)",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F10484410\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea (30% to 40%; severe diarrhea requiring dose reduction: 10% to 15%), biliary pain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: Aminotransferase increased (&ge;30%; &gt;3 times ULN: 2% to 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Frequency not defined:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: LDL cholesterol increased, total cholesterol increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Abdominal cramps, abdominal pain, anorexia, constipation, dyspepsia, flatulence, heartburn, nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Leukopenia",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F240030\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Presence of known hepatocyte dysfunction or bile ductal abnormalities (eg, intrahepatic cholestasis, primary biliary cirrhosis, sclerosing cholangitis); use in a patient with a gallbladder confirmed as nonvisualizing after two consecutive single doses of dye; radiopaque stones; gallstone complications or compelling reasons for gallbladder surgery (eg, unremitting acute cholecystitis, cholangitis, biliary obstruction, gallstone pancreatitis, biliary gastrointestinal fistula); pregnancy",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F240017\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Diarrhea: Dose-related diarrhea commonly occurs (up to 40% of patients). Diarrhea is usually mild and does not interfere with therapy; however, diarrhea may be severe and a temporary dosage reduction or discontinuation may be required.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hepatotoxicity: Drug-induced liver toxicity may occur (dose-related); close monitoring of serum aminotransferase levels recommended during therapy. Aminotransferase elevations &gt;3 times ULN have been reported; prompt discontinuation of therapy recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Colon cancer: Epidemiologic studies have suggested that bile acids may increase the risk of colon cancer. Evidence is weak and conflicting; however, a potential link between bile acids and colon cancer cannot be ruled out.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hepatic disease: Avoid or use with extreme caution in patients with hepatic impairment or elevated liver enzymes; use contraindicated in patients with known hepatocyte dysfunction or bile ductal abnormalities.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Appropriate use: Careful selection of appropriate patients is necessary prior to therapy; studies have shown dissolution rates are higher in patients with small (&lt;15 mm in diameter), radiolucent, and/or floatable stones. Radiopaque (calcified or partially calcified) stones and bile pigment stones do not respond to bile acid dissolution therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Length of therapy: Response to therapy should be monitored with oral cholecystograms or ultrasonograms. Complete dissolution should be confirmed by one repeat test 1-3 months after continued therapy. If partial dissolution is not observed by 9-12 months, complete dissolution is unlikely. If no response is observed by 18 months, therapy should be discontinued; safety beyond 24 months of use has not been established.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299012\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F240021\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aluminum Hydroxide: May decrease the serum concentration of Chenodiol. Management: Consider administration of chenodiol 2 hours before or 6 hours after aluminum-containing antacid products to prevent adsorption in the gastrointestinal tract.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bile Acid Sequestrants: May decrease the serum concentration of Chenodiol. Management: Administration of chenodiol 5 hours or more after bile acid sequestrants may reduce chenodiol adsorption in the gastrointestinal tract.  Monitor for decreased therapeutic effects of chenodiol in patients receiving bile acid sequestrants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Estrogen Derivatives: May diminish the therapeutic effect of Chenodiol. Management: Monitor clinical response to chenodiol closely when used together with any estrogen derivative.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fibric Acid Derivatives: May diminish the therapeutic effect of Chenodiol. Management: Monitor clinical response to chenodiol closely when used together with any fibric acid derivative.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F240023\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     X (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F10484407\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hepatic, renal, and adrenal lesions were observed in some animal reproduction studies. Use during pregnancy is contraindicated.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F10484408\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16321898\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Chenodal Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     250 mg (100): $10320.00",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F240025\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral cholecystograms and/or ultrasonograms (6-9 month intervals for response to therapy); dissolutions of stones should be confirmed 1-3 months later; serum aminotransferase levels (monthly for first 3 months, then every 3 months during therapy); serum cholesterol (every 6 months)",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F5539772\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Aylehning (TW);",
"     </li>",
"     <li>",
"      Chebil (PT);",
"     </li>",
"     <li>",
"      Chendol (GB, MY, PT);",
"     </li>",
"     <li>",
"      Cheno (TW);",
"     </li>",
"     <li>",
"      Chenofalk (AT, BE, CH, CZ, DE, GB, HK, HN, ID, IT, MY, NL, PH);",
"     </li>",
"     <li>",
"      Chenossil (IT);",
"     </li>",
"     <li>",
"      Quenobilan (ES);",
"     </li>",
"     <li>",
"      Theramatic (GR)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F240015\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Chenodiol (chenodeoxycholic acid) is a naturally occurring human bile acid, normally constituting one-third of the total bile acid pool. Synthesis of chenodiol is regulated by the relative composition and flux of cholesterol and bile acids through the hepatocyte by a negative feedback effect on the rate-limiting enzymes for synthesis of cholesterol (HMG-CoA reductase) and bile acids (cholesterol 7 alpha-hydroxyl). In patients with cholesterol gallstones, chenodiol is believed to suppress hepatic synthesis of cholesterol and cholic acid, and inhibit biliary cholesterol secretion, which leads to increased production of cholesterol unsaturated bile thereby allowing for dissolution of gallstones.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F10484414\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Absorption: Well absorbed from the small intestine",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism: Converted hepatically to taurine and glycine conjugates and secreted in bile; extensive first-pass hepatic clearance; undergoes enterohepatic circulation; further metabolized in colon by bacteria to lithocholic acid; small portion of lithocholate is absorbed and converted to sulfolithocholyl conjugates in the liver",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Excretion: Feces (80%, as lithocholate)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Bel, S, Garcia-Patos V, Rodriquez L, et al, &ldquo;Cerebrotendinous Xanthomatosis,&rdquo;",
"      <i>",
"       J Am Acad Dermatol",
"      </i>",
"      , 2001, 45(2):292-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/19/33076/abstract-text/11464194/pubmed\" id=\"11464194\" target=\"_blank\">",
"        11464194",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Berginer VM, Salen G, and Shefer S, &ldquo;Long-Term Treatment of Cerebrotendinous Xanthomatosis With Chenodeoxycholic Acid,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1984, 311(26):1649-52.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/19/33076/abstract-text/6504105/pubmed\" id=\"6504105\" target=\"_blank\">",
"        6504105",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bonnot O, Fraidakis MJ, Lucanto R, et al, &ldquo;Cerebrotendinous Xanthomatosis Presenting With Severe externalized disorder: Improvement After One Year of Treatment With Chenodeoxycholic Acid,&rdquo;",
"      <i>",
"       CNS Spectr",
"      </i>",
"      , 2010, 15(4):231-6.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Federico A, Dotti MT, and Gallus GN, (Updated January 25, 2008). &ldquo;Cerebrotendinous Xanthomatosis.&rdquo; In:",
"      <i>",
"       GeneReviews",
"      </i>",
"      at GeneTests: Medical Genetics Information Resource (database online). Copyright, University of Washington, Seattle. 1997-2010. Available at file://www.genetests.org. Accessed August 2, 2010.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/19/33076/abstract-text/20301583/pubmed\" id=\"20301583\" target=\"_blank\">",
"        20301583",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Jazrawi RP, Pigozzi MG, Galatola G, et al, &ldquo;Optimum Bile Acid Treatment for Rapid Gall Stone Dissolution,&rdquo;",
"      <i>",
"       Gut",
"      </i>",
"      , 1992, 33(3):381-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/19/33076/abstract-text/1568660/pubmed\" id=\"1568660\" target=\"_blank\">",
"        1568660",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kelly E, Williams JD, and Organ CH, &ldquo;A History of the Dissolution of Retained Choledocholithiasis,&rdquo;",
"      <i>",
"       Am J Surg",
"      </i>",
"      , 2000, 180(2):86-98.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/19/33076/abstract-text/11044519/pubmed\" id=\"11044519\" target=\"_blank\">",
"        11044519",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Petroni ML, Jazrawi RP, Pazzi P, et al, &ldquo;Ursodeoxycholic Acid Alone or With Chenodeoxycholic Acid for Cholesterol Gallstones: A Randomized Multicentre Trial. The British-Italian Gallstone Study Group,&rdquo;",
"      <i>",
"       Aliment Pharmacol Ther",
"      </i>",
"      , 2001, 15(1):123-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/19/33076/abstract-text/11136285/pubmed\" id=\"11136285\" target=\"_blank\">",
"        11136285",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Van Heijst AJ, Verrips A, Wevers RA, et al, &ldquo;Treatment and Follow-up of Children With Cerebrotendinous Xanthomatosis,&rdquo;",
"      <i>",
"       Eur J Pediatr",
"      </i>",
"      , 1998, 157(4):313-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/19/33076/abstract-text/9578968/pubmed\" id=\"9578968\" target=\"_blank\">",
"        9578968",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15546 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-115.66.252.144-6720EAAD2F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_19_33076=[""].join("\n");
var outline_f32_19_33076=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10484405\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13806079\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10484462\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10484461\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15682577\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10484463\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F240027\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F240012\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F240028\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10484406\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10484410\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F240030\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F240017\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299012\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F240021\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F240023\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10484407\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10484408\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16321898\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F240025\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5539772\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F240015\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10484414\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/15546\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/15546|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?9/21/9556?source=related_link\">",
"      Chenodeoxycholic acid (chenodiol): Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_19_33077="Nail pits aa";
var content_f32_19_33077=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F73527%7EDERM%2F64919&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F73527%7EDERM%2F64919&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Nail pitting",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Numerous pits are present in this nail from a patient with alopecia areata.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Trachyonychia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 258px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Rough surfaces of nail plates with longitudinal ridging are present in this patient with trachyonychia secondary to alopecia areata.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_19_33077=[""].join("\n");
var outline_f32_19_33077=null;
var title_f32_19_33078="Mucoepidermoid carcinoma Light";
var content_f32_19_33078=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F60211&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F60211&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Mucoepidermoid carcinoma of salivary gland",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 369px; height: 277px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Low power photomicrograph of a mucoepidermoid carcinoma; these tumors range from well-circumscribed cystic tumors with a predominance of mucous cells to solid infiltrative tumors composed almost entirely of non-keratinizing squamous and intermediate cells.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of G Kenneth Haines, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_19_33078=[""].join("\n");
var outline_f32_19_33078=null;
var title_f32_19_33079="Chronic eosinophilic leukemia with FIP1L1-PDGFRA";
var content_f32_19_33079=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F88547&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F88547&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Chronic eosinophilic leukemia with FIP1L1-PDGFRA",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 419px; height: 514px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Peripheral blood (panels A-B) and bone marrow aspirate (panel C) samples from a patient with myeloproliferative neoplasm with eosinophilia and abnormalities of PDGFRA.&nbsp;The peripheral blood film shows eosinophils with abnormal size, granulation, and nuclear lobulation. Red blood cells and platelets are normal and there are no circulating blast cells. The bone marrow exhibits eosinophilic hyperplasia and increased myeloid blast cells (panel C;&nbsp;white arrows show blast cells). Abnormal eosinophils with dysplastic granules are present.",
"    <br>",
"     <div class=\"footnotes\">",
"     </div>",
"     <div class=\"reference\">",
"      This research was originally published in Blood. Verdu J, de Paz F. Chronic eosinophilic leukemia with FIP1L1-PDGFRA. Blood 2013; 121:1254. Copyright &copy; 2013 The American Society of Hematology.",
"     </div>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_19_33079=[""].join("\n");
var outline_f32_19_33079=null;
var title_f32_19_33080="Sildenafil: Drug information";
var content_f32_19_33080=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Sildenafil: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?27/8/27781?source=see_link\">",
"    see \"Sildenafil: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?37/9/38041?source=see_link\">",
"    see \"Sildenafil: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block spa drugH1Div\" id=\"F14965068\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Special Alerts",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      FDA Issues Safety Recommendation Regarding Sildenafil (Revatio&reg;) Use in Children and Adolescents",
"     </span>",
"     <span class=\"collapsible-date\">",
"      August 2012",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       The Food and Drug Administration (FDA) is recommending to healthcare providers and their medical care organizations that Revatio&reg; (sildenafil) not be used to treat pulmonary arterial hypertension (PAH) in pediatric patients (1-17 years of age) due to a dose-dependent increased mortality risk observed in a long-term (&le;7 years) study. The Sildenafil in Treatment-Naive Children, Aged 1&ndash;17 Years, With Pulmonary Arterial Hypertension (STARTS-1, 2) study, a randomized, double-blind, international, multicenter, placebo-controlled, parallel-group trial, included 234 pediatric patients (1-17 years, weight &ge;8 kg) with PAH (mild-to-moderate symptoms) and evaluated 3 doses (low, medium, and high) of sildenafil on long-term mortality (Barst, 2012). Patients were randomized according to weight into the 3 dosage levels with doses administered 3 times daily:",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"       <b>",
"        Low dose:",
"       </b>",
"       Weight &gt;20 kg: 10 mg per dose",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"       <b>",
"        Medium dose:",
"       </b>",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;\">",
"       Weight 8-20 kg: 10 mg per dose",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;\">",
"       Weight &gt;20-45 kg: 20 mg per dose",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;\">",
"       Weight &gt; 45 kg: 40 mg per dose",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"       <b>",
"        High dose:",
"       </b>",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;\">",
"       Weight 8-20 kg: 20 mg per dose",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;\">",
"       Weight &gt;20-45: 40 mg per dose",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;\">",
"       Weight &gt;45 kg: 80 mg per dose",
"      </p>",
"      <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;\">",
"       Low-, medium-, and high-dose levels were based upon desired steady state concentrations of 47, 140, and 373 ng/mL respectively; these concentrations are expected to inhibit 53%, 77%, and 90% of phosphodiesterase type 5 activity",
"       <i>",
"        in vitro",
"       </i>",
"       .",
"      </p>",
"      <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;\">",
"       An increased risk of death was observed after 2 years of therapy and appeared to be dose-dependent with the highest risk in the high-dose group after &ge;3 years of treatment (20% vs 9%, and 14% in the low- and medium-dose group); most deaths (74%) occurred in patients with idiopathic and hereditary PAH. The most frequent causes of death in the trial were pulmonary hypertension and heart failure which are also the most common causes of death in patients with PAH. Results did not show that low-dose sildenafil was effective at improving exercise ability.",
"      </p>",
"      <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;\">",
"       A new warning stating the use of Revatio&reg; is not recommended in pediatric patients has been added to the labeling. Revatio&reg; is indicated for the treatment of PAH by relaxing the blood vessels in the lungs to reduce blood pressure and is approved to improve exercise ability and delay clinical worsening of PAH in adult patients (WHO Group I). The FDA is requiring Pfizer, the manufacturer of Revatio&reg;, to evaluate its effect on the risk of death in adults with PAH.",
"      </p>",
"      <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;\">",
"       Patients and caregivers are advised to not change the dose or stop taking Revatio&reg; without talking with their healthcare provider. Healthcare providers were reminded that use of this product, particularly long-term use, in children is an off-label indication, is not approved by the FDA, and is not recommended.",
"      </p>",
"      <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;\">",
"       For additional information, refer to",
"       <a href=\"file://www.fda.gov/Drugs/DrugSafety/ucm317123.htm\" target=\"_blank\">",
"        file://www.fda.gov/Drugs/DrugSafety/ucm317123.htm",
"       </a>",
"       .",
"      </p>",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       Barst RJ, Ivy DD, Gaitan G, et al, &ldquo;A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of Oral Sildenafil Citrate in Treatment-Na&iuml;ve Children With Pulmonary Arterial Hypertension,&rdquo;",
"       <i>",
"        Circulation",
"       </i>",
"       , 2012, 125(2):324-34.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F220995\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Revatio&reg;;",
"     </li>",
"     <li>",
"      Viagra&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F220996\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Sildenafil&reg;;",
"     </li>",
"     <li>",
"      CO Sildenafil;",
"     </li>",
"     <li>",
"      GD-Sildenafil;",
"     </li>",
"     <li>",
"      PMS-Sildenafil;",
"     </li>",
"     <li>",
"      ratio-Sildenafil R;",
"     </li>",
"     <li>",
"      Revatio&reg;;",
"     </li>",
"     <li>",
"      Teva-Sildenafil;",
"     </li>",
"     <li>",
"      Viagra&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F221028\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Phosphodiesterase-5 Enzyme Inhibitor",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F221000\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Erectile dysfunction",
"     </b>",
"     (Viagra&reg;): Oral: Usual dose: 50 mg once daily 1 hour (range: 30 minutes to 4 hours) before sexual activity; dosing range: 25-100 mg once daily.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Pulmonary arterial hypertension (PAH)",
"     </b>",
"     (Revatio&reg;):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V.: 10 mg 3 times/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral: 20 mg 3 times/day, taken 4-6 hours apart; maximum recommended dose: 20 mg 3 times/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Dosage considerations for patients stable on alpha-blockers:",
"     </b>",
"     Viagra&reg;: Initial: 25 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Dosage adjustment for concomitant use of potent CYP34A inhibitors:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Revatio&reg;:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Erythromycin: No dosage adjustment",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Itraconazole, ketoconazole: Not recommended",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Protease inhibitors: Contraindicated",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Viagra&reg;:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Erythromycin, itraconazole, ketoconazole: Starting dose of 25 mg should be considered",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Protease inhibitors: Maximum sildenafil dose: 25 mg every 48 hours",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F221001\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Elderly &gt;65 years: Use with caution.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Revatio&reg;: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Viagra&reg;: Starting dose of 25 mg should be considered.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F221002\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Revatio&reg;: Dose adjustment not necessary",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Viagra&reg;: Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute: Starting dose of 25 mg should be considered.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F221003\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Revatio&reg;: Child-Pugh class A or B: Dose adjustment not necessary; not studied in severe impairment (Child-Pugh class C).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Viagra&reg;: Child-Pugh class A or B: Starting dose of 25 mg should be considered; not studied in severe impairment (Child-Pugh class C).",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F220969\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Revatio&reg;: 0.8 mg/mL (12.5 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 20 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Revatio&reg;: 20 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Viagra&reg;: 25 mg, 50 mg, 100 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F220955\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Tablet",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F220971\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Revatio&reg;: Administer tablets without regard to meals at least 4-6 hours apart. Administer injection as an I.V. bolus.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Viagra&reg;: Administer orally 30 minutes to 4 hours before sexual activity",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F220970\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Revatio&reg;: Treatment of pulmonary arterial hypertension (PAH) (WHO Group I) to improve exercise ability and delay clinical worsening. Efficacy established based upon short-term studies (12-16 weeks ).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Viagra&reg;: Treatment of erectile dysfunction (ED)",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F221025\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Pulmonary hypertension (WHO Group II, III, and IV); persistent pulmonary hypertension after recent left ventricular assist device placement",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F221036\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Revatio&reg; may be confused with ReVia&reg;, Revonto&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Sildenafil may be confused with silodosin, tadalafil, vardenafil",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Viagra&reg; may be confused with Allegra&reg;, Vaniqa&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F221026\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Based upon normal doses for either indication or route. (Adverse effects such as flushing, diarrhea, myalgia, and visual disturbances may be increased with adult doses &gt;100 mg/24 hours.)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Headache (16% to 46%)",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Dyspepsia (7% to 17%; dose related)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     2% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Flushing (10%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Insomnia (&le;7%), pyrexia (6%), dizziness (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Erythema (6%), rash (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea (3% to 9%), gastritis (&le;3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Urinary tract infection (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: LFTs increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Myalgia (&le;7%), paresthesia (&le;3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Abnormal vision (color changes, blurred vision, or increased sensitivity to light 3% to 11%; dose related)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Epistaxis (9% to 13%), dyspnea exacerbated (&le;7%), nasal congestion (4%), rhinitis (4%), sinusitis (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;2% (Limited to important or life-threatening): Allergic reaction, amnesia (transient global), anemia, angina pectoris, anorgasmia, asthma, AV block, cardiac arrest, cardiomyopathy, cataract, cerebral thrombosis, cerebrovascular hemorrhage, colitis, cystitis, depression, dysphagia, edema, exfoliative dermatitis, eye hemorrhage, gout, hearing decreased, hearing loss, heart failure, hematuria, hemorrhage, hyper-/hypoglycemia, hypernatremia, hyper-/hypotension, hyperuricemia, intracerebral hemorrhage, intraocular pressure increased, leukopenia, migraine, myocardial ischemia, MI, myasthenia, mydriasis, neuralgia, nonarteritic ischemic optic neuropathy (NAION), orthostatic hypotension, palpitation, priapism, pulmonary hemorrhage, rectal hemorrhage, retinal vascular disease or bleeding, seizure, shock, sickle cell crisis (vaso-occlusive crisis in patients with pulmonary hypertension associated with sickle cell disease), stomatitis, subarachnoid hemorrhage, syncope, tachycardia, tendon rupture, TIA, urinary incontinence, ventricular arrhythmia, vertigo, visual field loss, vitreous detachment/traction, vomiting",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F220974\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to sildenafil or any component of the formulation; concurrent use (regularly/intermittently) of organic nitrates in any form (eg, nitroglycerin, isosorbide dinitrate); concurrent use with a protease inhibitor regimen when sildenafil used for pulmonary artery hypertension (eg, Revatio&reg;)",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F220959\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Color discrimination: May cause dose-related impairment of color discrimination. Use caution in patients with retinitis pigmentosa; a minority have genetic disorders of retinal phosphodiesterases (no safety information available).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hearing loss: Sudden decrease or loss of hearing has been reported rarely; hearing changes may be accompanied by tinnitus and dizziness. A direct relationship between therapy and hearing loss has not been determined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypotension: Decreases in blood pressure may occur due to vasodilator effects; use with caution in patients with left ventricular outflow obstruction (aortic stenosis or hypertrophic obstructive cardiomyopathy), those on antihypertensive therapy, with resting hypotension (BP &lt;90/50 mm Hg), fluid depletion, or autonomic dysfunction; may be more sensitive to hypotensive actions. Patients should be hemodynamically stable prior to initiating therapy at the lowest possible dose. Avoid or limit concurrent substantial ethanol consumption as this may increase the risk of symptomatic hypotension. Monitor blood pressure when combining with medications that lower blood pressure.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Priapism: Painful erection &gt;6 hours in duration; rare. Educate patient to seek medical assistance for erection lasting &gt;4 hours.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pulmonary edema: If pulmonary edema occurs when treating pulmonary arterial hypertension (PAH), consider the possibility of pulmonary veno-occlusive disease (PVOD); continued use is not recommended in patient with PVOD.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Vision loss: Vision loss may occur rarely and be a sign of nonarteritic anterior ischemic optic neuropathy (NAION). Risk may be increased with history of vision loss. Other risk factors for NAION include low cup-to-disc ratio (&ldquo;crowded disc&rdquo;), coronary artery disease, diabetes, hypertension, hyperlipidemia, smoking, and &gt;50 years of age. Safety and efficacy were not studied in patients with known degenerative retinal disorders (eg, retinitis pigmentosa); use is not recommended. A direct relationship between therapy and vision loss has not been determined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anatomical penis deformation: Use with caution in patients with anatomical deformation of the penis (angulation, cavernosal fibrosis, or Peyronie's disease).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bleeding disorders: Use with caution in patients with bleeding disorders; safety and efficacy have not been established.",
"     <i>",
"      In vitro",
"     </i>",
"     studies have suggested a decreased effect on platelet aggregation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use with caution in patients with hypotension (&lt;90/50 mm Hg); uncontrolled hypertension (&gt;170/110 mm Hg); life-threatening arrhythmias, stroke or MI within the last 6 months; cardiac failure or coronary artery disease causing unstable angina; safety and efficacy have not been studied in these patients. Use caution in patients with left ventricular outflow obstruction (eg, aortic stenosis). There is a degree of cardiac risk associated with sexual activity; therefore, physicians should consider the cardiovascular status of their patients prior to initiating any treatment for erectile dysfunction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Conditions predisposing to priapism: Use with caution in patients who have conditions which may predispose them to priapism (sickle cell anemia, multiple myeloma, leukemia). All patients should be instructed to seek immediate medical attention if erection persists &gt;4 hours.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Viagra&reg;: Use with caution in patients with hepatic impairment; use lowest starting dose (25 mg). Revatio&reg;: No dosage adjustment required for mild-to-moderate impairment; has not been studied in patients with severe impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Peptic ulcer disease: Use with caution in patients with active peptic ulcer disease; safety and efficacy have not been established.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; PAH: Sudden cessation of sildenafil monotherapy could result in an exacerbation of PAH. Efficacy in adult patients determined through short-term (12-16 week) studies; safety of longer-term use is unclear. A long-term use trial in pediatric patients showed increased mortality in the high dose groups (20-80 mg [depending upon weight] 3 times/day) after 2 years of use (Barst, 2012).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Viagra&reg;: Use with caution in patients with renal impairment; dose adjustment may be needed; use lowest starting dose (25 mg) in severe dysfunction (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute). Revatio&reg;: No dosage adjustment required for any degree of impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sickle cell anemia: Treatment of pulmonary hypertension with sildenafil in this patient population may lead to more hospitalizations for management of vaso-occlusive crises. The effectiveness of sildenafil has not been established in pulmonary hypertension secondary to sickle cell disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Alpha-blockers: Use with caution in patients taking alpha-blockers; may cause symptomatic hypotension. Safety of this combination may be affected by other antihypertensives and intravascular volume depletion. Patients should be hemodynamically stable prior to initiating therapy. Initiate sildenafil at the lowest recommended dose. Alpha-blockers should be initiated at the lowest recommended dose in patients currently receiving sildenafil.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bosentan: Efficacy of PAH treatment with concurrent bosentan therapy has not been evaluated; use with caution.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; High potential for interactions: Use with caution in patients taking strong CYP3A4 inhibitors (eg, ritonavir can increase sildenafil levels, initiate sildenafil at decreased dose; see Drug Interactions); consider alternative agents that avoid or lessen the potential for CYP-mediated interactions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Nitrates: Concomitant (regularly/intermittently) use with all forms of nitrates is contraindicated. If nitrate administration is medically necessary, it is not known when nitrates can be safely administered following the use of sildenafil (per manufacturer); the ACC/AHA 2007 guidelines supports administration of nitrates only if 24 hours have elapsed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Other treatments for erectile dysfunction: Safety and efficacy with other treatments for erectile dysfunction have not been established; use is not recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Use of Revatio&reg;, especially chronic use, is not recommended in children. Increased mortality seen in long-term (mean: 3 years) study at high dose (20-80 mg [depending upon weight] 3 times/day).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use with caution; dose adjustment may be required.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Potential underlying causes of erectile dysfunction should be evaluated prior to treatment.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F221022\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP1A2 (minor), CYP2C19 (minor), CYP2C9 (minor), CYP2D6 (minor), CYP2E1 (minor), CYP3A4 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2C9 (weak), CYP3A4 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F220964\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): May enhance the hypotensive effect of Phosphodiesterase 5 Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha1-Blockers: Phosphodiesterase 5 Inhibitors may enhance the hypotensive effect of Alpha1-Blockers.  Management: Ensure patient is stable on one agent prior to initiating the other, and always initiate combination using the lowest possible dose of the drug being added. When tadalafil is used for treatment of BPH, concurrent alpha 1-blockers are not recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alprostadil: Phosphodiesterase 5 Inhibitors may enhance the adverse/toxic effect of Alprostadil.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amyl Nitrite: Phosphodiesterase 5 Inhibitors may enhance the vasodilatory effect of Amyl Nitrite.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antihypertensives: Phosphodiesterase 5 Inhibitors may enhance the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Boceprevir: May increase the serum concentration of Sildenafil. Management: Avoid sildenafil when used for treatment of pulmonary arterial hypertension in patients receiving boceprevir.  Sildenafil for erectile dysfunction should be limited to 25 mg every other day with close monitoring for sildenafil toxicity.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosentan: May decrease the serum concentration of Phosphodiesterase 5 Inhibitors. Phosphodiesterase 5 Inhibitors may increase the serum concentration of Bosentan.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cobicistat: May increase the serum concentration of Sildenafil. Management: Use of sildenafil for pulmonary hypertension with the elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate combination product is contraindicated.  Used for erectile dysfunction, sildenafil doses should be limited to 25 mg per 48 hrs.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May increase the serum concentration of Sildenafil. Management: When used for treatment of pulmonary arterial hypertension, use of sildenafil with strong CYP3A4 inhibitors should be avoided.  When used for erectile dysfunction, starting dose should be reduced to 25 mg.  Max dose with ritonavir is 25 mg per 48 hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Erythromycin (Systemic): May increase the serum concentration of Sildenafil. Management: When used for treatment of pulmonary artery hypertension, concurrent use with erythromycin is not recommended.  When used for treatment of erectile dysfunction, consider using a lower starting dose of 25 mg in patients who are also taking erythromycin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Etravirine: May decrease the serum concentration of Phosphodiesterase 5 Inhibitors. Management: No empiric dosage adjustments are recommended with concomitant therapy; however, dose of the phosphodiesterase inhibitor may need to be altered based on clinical response.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluconazole: May increase the serum concentration of Sildenafil.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (CYP3A4 Inducers): May increase the metabolism of CYP3A4 Substrates. Management: Consider avoiding CYP3A4 inducing herbs in order to avoid therapeutic failure of the substrate. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HMG-CoA Reductase Inhibitors: Sildenafil may decrease the metabolism of HMG-CoA Reductase Inhibitors.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Fluvastatin; Pravastatin; Rosuvastatin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Itraconazole: May increase the serum concentration of Sildenafil. Management: Concurrent itraconazole is not recommended when sildenafil is used for treatment of pulmonary arterial hypertension. If sildenafil is used to treat erectile dysfunction, an initial dose of 25 mg is recommended with concurrent itraconazole.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketoconazole (Systemic): May increase the serum concentration of Sildenafil. Management: Concurrent ketoconazole is not recommended when sildenafil is used for treatment of pulmonary arterial hypertension. If sildenafil is used to treat erectile dysfunction, an initial dose of 25 mg is recommended with concurrent ketoconazole.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Limit the maximum adult dose of lomitapide to 30 mg daily when used in combination with any weak CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lorcaserin: May enhance the adverse/toxic effect of Phosphodiesterase 5 Inhibitors. Specifically, the risk of developing priapism may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP3A4 Substrates. Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphodiesterase 5 Inhibitors: May enhance the adverse/toxic effect of other Phosphodiesterase 5 Inhibitors.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Posaconazole: May increase the serum concentration of Sildenafil. Management: Concurrent posaconazole is not recommended when sildenafil is used for treatment of pulmonary arterial hypertension. If sildenafil is used to treat erectile dysfunction, an initial dose of 25 mg is recommended with concurrent posaconazole.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protease Inhibitors: May increase the serum concentration of Sildenafil. Management: Erectile dysfunction: sildenafil max = 25 mg/48 hrs with ritonavir, atazanavir, or darunavir; starting dose = 25 mg with other protease inhibitors (adult doses).  Contraindicated if sildenafil being used for pulmonary arterial hypertension.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sapropterin: May enhance the hypotensive effect of Phosphodiesterase 5 Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: May increase the serum concentration of Sildenafil. Management: Concurrent use of sildenafil for treatment of pulmonary arterial hypertension is contraindicated with telaprevir.  Sildenafil for erectile dysfunction should be limited to 25 mg per 48 hours, with close monitoring for sildenafil toxicity.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vasodilators (Organic Nitrates): Phosphodiesterase 5 Inhibitors may enhance the vasodilatory effect of Vasodilators (Organic Nitrates).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Voriconazole: May increase the serum concentration of Sildenafil. Management: Concurrent voriconazole is not recommended when sildenafil is used for treatment of pulmonary arterial hypertension. If sildenafil is used to treat erectile dysfunction, an initial dose of 25 mg is recommended with concurrent voriconazole.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F220991\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;display:inline\">",
"     Ethanol: Substantial consumption of ethanol may increase the risk of hypotension and orthostasis. Lower ethanol consumption has not been associated with significant changes in blood pressure or increase in orthostatic symptoms. Management: Avoid or limit ethanol consumption.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Food: Avoid grapefruit juice.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: St John's wort may decrease sildenafil levels. Management: Avoid St John's wort.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F220966\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F220978\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects were not observed in animal studies. There are no adequate and well-controlled studies in pregnant women. Less than 0.001% appears in the semen.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F786452\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-right:0em;margin-top:0em;text-align:justify;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F16571140\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is not known if sildenafil is excreted in breast milk. The manufacturer recommends that caution be exercised when administering sildenafil to nursing women.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F9614168\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Avoid grapefruit juice.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F220977\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Revatio Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg/12.5 mL (12.5 mL): $146.70",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Revatio Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20 mg (90): $2204.81",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Sildenafil Citrate Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20 mg (90): $1800.26",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Viagra Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25 mg (30): $877.33",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg (30): $877.33",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg (30): $877.33",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F14971852\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     PAH: Monitor blood pressure and pulse when used concurrently with medications that lower blood pressure",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F220980\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Adonix (PH);",
"     </li>",
"     <li>",
"      Andros (PH);",
"     </li>",
"     <li>",
"      Aphrodil (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Edegra (IN);",
"     </li>",
"     <li>",
"      Ejertol (CO);",
"     </li>",
"     <li>",
"      Elonza (TH);",
"     </li>",
"     <li>",
"      Emposil (ID);",
"     </li>",
"     <li>",
"      Erectol (AR);",
"     </li>",
"     <li>",
"      Erilin (CO);",
"     </li>",
"     <li>",
"      Eroton (BG);",
"     </li>",
"     <li>",
"      Eroxim (CO);",
"     </li>",
"     <li>",
"      Neo-Up (PH);",
"     </li>",
"     <li>",
"      Patrex (SE);",
"     </li>",
"     <li>",
"      Penegra (BF, BJ, CI, ET, GH, GM, GN, IN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZM, ZW);",
"     </li>",
"     <li>",
"      Revatio (AT, AU, BE, CH, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HK, IE, IL, IT, KP, MT, NL, NO, NZ, PL, PT, RU, SE, SK, TH, TR, TW);",
"     </li>",
"     <li>",
"      Rigix (PY);",
"     </li>",
"     <li>",
"      Ripol (CN);",
"     </li>",
"     <li>",
"      Sildefil (AR);",
"     </li>",
"     <li>",
"      Supra (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Tigerfil (PH);",
"     </li>",
"     <li>",
"      Viagra (AE, AT, AU, BE, BF, BH, BJ, BR, CH, CI, CL, CN, CO, CR, CY, CZ, DE, DK, DO, EC, EE, EG, ES, ET, FI, FR, GB, GH, GM, GN, GR, GT, HK, HN, HU, ID, IE, IL, IQ, IR, IT, JO, JP, KE, KP, KW, LB, LR, LY, MA, ML, MR, MT, MU, MW, MX, MY, NE, NG, NI, NL, NO, NZ, OM, PA, PE, PH, PL, PT, QA, RU, SA, SC, SD, SE, SG, SK, SL, SN, SV, SY, TH, TN, TR, TW, TZ, UG, UY, VE, YE, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Vimax (ID);",
"     </li>",
"     <li>",
"      Xex (EC);",
"     </li>",
"     <li>",
"      Zilden (PH);",
"     </li>",
"     <li>",
"      Zwagra (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F220958\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Erectile dysfunction: Does not directly cause penile erections, but affects the response to sexual stimulation. The physiologic mechanism of erection of the penis involves release of nitric oxide (NO) in the corpus cavernosum during sexual stimulation. NO then activates the enzyme guanylate cyclase, which results in increased levels of cyclic guanosine monophosphate (cGMP), producing smooth muscle relaxation and inflow of blood to the corpus cavernosum. Sildenafil enhances the effect of NO by inhibiting phosphodiesterase type 5 (PDE-5), which is responsible for degradation of cGMP in the corpus cavernosum; when sexual stimulation causes local release of NO, inhibition of PDE-5 by sildenafil causes increased levels of cGMP in the corpus cavernosum, resulting in smooth muscle relaxation and inflow of blood to the corpus cavernosum; at recommended doses, it has no effect in the absence of sexual stimulation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Pulmonary arterial hypertension (PAH): Inhibits phosphodiesterase type 5 (PDE-5) in smooth muscle of pulmonary vasculature where PDE-5 is responsible for the degradation of cyclic guanosine monophosphate (cGMP). Increased cGMP concentration results in pulmonary vasculature relaxation; vasodilation in the pulmonary bed and the systemic circulation (to a lesser degree) may occur.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F220973\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: ~60 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: 2-4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Rapid; slower with a high-fat meal",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      dss",
"     </sub>",
"     : 105 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding, plasma: ~96%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic via CYP3A4 (major) and CYP2C9 (minor route); forms N-desmethyl metabolite (active)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: 40% (25% to 63%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: ~4 hours; the elderly and those with severe renal impairment have reduced clearance of sildenafil and its active N-desmethyl metabolite",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak: 30-120 minutes; delayed by 60 minutes with a high-fat meal",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Feces (~80%); urine (~13%)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Anderson JL, Adams CD, Antman EM, et al, \"2011 ACCF/AHA Focused Update Incorporated Into the ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,\"",
"      <i>",
"       Circulation",
"      </i>",
"      , 2011, 123(18):e426-579.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/19/33080/abstract-text/21444888/pubmed\" id=\"21444888\" target=\"_blank\">",
"        21444888",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Antman EM, Anbe DT, Armstrong PW, et al, &ldquo;ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of Patients with Acute Myocardial Infarction),&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2004, 110(9):e82-292.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/19/33080/abstract-text/15339869/pubmed\" id=\"15339869\" target=\"_blank\">",
"        15339869",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Badesch DB, Abman SH, Simonneau G, et al, &ldquo;Medical Therapy for Pulmonary Arterial Hypertension: Updated ACCP Evidence-Based Clinical Practice Guidelines,&rdquo;",
"      <i>",
"       Chest",
"      </i>",
"      , 2007, 131(6):1917-28.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/19/33080/abstract-text/17565025/pubmed\" id=\"17565025\" target=\"_blank\">",
"        17565025",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Barst RJ, Ivy DD, Gaitan G, et al, &ldquo;A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of Oral Sildenafil Citrate in Treatment-Na&iuml;ve Children With Pulmonary Arterial Hypertension,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2012, 125(2):324-34.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/19/33080/abstract-text/22128226/pubmed\" id=\"22128226\" target=\"_blank\">",
"        22128226",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Behling A, Rohde LE, Colombo FC, et al, \"Effects of 5'-Phosphodiesterase Four-Week Long Inhibition With Sildenafil in Patients With Chronic Heart Failure: A Double-Blind, Placebo-Controlled Clinical Trial,\"",
"      <i>",
"       J Card Fail",
"      </i>",
"      , 2008, 14(3):189-97",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/19/33080/abstract-text/18381181/pubmed\" id=\"18381181\" target=\"_blank\">",
"        18381181",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Blanco I, Gimeno E, Munoz PA, et al, \"Hemodynamic and Gas Exchange Effects of Sildenafil in Patients With Chronic Obstructive Pulmonary Disease and Pulmonary Hypertension,\"",
"      <i>",
"       Am J Respir Crit Care Med",
"      </i>",
"      , 2010, 181(3):270-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/19/33080/abstract-text/19875684/pubmed\" id=\"19875684\" target=\"_blank\">",
"        19875684",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cheitlin MD, Hutter AM Jr, Brindis RG, et al, &ldquo;Use of Sildenafil (Viagra&reg;) in Patients With Cardiovascular Disease,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 1999, 33(1):273-82.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/19/33080/abstract-text/9935041/pubmed\" id=\"9935041\" target=\"_blank\">",
"        9935041",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Galie N, Ghofrani HA, Torbicki A, et al, &ldquo;Sildenafil Citrate Therapy for Pulmonary Arterial Hypertension,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2005, 353(20):2148-57.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/19/33080/abstract-text/16291984/pubmed\" id=\"16291984\" target=\"_blank\">",
"        16291984",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Jackson G and Chambers J, &ldquo;Sildenafil for Primary Pulmonary Hypertension: Short and Long-Term Symptomatic Benefit,&rdquo;",
"      <i>",
"       Int J Clin Pract",
"      </i>",
"      , 2002 56(5):397-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/19/33080/abstract-text/12137450/pubmed\" id=\"12137450\" target=\"_blank\">",
"        12137450",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Jackson G, Rosen RC, Kloner RA, et al, &ldquo;The Second Princeton Consensus on Sexual Dysfunction and Cardiac Risk: New Guidelines for Sexual Medicine,&rdquo;",
"      <i>",
"       J Sex Med",
"      </i>",
"      , 2006, 3(1):28-36.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/19/33080/abstract-text/16409215/pubmed\" id=\"16409215\" target=\"_blank\">",
"        16409215",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Karatza AA, Bush A, and Magee AG, &ldquo;Safety and Efficacy of Sildenafil Therapy in Children With Pulmonary Hypertension,&rdquo;",
"      <i>",
"       Int J Cardiol",
"      </i>",
"      , 2005, 100(2):267-73.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Karatza AA, Narang I, Rosenthal M, et al, &ldquo;Treatment of Primary Pulmonary Hypertension With Oral Sildenafil,&rdquo;",
"      <i>",
"       Respiration",
"      </i>",
"      , 2004, 71(2):192-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/19/33080/abstract-text/15031578/pubmed\" id=\"15031578\" target=\"_blank\">",
"        15031578",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Keogh AM, Jabbour A, Hayward CS, et al, &ldquo;Clinical Deterioration After Sildenafil Cessation In Patients With Pulmonary Hypertension,&rdquo;",
"      <i>",
"       Vasc Health Risk Manag",
"      </i>",
"      , 2008, 4(5):1111-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/19/33080/abstract-text/19183760/pubmed\" id=\"19183760\" target=\"_blank\">",
"        19183760",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      McLaughlin VV, Archer SL, Badesch DB, et al, &ldquo;ACCF/AHA 2009 Expert Consensus Document on Pulmonary Hypertension. A Report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association Developed in Collaboration With the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2009, 53(17):1573-619.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/19/33080/abstract-text/19389575/pubmed\" id=\"19389575\" target=\"_blank\">",
"        19389575",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      McVary KT, &ldquo;Clinical Practice. Erectile Dysfunction,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2007, 357(24):2472-81.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/19/33080/abstract-text/18077811/pubmed\" id=\"18077811\" target=\"_blank\">",
"        18077811",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Phillips BG, Kato M, Pesek CA, et al, &ldquo;Sympathetic Activation by Sildenafil,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2000, 102(25):3068-73.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/19/33080/abstract-text/11120696/pubmed\" id=\"11120696\" target=\"_blank\">",
"        11120696",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Prasad S, Wilkinson J, and Gatzoulis MA, &ldquo;Sildenafil in Primary Pulmonary Hypertension,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2000, 343(18):1342.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/19/33080/abstract-text/11183578/pubmed\" id=\"11183578\" target=\"_blank\">",
"        11183578",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Simonneau G, Rubin LJ, Gali&egrave; N, et al, &ldquo;Addition of Sildenafil to Long-Term Intravenous Epoprostenol Therapy in Patients With Pulmonary Arterial Hypertension: A Randomized Trial,&rdquo;",
"      <i>",
"       Ann Intern Med",
"      </i>",
"      , 2008, 149(8):521-30.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/19/33080/abstract-text/18936500/pubmed\" id=\"18936500\" target=\"_blank\">",
"        18936500",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tedford RJ, Hemnes AR, Russell SD, et al, \"PDE5A Inhibitor Treatment of Persistent Pulmonary Hypertension After Mechanical Circulatory Support,\"",
"      <i>",
"       Circ Heart Fail",
"      </i>",
"      , 2008, 1(4):213-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/19/33080/abstract-text/19808294/pubmed\" id=\"19808294\" target=\"_blank\">",
"        19808294",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Toshner MR, Gopalan D, Suntharalingam J, et al, \"Pulmonary Arterial Size and Response to Sildenafil in Chronic Thromboembolic Pulmonary Hypertension,\"",
"      <i>",
"       J Heart Lung Transplant",
"      </i>",
"      , 2010, 29(6):610-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/19/33080/abstract-text/20227301/pubmed\" id=\"20227301\" target=\"_blank\">",
"        20227301",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9643 Version 45.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-B2407C6BAC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_19_33080=[""].join("\n");
var outline_f32_19_33080=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14965068\">",
"      Special Alerts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220995\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220996\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221028\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221000\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221001\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221002\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221003\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220969\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220955\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220971\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220970\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221025\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221036\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221026\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220974\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220959\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221022\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220964\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220991\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220966\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220978\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F786452\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16571140\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9614168\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220977\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14971852\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220980\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220958\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220973\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9643\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9643|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?27/8/27781?source=related_link\">",
"      Sildenafil: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?37/9/38041?source=related_link\">",
"      Sildenafil: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_19_33081="Beta blocker poisoning";
var content_f32_19_33081=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Beta blocker poisoning",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/19/33081/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/19/33081/contributors\">",
"     Ellen Lemkin, MD, PharmD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/19/33081/contributors\">",
"     Fermin Barrueto, Jr, MD, FACEP, FAAEM, FACMT",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/19/33081/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/19/33081/contributors\">",
"     Stephen J Traub, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/19/33081/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/19/33081/contributors\">",
"     Jonathan Grayzel, MD, FAAEM",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?32/19/33081/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 5, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Beta adrenergic antagonists (beta blockers) have been in clinical use for more than 30 years, and are employed in the management of a range of disorders, including hypertension, ischemic heart disease, heart failure, arrhythmias, migraine headache, tremor, portal hypertension, and aortic dissection. Although safe for most patients when taken as prescribed, beta blocker toxicity is associated with significant morbidity and mortality. In 2006, there were 9041 single beta blocker exposures reported to poison centers in the United States. Of these, there were 613 moderate or major adverse outcomes and four deaths [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/19/33081/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Complications following beta blocker overdose are related to excessive beta adrenergic blockade, and occasionally the proarrhythmic (membrane-stabilizing) activity of these agents on cardiac conduction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/19/33081/abstract/2\">",
"     2",
"    </a>",
"    ]. Ingestion of other cardioactive agents in association with beta blockers increases mortality following overdose [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/19/33081/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. Common and potentially dangerous coingestions include calcium channel blockers, cyclic antidepressants, and neuroleptics [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/19/33081/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An overview of beta blocker intoxication will be presented here. A summary table to facilitate emergent management is provided (",
"    <a class=\"graphic graphic_table graphicRef82572 \" href=\"mobipreview.htm?0/3/53\">",
"     table 1",
"    </a>",
"    ). A general approach to an adult patient with possible drug intoxication, and an overview of adverse effects of beta blockade, are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/6/1129?source=see_link\">",
"     \"General approach to drug poisoning in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/39/3704?source=see_link\">",
"     \"Major side effects of beta blockers\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PHARMACOLOGY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Receptor types and general mechanism",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are at least three distinct types of beta receptors:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beta 1, which are found primarily in heart muscle. Activation of these receptors results in an increase in heart rate, contractility, atrioventricular (AV) conduction, and a decrease in AV node refractoriness.",
"     </li>",
"     <li>",
"      Beta 2, which are present in heart muscle but are more prominent in bronchial and peripheral vascular smooth muscle. Activation of these receptors results in vasodilation and bronchodilation.",
"     </li>",
"     <li>",
"      Beta 3, which are found in adipose tissue and the heart. Activation of these receptors may mediate catecholamine-induced thermogenesis and may reduce cardiac contractility.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Competitive antagonism of the beta receptor decreases cellular levels of cyclic adenosine monophosphate (cAMP). Beta-1 selective blockade results in depressed myocardial contractility, decreased automaticity in pacemaker cells, and decreased conduction velocity through the atrioventricular node [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/19/33081/abstract/3\">",
"     3",
"    </a>",
"    ]. The lungs, peripheral blood vessels, glucose metabolism, and central nervous system are all affected by beta blockade. Nonselective beta blockade results in systemic effects including bronchoconstriction, impaired gluconeogenesis, and decreased insulin release. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/39/3704?source=see_link\">",
"     \"Major side effects of beta blockers\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CELLULAR TOXICOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are many beta blockers available for clinical use, and although they all inhibit the beta-adrenoreceptor, there are several characteristics that differ among these agents. Following overdose, manifestations of toxicity are observed in varying degrees, depending on the specific agent and dose involved [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/19/33081/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. In addition to beta-adrenoreceptor blockade, three properties that affect toxicity include the membrane stabilizing activity (MSA), lipophilicity, and intrinsic sympathomimetic activity (ISA) of the ingested agent (",
"    <a class=\"graphic graphic_table graphicRef82571 \" href=\"mobipreview.htm?14/26/14766\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Membrane stabilizing activity (MSA) &ndash; Membrane stabilizing agents (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/49/8986?source=see_link\">",
"       propranolol",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?36/11/37047?source=see_link\">",
"       acebutolol",
"      </a>",
"      ) inhibit myocardial fast sodium channels, which can result in a widened QRS interval and may potentiate other dysrhythmias.",
"     </li>",
"     <li>",
"      Lipophilicity &ndash; Beta blockers with high lipid solubility (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/49/8986?source=see_link\">",
"       propranolol",
"      </a>",
"      ) rapidly cross the blood brain barrier into the central nervous system, predisposing to neurologic sequelae such as seizures and delirium. Beta Blockers with this characteristic are more amenable to treatment with 20 percent lipid emulsion therapy in the setting of a clinically significant overdose [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/19/33081/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Intrinsic sympathomimetic activity (ISA) &ndash; Many agents demonstrate a partial agonist effect at the beta receptor site, resulting in less bradycardia and hypotension in therapeutic and supratherapeutic doses. Bronchoconstriction is also less likely to occur with compounds that possess intrinsic sympathomimetic activity (ISA), or beta-1 selectivity. However, the protective effects of ISA do not completely prevent cardiovascular toxicity following intentional or accidental overdose.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     TOXICITY OF SPECIFIC AGENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Of all the variables contributing to toxicity, membrane stabilizing activity (MSA) appears to have the greatest influence on adverse cardiovascular effects (",
"    <a class=\"graphic graphic_table graphicRef82571 \" href=\"mobipreview.htm?14/26/14766\">",
"     table 2",
"    </a>",
"    ). Agents with significant MSA include",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/49/8986?source=see_link\">",
"     propranolol",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/11/37047?source=see_link\">",
"     acebutolol",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/11/32944?source=see_link\">",
"     betaxolol",
"    </a>",
"    , and oxprenolol. The effect of MSA is thought to be negligible at therapeutic doses, but in overdose can cause significant cardiovascular morbidity. In one retrospective study, 94 percent",
"    <span class=\"nowrap\">",
"     (15/16)",
"    </span>",
"    of patients with cardiovascular toxicity had a history of ingesting beta blockers with MSA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/19/33081/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/11/37047?source=see_link\">",
"     Acebutolol",
"    </a>",
"    , a cardioselective agent with partial agonist activity and significant MSA, is one of the most toxic beta blockers in overdose [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/19/33081/abstract/6\">",
"     6",
"    </a>",
"    ]. Acebutolol toxicity may predispose the patient to ventricular repolarization resulting in arrhythmias [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/19/33081/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/13/21721?source=see_link\">",
"     Sotalol",
"    </a>",
"    combines class III antidysrhythmic properties with beta adrenergic antagonism. Sotalol prolongs the action potential duration and increases the refractory period by blocking delayed potassium channels. This leads to prolongation of the QTc interval, and can contribute to the development of Torsades de Pointes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/19/33081/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/10/28841?source=see_link\">",
"     \"Therapeutic use and major side effects of sotalol\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/55/23418?source=see_link&amp;anchor=H4#H4\">",
"     \"Acquired long QT syndrome\", section on 'Drug-induced TdP'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/22/9577?source=see_link\">",
"     Carvedilol",
"    </a>",
"    has been associated with toxic epidermal necrolysis at therapeutic levels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/19/33081/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     PHARMACOKINETICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In therapeutic use, most beta blockers have half-lives ranging from two to eight hours, but kinetics can change in overdose (",
"    <a class=\"graphic graphic_table graphicRef82571 \" href=\"mobipreview.htm?14/26/14766\">",
"     table 2",
"    </a>",
"    ). Ingestion of sustained release preparations can delay the onset of symptoms and substantially prolong the duration of toxicity.",
"   </p>",
"   <p>",
"    Many beta blockers are metabolized via the liver.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/37/40536?source=see_link\">",
"     Esmolol",
"    </a>",
"    is metabolized by erythrocyte esterases.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/46/30440?source=see_link\">",
"     Atenolol",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/29/2520?source=see_link\">",
"     bisoprolol",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/45/35544?source=see_link\">",
"     labetalol",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/13/21721?source=see_link\">",
"     sotalol",
"    </a>",
"    are eliminated by the kidney.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES OF OVERDOSE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diagnosis of beta blocker intoxication is made on the basis of history and clinical presentation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data obtained should include the specific agent, amount ingested, time of ingestion, and any coingestions. Historical features that suggest increased risk for severe toxicity include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Coingestion of other cardioactive agents",
"     </li>",
"     <li>",
"      Underlying cardiac disease (eg, heart failure)",
"     </li>",
"     <li>",
"      Ingestion of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?21/13/21721?source=see_link\">",
"       sotalol",
"      </a>",
"      or another agent with membrane-stabilizing activity (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/49/8986?source=see_link\">",
"       propranolol",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?36/11/37047?source=see_link\">",
"       acebutolol",
"      </a>",
"      ) (see",
"      <a class=\"local\" href=\"#H5\">",
"       'Toxicity of specific agents'",
"      </a>",
"      above)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Any possible witnesses and emergency medical services (EMS) personnel who may have recovered pill bottles at the scene should be contacted. The patient's pharmacy may provide valuable information regarding prescribed medications, the date of the most recent refill, and the total number of pills dispensed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Physical findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients who overdose on beta blockers become symptomatic within two hours following ingestion, and nearly all develop symptoms within six hours [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/19/33081/abstract/2,9\">",
"     2,9",
"    </a>",
"    ]. Exceptions to this general rule include ingestions of sustained release medications and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/13/21721?source=see_link\">",
"     sotalol",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/19/33081/abstract/10\">",
"     10",
"    </a>",
"    ]. In these cases, delayed toxicity up to 24 hours after ingestion can occur.",
"   </p>",
"   <p>",
"    Bradycardia and hypotension are the most common effects, and in severe overdoses can result in profound myocardial depression and cardiogenic shock. Ventricular dysrhythmias are seen more frequently following",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/49/8986?source=see_link\">",
"     propranolol",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/11/37047?source=see_link\">",
"     acebutolol",
"    </a>",
"    exposures, probably because of the increased membrane-stabilizing activity (MSA) of these agents (",
"    <a class=\"graphic graphic_table graphicRef82571 \" href=\"mobipreview.htm?14/26/14766\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/19/33081/abstract/2,11\">",
"     2,11",
"    </a>",
"    ]. Other potential effects of severe toxicity include mental status change, seizure, hypoglycemia, and bronchospasm.",
"   </p>",
"   <p>",
"    Mental status changes, including delirium, coma, and seizures, occur most frequently in patients with severe hypotension, but can occur in those with normal blood pressure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/19/33081/abstract/12\">",
"     12",
"    </a>",
"    ]. Similarly, respiratory depression usually occurs in hypotensive, comatose patients, but has been reported in awake patients. Specific agents, particularly",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/49/8986?source=see_link\">",
"     propranolol",
"    </a>",
"    , are associated with neurologic effects in the absence of cerebral hypoperfusion. This was demonstrated in a report comparing the clinical course of patients following overdose with either propranolol or other beta blockers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/19/33081/abstract/9\">",
"     9",
"    </a>",
"    ]. Although the minimum pulse and systolic and diastolic ranges were not significantly different between groups, 29 percent of the propranolol group experienced seizures versus none in the non-propranolol group. This difference is probably due to the increased lipophilicity of propranolol, allowing rapid diffusion into the central nervous system.",
"   </p>",
"   <p>",
"    In addition to the cardiovascular and neurologic manifestations, bronchospasm and hypoglycemia can complicate acute beta blocker intoxication. Early recognition and prompt treatment of hypoglycemia is critical. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Management'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     LABORATORY EVALUATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Laboratory studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although serum concentrations of most beta blockers can be measured, they cannot be obtained in time to be clinically useful and are generally performed only for academic or forensic purposes.",
"   </p>",
"   <p>",
"    In patients with beta blocker overdose, we generally obtain the following studies: an electrocardiogram (ECG), a fingerstick glucose, serum electrolytes including calcium, and blood urea nitrogen and creatinine levels. If calcium is administered repeatedly, levels should be measured every four to six hours. If an",
"    <span class=\"nowrap\">",
"     insulin/glucose",
"    </span>",
"    treatment regimen is used, glucose and potassium levels must be measured every 30 to 60 minutes. (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Insulin and glucose'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H18\">",
"     'Calcium'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Routine laboratory evaluation of any poisoned patient should include",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    and salicylate levels, to rule out these common coingestions, and a pregnancy test in women of childbearing age.",
"   </p>",
"   <p>",
"    A serum lactate concentration above 3",
"    <span class=\"nowrap\">",
"     mmol/L",
"    </span>",
"    is used to predict life-threatening overdose of some medications. However, this may be an insensitive finding with beta blocker overdose. In one retrospective study, four of nine deaths associated with beta blocker poisoning were associated with serum lactate concentrations below 3",
"    <span class=\"nowrap\">",
"     mmol/L",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/19/33081/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Additional tests are obtained based upon clinical findings. As an example, a plain chest radiograph is obtained in patients with signs of pulmonary edema.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Electrocardiogram",
"    </span>",
"    &nbsp;&mdash;&nbsp;Beta blockers decrease conduction velocity across the atrioventricular (AV) node, resulting in PR prolongation; they also slow automaticity within the sinoatrial (SA) node, causing bradycardia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/19/33081/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    QRS prolongation occurs more commonly when beta blockers with membrane stabilizing activity (MSA) are ingested. Significant QTc prolongation can develop following",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/13/21721?source=see_link\">",
"     sotalol",
"    </a>",
"    overdose as a result of its independent Class III antiarrhythmic activity. In severe poisoning, the electrocardiogram (ECG) can show",
"    <strong>",
"     ANY",
"    </strong>",
"    bradydysrhythmia, and can progress to asystole. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/33/13850?source=see_link&amp;anchor=H9#H9\">",
"     \"Advanced cardiac life support (ACLS) in adults\", section on 'Asystole and pulseless electrical activity'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A Brugada-like ECG pattern has been reported in the setting of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/49/8986?source=see_link\">",
"     propranolol",
"    </a>",
"    poisoning, suggesting that other beta blockers that are lipophilic or possess membrane stabilizing activity might have similar effects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/19/33081/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H56212731\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many drugs can cause profound hypotension or bradydysrhythmia in overdose. Calcium channel blockers,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/53/19289?source=see_link\">",
"     clonidine",
"    </a>",
"    , and cholinergic agents must be considered when evaluating bradydysrhythmia potentially caused by a toxic ingestion.",
"   </p>",
"   <p>",
"    Calcium channel blockers are less likely than beta blockers to produce alterations in mental status, and frequently do not do so unless the patient is in profound shock. Hyperglycemia occurs more often with calcium channel blocker toxicity, while beta blockers are associated with hypoglycemia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/63/31736?source=see_link\">",
"     \"Calcium channel blocker poisoning\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Nausea and vomiting occur more often with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    toxicity than beta blocker toxicity. Digoxin may cause characteristic changes in an electrocardiogram, such as scooped ST segment depressions. Digoxin is more likely to produce rhythms of increased automaticity, such as atrial tachycardia with atrioventricular block, premature ventricular contractions, or ventricular arrhythmias. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/13/25817?source=see_link\">",
"     \"Digitalis (cardiac glycoside) poisoning\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/53/19289?source=see_link\">",
"     Clonidine",
"    </a>",
"    produces a constellation of signs that can resemble opioid overdose, including somnolence and miosis, but are accompanied by hypotension and bradycardia.",
"   </p>",
"   <p>",
"    Overdose of a cholinergic agent can present with bradycardia but also includes other characteristic features (salivation, lacrimation, urination, defecation, GI upset, and muscle excitability).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Acute stabilization and overview of therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;First, secure the airway and provide advanced cardiac life support as necessary (",
"    <a class=\"graphic graphic_table graphicRef82572 \" href=\"mobipreview.htm?0/3/53\">",
"     table 1",
"    </a>",
"    ).",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/23/11640?source=see_link\">",
"     Atropine",
"    </a>",
"    should be given early in bradycardic patients and as a pretreatment agent when rapid sequence intubation is required [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/19/33081/abstract/16\">",
"     16",
"    </a>",
"    ]. Establish intravenous access and provide continuous cardiac monitoring. A summary table to facilitate emergent management is provided (",
"    <a class=\"graphic graphic_table graphicRef82572 \" href=\"mobipreview.htm?0/3/53\">",
"     table 1",
"    </a>",
"    ). &nbsp; (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/55/1912?source=see_link\">",
"     \"Rapid sequence intubation in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/33/13850?source=see_link\">",
"     \"Advanced cardiac life support (ACLS) in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Treat hypotension with intravenous (IV) boluses of isotonic fluid; treat symptomatic bradycardia with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/23/11640?source=see_link\">",
"     atropine",
"    </a>",
"    . Atropine is given in a dose of 0.5 to 1 mg every three to five minutes up to a total of 0.03 to 0.04",
"    <span class=\"nowrap\">",
"     mg/kg.",
"    </span>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/52/840?source=see_link\">",
"     Sodium bicarbonate",
"    </a>",
"    and magnesium may be needed to treat some arrhythmias. (See",
"    <a class=\"local\" href=\"#H23\">",
"     'Other therapies'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Treat symptomatic hypoglycemia with IV dextrose. For adults, administer boluses of 50 percent dextrose in water (D50W); for children administer an appropriate IV bolus of dextrose (0.25",
"    <span class=\"nowrap\">",
"     g/kg",
"    </span>",
"    body weight). In infants and young children this is usually given as 2.5",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    of 10 percent dextrose solution. Multiple doses of dextrose may be necessary. Treatment of hypoglycemia in children is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/0/8201?source=see_link\">",
"     \"Approach to hypoglycemia in infants and children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Treat seizures with benzodiazepines (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/8/8329?source=see_link\">",
"     lorazepam",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/11/19642?source=see_link\">",
"     \"Status epilepticus in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    IV fluid and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/23/11640?source=see_link\">",
"     atropine",
"    </a>",
"    often do not completely reverse the cardiotoxic effects of beta blocker overdose. In such cases, we give additional treatments based upon the severity of the presentation. These treatments may include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      IV",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/32/25093?source=see_link\">",
"       glucagon",
"      </a>",
"     </li>",
"     <li>",
"      IV calcium salts",
"     </li>",
"     <li>",
"      Vasopressor",
"     </li>",
"     <li>",
"      High dose insulin and glucose infusions",
"     </li>",
"     <li>",
"      Lipid emulsion therapy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These therapeutic options are discussed below. (See",
"    <a class=\"local\" href=\"#H61484287\">",
"     'Approach to the selection of specific therapies'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Hemodialysis may be needed in specific circumstances, although this is uncommon. In such cases a nephrologist should be contacted early in the patient&rsquo;s course. (See",
"    <a class=\"local\" href=\"#H23\">",
"     'Other therapies'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Many patients with isolated beta blocker overdose remain asymptomatic and can be discharged after a period of observation. (See",
"    <a class=\"local\" href=\"#H25\">",
"     'Disposition'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H61484287\">",
"    <span class=\"h2\">",
"     Approach to the selection of specific therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although it is ideal to institute treatments individually to assess their success or failure, this is often not possible in patients who are severely ill from a beta blocker poisoning. Our suggested approaches to therapy based upon the severity of the clinical presentation are described here; a summary table to facilitate emergent management is provided (",
"    <a class=\"graphic graphic_table graphicRef82572 \" href=\"mobipreview.htm?0/3/53\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H61484294\">",
"    <span class=\"h3\">",
"     Severely symptomatic patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;Our suggested approach to patients manifesting signs of severe beta blocker poisoning (profound hypotension",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    severe bradycardia, depressed mental status) consists of multiple",
"    <strong>",
"     simultaneous",
"    </strong>",
"    interventions, including",
"    <strong>",
"     all",
"    </strong>",
"    of the following treatments [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/19/33081/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Stabilization of the airway as necessary (avoid induction agents that exacerbate hypotension)",
"     </li>",
"     <li>",
"      Additional IV boluses of isotonic crystalloid",
"     </li>",
"     <li>",
"      IV",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/32/25093?source=see_link\">",
"       glucagon",
"      </a>",
"     </li>",
"     <li>",
"      IV calcium salts",
"     </li>",
"     <li>",
"      Vasopressor (eg, epinephrine)",
"     </li>",
"     <li>",
"      IV high-dose insulin and glucose",
"     </li>",
"     <li>",
"      IV lipid emulsion therapy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Dosing for each of these therapies is provided below. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Specific therapies'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H61484301\">",
"    <span class=\"h3\">",
"     Mildly symptomatic patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;Our suggested approach to patients with mild hypotension or bradycardia begins with IV boluses of isotonic crystalloid and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/23/11640?source=see_link\">",
"     atropine",
"    </a>",
"    respectively. However, these therapies often do not completely reverse the cardiotoxic effects of beta blocker poisoning. In such cases, we add the following treatments in succession based upon patient response. As an example, we begin treatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/32/25093?source=see_link\">",
"     glucagon",
"    </a>",
"    if IV crystalloid does not adequately improve the patient&rsquo;s blood pressure, but if hypotension resolves following treatment with glucagon, we do",
"    <strong>",
"     not",
"    </strong>",
"    proceed to IV calcium salts or any other treatment.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      IV",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/32/25093?source=see_link\">",
"       glucagon",
"      </a>",
"     </li>",
"     <li>",
"      IV calcium salts",
"     </li>",
"     <li>",
"      IV high-dose insulin and glucose",
"     </li>",
"     <li>",
"      IV vasopressor (eg, epinephrine)",
"     </li>",
"     <li>",
"      IV lipid emulsion therapy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A period of 15 minutes is reasonable to determine the effectiveness of a specific therapy before proceeding to the next treatment. Dosing for each of these therapies is provided below. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Specific therapies'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H61484308\">",
"    <span class=\"h3\">",
"     Asymptomatic patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many patients with an isolated beta blocker overdose remain asymptomatic and may be discharged after a period of observation, unless the overdose was intentional. (See",
"    <a class=\"local\" href=\"#H25\">",
"     'Disposition'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Specific therapies",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Glucagon",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite limited data,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/32/25093?source=see_link\">",
"     glucagon",
"    </a>",
"    is considered first-line, antidotal treatment for beta blocker overdose [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/19/33081/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. Intravenous (IV) glucagon is given as a slow bolus dose followed by continuous infusion. An initial bolus of 5 mg intravenously is administered over one minute; if there is no increase in pulse or blood pressure after 10 to 15 minutes, a second bolus should be administered. The initial pediatric dose is 50",
"    <span class=\"nowrap\">",
"     micrograms/kg.",
"    </span>",
"    An effect should be observed within one to three minutes, with a peak response at five to seven minutes. If there is no observed effect after 10 minutes following a second dose, it is unlikely an infusion will provide benefit.",
"   </p>",
"   <p>",
"    If there is an increase in pulse or blood pressure, an infusion is started at a rate of 2 to 5",
"    <span class=\"nowrap\">",
"     mg/hour",
"    </span>",
"    (pediatric dose 70",
"    <span class=\"nowrap\">",
"     micrograms/kg/hour).",
"    </span>",
"    The goal is to maintain a mean arterial pressure of 60 mmHg. If this cannot be achieved, additional therapies are implemented in a sequential manner, beginning with calcium salts. When used as a sole agent in humans,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/32/25093?source=see_link\">",
"     glucagon",
"    </a>",
"    has been associated with treatment failures.",
"   </p>",
"   <p>",
"    Vomiting is common following administration of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/32/25093?source=see_link\">",
"     glucagon",
"    </a>",
"    . We suggest prophylactic or concurrent administration of a serotonin antagonist antiemetic (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/2/21544?source=see_link\">",
"     ondansetron",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/48/19208?source=see_link\">",
"     \"Characteristics of antiemetic drugs\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/32/25093?source=see_link\">",
"     Glucagon",
"    </a>",
"    activates adenylate cyclase at a site independent from beta-adrenergic agents, causing an increase in adenosine 3'-5'-cyclic monophosphate (cAMP). Elevations in cAMP increase the intracellular pool of calcium available for release during depolarization, augmenting contractility. The successful use of glucagon to manage beta blocker toxicity has been documented in many case reports, but no controlled trials involving humans have been conducted [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/19/33081/abstract/21\">",
"     21",
"    </a>",
"    ]. One review of the available controlled trials in animal models found that glucagon increased heart rate (HR), at least transiently, but had minimal effect on mean arterial pressure (MAP) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/19/33081/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In 2006, a trial comparing vasopressin with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/32/25093?source=see_link\">",
"     glucagon",
"    </a>",
"    in a swine model of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/49/8986?source=see_link\">",
"     propranolol",
"    </a>",
"    overdose found no difference in survival at four hours [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/19/33081/abstract/22\">",
"     22",
"    </a>",
"    ]. No difference was detected in HR, MAP, systolic BP, or cardiac output, except in the first hour, when vasopressin caused a marked increase in MAP and systolic BP. Notably, cardiac output did not improve following glucagon administration.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Calcium",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of case reports demonstrate the efficacy of IV calcium salts in treating beta blocker toxicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/19/33081/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. Either",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15799?source=see_link\">",
"     calcium chloride",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/11/18616?source=see_link\">",
"     calcium gluconate",
"    </a>",
"    may be given.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15799?source=see_link\">",
"     Calcium chloride",
"    </a>",
"    , 1 g of a 10 percent solution (10 mL), is given as a slow push, and should be administered via a central venous catheter. The dose may be repeated up to a total of 3 grams. The pediatric dose is 20",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    (maximum dose is 1 g); up to 60",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    may be given.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/11/18616?source=see_link\">",
"     Calcium gluconate",
"    </a>",
"    should be given if only peripheral IV access is available. The percentage of elemental calcium in calcium gluconate is one-third that of the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15799?source=see_link\">",
"     calcium chloride",
"    </a>",
"    &nbsp;salt, so 30 mL of a 10 percent solution should be administered as an initial dose. In children, give 60",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per dose (maximum dose is 3 g).",
"   </p>",
"   <p>",
"    Clinicians must monitor serum calcium concentrations if treatment with an IV calcium salt is given. Lethal iatrogenic overdose has been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/19/33081/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    IV calcium salts may improve hemodynamic parameters by increasing inotropy. Animal models suggest that calcium salts increase blood pressure and cardiac output, but do not increase heart rate, following combined calcium channel blocker and beta blocker overdose [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/19/33081/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Vasopressor (catecholamine)",
"    </span>",
"    &nbsp;&mdash;&nbsp;In animal models and human case reports, treatment of beta blocker overdose with catecholamine infusion alone has resulted in poor outcomes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/19/33081/abstract/27-29\">",
"     27-29",
"    </a>",
"    ]. Nevertheless, we suggest adding catecholamine infusions if the combination of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/23/11640?source=see_link\">",
"     atropine",
"    </a>",
"    , IV fluids,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/32/25093?source=see_link\">",
"     glucagon",
"    </a>",
"    , and IV calcium salts are unsuccessful in improving cardiovascular performance. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/35/40505?source=see_link\">",
"     \"Use of vasopressors and inotropes\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An infusion of epinephrine at 1",
"    <span class=\"nowrap\">",
"     microgram/minute",
"    </span>",
"    can be started and titrated upwards to maintain a MAP of 60 mmHg. Pediatric dosing starts at 0.1",
"    <span class=\"nowrap\">",
"     micrograms/kg/minute",
"    </span>",
"    and is titrated upwards based upon the patient's MAP. High infusion rates may be necessary to overcome competitive inhibition. An arterial line may be needed to monitor blood pressure.",
"   </p>",
"   <p>",
"    Catecholamines exert positive inotropic and chronotropic activity on the myocardium by stimulating adrenergic receptors and increasing the concentration of cAMP. One possible explanation for the lack of effectiveness of catecholamines in beta blocker overdose is that high doses are often required to achieve a therapeutic effect, and such doses may increase the risk of arrhythmia. In addition, some speculate that unopposed alpha constriction increases the cardiac workload, diminishing stroke volume and cardiac output.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Insulin and glucose",
"    </span>",
"    &nbsp;&mdash;&nbsp;High-dose insulin shows promise as a treatment for beta blocker toxicity, but evidence remains preliminary [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/19/33081/abstract/30\">",
"     30",
"    </a>",
"    ]. In patients who manifest hemodynamic instability refractory to the other therapeutic modalities described above, we suggest a trial of high-dose insulin and glucose.",
"   </p>",
"   <p>",
"    The dosing regimen for high-dose insulin is described in detail separately. Of note, hypoglycemia is a possible complication of this treatment since the dose of insulin is much higher (approximately 10-fold) than that typically given for diabetic ketoacidosis. When necessary, euglycemia can be maintained by means of a continuous IV infusion of 5 to 10 percent dextrose. A hemodynamic response to high-dose insulin therapy is delayed for 30 to 60 minutes, therefore simultaneous implementation of other therapies to support the patient's pulse and blood pressure are generally required. Repletion of potassium and magnesium may be needed. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/63/31736?source=see_link&amp;anchor=H16#H16\">",
"     \"Calcium channel blocker poisoning\", section on 'Insulin and glucose'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Animal studies and case reports of both isolated beta blocker overdose and combined calcium channel blocker and beta blocker overdose suggest that treatment with high dose insulin and glucose may be effective [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/19/33081/abstract/26,30,31\">",
"     26,30,31",
"    </a>",
"    ]. However, the role for this therapy in pure beta blocker overdose is not settled.",
"   </p>",
"   <p>",
"    One study of insulin therapy in",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/49/8986?source=see_link\">",
"     propranolol",
"    </a>",
"    toxicity was terminated early when every pig in the insulin and glucose treatment group achieved the study goal of four hour survival, while those treated with vasopressin and epinephrine died within 90 minutes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/19/33081/abstract/27\">",
"     27",
"    </a>",
"    ]. Cardiac output (CO) in animals treated with insulin and glucose increased throughout the trial; CO in animals treated with vasopressin and epinephrine decreased until death.",
"   </p>",
"   <p>",
"    The pathophysiology of beta-blocker intoxication is similar in many respects to that of calcium channel blocker (CCB) intoxication, for which high dose insulin and glucose has been more extensively studied. Although the mechanism is not completely understood, both CCB and beta blocker poisoning appear to interfere with myocyte metabolism. In addition, beta blockers inhibit pancreatic insulin release further reducing available glucose and diminishing CO. Insulin appears to improve inotropy by providing substrate for aerobic metabolism within the myocyte.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8781788\">",
"    <span class=\"h3\">",
"     Lipid emulsion therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lipid emulsions are the fats used in",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/40/42628?source=see_link\">",
"     total parenteral nutrition",
"    </a>",
"    (TPN). Initially used to treat overdoses of local anesthetics such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/60/34758?source=see_link\">",
"     bupivacaine",
"    </a>",
"    , intravenous lipid emulsion (ILE) has been used to treat poisonings involving a number of other lipophilic medications. A more complete discussion of ILE, including suggested dosing, is found separately [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/19/33081/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/63/31736?source=see_link&amp;anchor=H6162826#H6162826\">",
"     \"Calcium channel blocker poisoning\", section on 'Lipid emulsion therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Studies of ILE therapy are preliminary. A systematic review of lipid emulsion therapy for acute poisoning found the overall quality of studies supporting this treatment to be weak but found evidence of benefit in patients with toxicity from",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/18/9514?source=see_link\">",
"     verapamil",
"    </a>",
"    , beta blockers, some tricyclic antidepressants,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/60/34758?source=see_link\">",
"     bupivacaine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/38/30312?source=see_link\">",
"     chlorpromazine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/19/33081/abstract/32\">",
"     32",
"    </a>",
"    ]. ILE may have a useful role in the treatment of patients who are hemodynamically unstable from such poisonings after more traditional therapies (IV fluids,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/23/11640?source=see_link\">",
"     atropine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/32/25093?source=see_link\">",
"     glucagon",
"    </a>",
"    , high dose insulin and glucose, and vasopressors) have failed to restore hemodynamic stability. ILE has been used successfully in documented cases of severe beta blocker overdose [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/19/33081/abstract/33,34\">",
"     33,34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Phosphodiesterase inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Phosphodiesterase inhibitors, such as inamrinone (formerly known as amrinone),",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/18/3366?source=see_link\">",
"     milrinone",
"    </a>",
"    , and enoximone, inhibit the breakdown of cAMP by phosphodiesterases, thus increasing intracellular cAMP levels. Treatment with phosphodiesterase inhibitors is experimental and should only be used in patients with life-threatening overdose when all other treatments are failing.",
"   </p>",
"   <p>",
"    In a case report of an iatrogenic",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/45/35544?source=see_link\">",
"     labetalol",
"    </a>",
"    overdose, administration of inamrinone improved the cardiac index, stroke volume, pulmonary capillary wedge pressure, and mental status when added to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/32/25093?source=see_link\">",
"     glucagon",
"    </a>",
"    , dopamine, and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/36/39488?source=see_link\">",
"     phenylephrine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/19/33081/abstract/35\">",
"     35",
"    </a>",
"    ]. Another case report described the successful use of enoximone following acute ingestion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/19/33081/abstract/36\">",
"     36",
"    </a>",
"    ]. IV therapy with a phosphodiesterase inhibitor can be associated with GI disturbances, hypotension, agitation, anxiety, headaches, and insomnia. Proarrhythmic effects and hypotension are the more common adverse reactions. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Gastrointestinal (GI) decontamination",
"    </span>",
"    &nbsp;&mdash;&nbsp;GI decontamination may involve",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/52/39750?source=see_link\">",
"     activated charcoal",
"    </a>",
"    (AC), whole bowel irrigation, or gastric lavage; therapy is based upon clinical circumstance. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/58/16297?source=see_link\">",
"     \"Gastrointestinal decontamination of poisoned adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We suggest treatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/52/39750?source=see_link\">",
"     activated charcoal",
"    </a>",
"    (AC), 1",
"    <span class=\"nowrap\">",
"     g/kg",
"    </span>",
"    by mouth or nasogastric tube, in all patients who present within one to two hours of a known or suspected beta blocker ingestion, unless there are contraindications to its administration. Charcoal should be withheld in patients who are sedated and may not be able to protect their airway, unless endotracheal intubation is performed first. However, endotracheal intubation should not be performed solely for the purpose of giving charcoal.",
"   </p>",
"   <p>",
"    Asymptomatic patients who present more than two hours after a reported ingestion are unlikely to benefit from AC, and we do not recommend routine treatment in these patients.",
"   </p>",
"   <p>",
"    The role of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/52/39750?source=see_link\">",
"     activated charcoal",
"    </a>",
"    in symptomatic patients who present several hours after ingestion is more controversial. We suggest the administration of AC (1",
"    <span class=\"nowrap\">",
"     g/kg",
"    </span>",
"    by mouth or nasogastric tube) if there are no contraindications to charcoal administration. Although there are no data to suggest improved outcomes with AC in such patients, we believe that AC is a relatively safe intervention whose potential benefits in this situation outweigh its risks.",
"   </p>",
"   <p>",
"    Gastric lavage should not be routinely performed, but may be considered for patients who present within one hour following ingestion of a large quantity of medication. Large sustained or controlled release tablets may not pass through the oral gastric tube.",
"   </p>",
"   <p>",
"    Whole bowel irrigation is reserved for patients who have ingested sustained release or enteric coated preparations, or have suspected drug concretions (pharmacobezoars) in the GI tract.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Other therapies",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/52/840?source=see_link\">",
"       Sodium bicarbonate",
"      </a>",
"      &ndash; Sodium bicarbonate has been used successfully in the treatment of beta blocker induced arrhythmia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/19/33081/abstract/37,38\">",
"       37,38",
"      </a>",
"      ]. Because it is a relatively safe intervention, we suggest giving it as an adjunct for patients with QRS widening.",
"      <br/>",
"      <br/>",
"      The dose of sodium bicarbonate is 1 to 2",
"      <span class=\"nowrap\">",
"       mEq/kg",
"      </span>",
"      given as an IV push, which may be repeated. If treatment is effective, an infusion can be started. We mix 132 mEq of sodium bicarbonate in 1 liter of D5W and infuse at 250",
"      <span class=\"nowrap\">",
"       mL/hour",
"      </span>",
"      in adults, and at twice the maintenance fluid rate in children. The infusion is tapered once the arrhythmia resolves. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?35/24/36231?source=see_link\">",
"       \"Tricyclic antidepressant poisoning\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Magnesium &ndash; Magnesium may be administered when ventricular arrhythmias are present or hypomagnesemia is suspected.",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?21/13/21721?source=see_link\">",
"       Sotalol",
"      </a>",
"      has a high propensity to induce ventricular arrhythmias and will often require magnesium, administered as a 2 g IV bolus or as a continuous infusion.",
"     </li>",
"     <li>",
"      Intravenous pacing &ndash; Ventricular pacing may be effective in patients with profound bradycardia, or in patients with combined beta blocker and calcium channel blocker intoxication [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/19/33081/abstract/39\">",
"       39",
"      </a>",
"      ]. However, ventricular pacing frequently fails to capture, or increases the heart rate without a corresponding increase in perfusion [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/19/33081/abstract/40\">",
"       40",
"      </a>",
"      ]. IV pacing can be implemented if there is no response to pharmacologic therapies, and the patient remains bradycardic and hypotensive. Some authors note a decrease in blood pressure with pacing [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/19/33081/abstract/4\">",
"       4",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?20/61/21465?source=see_link\">",
"       \"Temporary cardiac pacing\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Intraaortic balloon pump &ndash; The intraaortic balloon pump has been used successfully after failure of pharmacologic management in severe cases of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/49/8986?source=see_link\">",
"       propranolol",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/46/30440?source=see_link\">",
"       atenolol",
"      </a>",
"      overdose [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/19/33081/abstract/41,42\">",
"       41,42",
"      </a>",
"      ] and in combined",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/18/9514?source=see_link\">",
"       verapamil",
"      </a>",
"      -SR (sustained release) and atenolol overdose [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/19/33081/abstract/43\">",
"       43",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?13/36/13896?source=see_link\">",
"       \"Intraaortic balloon pump counterpulsation\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Hemodialysis &ndash; Hemodialysis has a minimal role in the treatment of beta blocker overdose and is effective only with hydrophilic, minimally protein-bound beta blockers such as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/46/30440?source=see_link\">",
"       atenolol",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/19/33081/abstract/44\">",
"       44",
"      </a>",
"      ].",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/15/35063?source=see_link\">",
"       Nadolol",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?21/13/21721?source=see_link\">",
"       sotalol",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?36/11/37047?source=see_link\">",
"       acebutolol",
"      </a>",
"      , and atenolol are reportedly removed by hemodialysis, but",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/31/39417?source=see_link\">",
"       metoprolol",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/49/8986?source=see_link\">",
"       propranolol",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/2/31776?source=see_link\">",
"       timolol",
"      </a>",
"      are not.",
"      <br/>",
"      <br/>",
"      Hemodialysis is reserved for patients who have not improved despite aggressive medical intervention, have ingested a significant amount of a beta blocker that can be removed using dialysis (eg, acebutolol), or have ingested other cardioactive medications that may exacerbate toxicity. In such cases, the emergency clinician should contact a nephrologist early in the patient's course to avoid delays in preparing for hemodialysis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Continuous venovenous hemodialysis (VVHD) can be used if the patient is not able to tolerate traditional hemodialysis due to pronounced hypotension. The decision to initiate hemodialysis and the selection of the appropriate type is made in consultation with the nephrologist. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/4/26695?source=see_link\">",
"     \"Enhanced elimination of poisons\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Pediatric considerations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypoglycemia is seen more often in pediatric patients than adults. Management does not significantly differ from that in adults.",
"   </p>",
"   <p>",
"    We recommend 24 hours of observation in a monitored setting for any initially asymptomatic child who has ingested an extended release preparation,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/13/21721?source=see_link\">",
"     sotalol",
"    </a>",
"    , or multiple cardioactive agents. Outside of such cases, the great majority of isolated ingestions by young children are uneventful and they can be discharged after a six hour period of observation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/19/33081/abstract/45,46\">",
"     45,46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Children may be observed safely at home after the witnessed ingestion of a single beta blocker tablet and Poison Control Centers typically manage these exposures via telephone follow-up [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/19/33081/abstract/47,48\">",
"     47,48",
"    </a>",
"    ]. Should the patient's family call the Emergency Department (ED) for advice, it is prudent to advise them to bring the child to the ED for evaluation since follow-up can be problematic.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Disposition",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who have ingested a beta blocker and who manifest hemodynamic instability or an altered mental status should be admitted to a critical care unit for cardiac monitoring and further management.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/13/21721?source=see_link\">",
"     Sotalol",
"    </a>",
"    has a long half-life and toxicity may result in ventricular dysrhythmias. Thus, patients require 24 hours of inpatient cardiac monitoring following sotalol overdose, even if they are asymptomatic.",
"   </p>",
"   <p>",
"    Any person who has taken an overdose of a beta blocker with membrane stabilizing activity (",
"    <a class=\"graphic graphic_table graphicRef82571 \" href=\"mobipreview.htm?14/26/14766\">",
"     table 2",
"    </a>",
"    ) or multiple cardioactive medications is at increased risk of severe toxicity and should be observed in the emergency department for six hours. Patients who remain asymptomatic without need of intervention can be safely discharged. Patients who are asymptomatic at presentation after ingestion of a sustained release beta blocker should be observed for at least six hours to insure that symptoms do not develop [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/19/33081/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Asymptomatic adults who have inadvertently ingested an amount of beta blocking agent no greater than their total daily dose (excluding",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/13/21721?source=see_link\">",
"     sotalol",
"    </a>",
"    ) may be observed safely at home [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/19/33081/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     ADDITIONAL RESOURCES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Regional poison control centers in the United States are available at all times for consultation on patients who are critically ill, require admission, or have clinical pictures that are unclear (1-800-222-1222). In addition, some hospitals have clinical",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    medical toxicologists available for bedside consultation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    inpatient care. Whenever available, these are invaluable resources to help in the diagnosis and management of ingestions or overdoses. The World Health Organization provides a listing of international poison centers at its website:",
"    <a class=\"external\" href=\"file://www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html\">",
"     www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html",
"    </a>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Although beta blocker overdose generally follows a benign clinical course, patients with significant toxicity require aggressive medical management. A summary table to facilitate emergent management is provided (",
"      <a class=\"graphic graphic_table graphicRef82572 \" href=\"mobipreview.htm?0/3/53\">",
"       table 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Toxicity increases greatly when an agent has membrane stabilizing activity (MSA) (",
"      <a class=\"graphic graphic_table graphicRef82571 \" href=\"mobipreview.htm?14/26/14766\">",
"       table 2",
"      </a>",
"      ) or when other cardioactive agents are ingested concomitantly. Lipophilic agents cross the blood brain barrier and can cause neurologic dysfunction even in the absence of systemic hypotension (",
"      <a class=\"graphic graphic_table graphicRef82571 \" href=\"mobipreview.htm?14/26/14766\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Cellular toxicology'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5\">",
"       'Toxicity of specific agents'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?21/13/21721?source=see_link\">",
"       Sotalol",
"      </a>",
"      is a unique agent with an extended half-life that can cause QTc interval prolongation and severe ventricular arrhythmias in overdose.",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/49/8986?source=see_link\">",
"       Propranolol",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?36/11/37047?source=see_link\">",
"       acebutolol",
"      </a>",
"      possess properties that increase their potential toxicity. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Toxicity of specific agents'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H9\">",
"       'History'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most patients who develop toxicity from beta blocker overdose do so within two hours of ingestion, and virtually all do so within six hours. Bradycardia and hypotension are the most common effects. Cardiogenic shock and ventricular dysrhythmias can occur with severe overdose. Other potential effects of severe toxicity include mental status change, seizure, hypoglycemia, and bronchospasm. Hypoglycemia is seen more often in children. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Physical findings'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H24\">",
"       'Pediatric considerations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Obtain the following studies in patients with beta blocker poisoning: an electrocardiogram (ECG), a fingerstick glucose, serum electrolytes including calcium, and blood urea nitrogen and creatinine levels. Cardiac conduction delays can occur, most often a prolonged PR interval. In severe poisoning,",
"      <strong>",
"       ANY",
"      </strong>",
"      bradydysrhythmia can develop, and may progress to asystole. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Laboratory studies'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H13\">",
"       'Electrocardiogram'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with severely symptomatic beta blocker poisoning (eg, profound persistent hypotension or bradycardia), we suggest simultaneous treatment with all of the following therapies&nbsp;(",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Dosing is provided in the text and the rapid overview table (",
"      <a class=\"graphic graphic_table graphicRef82572 \" href=\"mobipreview.htm?0/3/53\">",
"       table 1",
"      </a>",
"      ). Severe beta blocker poisoning can be difficult to manage and consultation with a medical toxicologist or regional poison control center is prudent. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Acute stabilization and overview of therapy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H61484294\">",
"       'Severely symptomatic patients'",
"      </a>",
"      above.):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Stabilization of the airway as necessary (avoid induction agents that exacerbate hypotension)",
"     </li>",
"     <li>",
"      Additional IV boluses of isotonic crystalloid",
"     </li>",
"     <li>",
"      IV",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/32/25093?source=see_link\">",
"       glucagon",
"      </a>",
"     </li>",
"     <li>",
"      IV calcium salts",
"     </li>",
"     <li>",
"      Vasopressor (eg, epinephrine)",
"     </li>",
"     <li>",
"      IV high-dose insulin and glucose",
"     </li>",
"     <li>",
"      IV lipid emulsion therapy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients who are mildly symptomatic from beta blocker poisoning, and in whom IV fluids,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?11/23/11640?source=see_link\">",
"       atropine",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/32/25093?source=see_link\">",
"       glucagon",
"      </a>",
"      prove ineffective at reversing signs of cardiotoxicity, we suggest a stepwise treatment approach (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Give the following treatments, in succession, based upon patient response: IV calcium salts, lipid emulsion therapy, vasopressors, and high-dose insulin and glucose. The implementation of each therapeutic option is discussed in the text. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Acute stabilization and overview of therapy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H16\">",
"       'Specific therapies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/52/840?source=see_link\">",
"       Sodium bicarbonate",
"      </a>",
"      and magnesium may be needed to treat some arrhythmias. Hemodialysis may rarely be needed, in which case a nephrologist should be contacted early. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Other therapies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The length of observation following inadvertent overdose varies according to the type and number of medications ingested. (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Disposition'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/19/33081/abstract/1\">",
"      Bronstein AC, Spyker DA, Cantilena LR Jr, et al. 2006 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS). Clin Toxicol (Phila) 2007; 45:815.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/19/33081/abstract/2\">",
"      Love JN, Howell JM, Litovitz TL, Klein-Schwartz W. Acute beta blocker overdose: factors associated with the development of cardiovascular morbidity. J Toxicol Clin Toxicol 2000; 38:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/19/33081/abstract/3\">",
"      Vucini S, Joksovi D, Jovanovi D, et al. Factors influencing the degree and outcome of acute beta-blockers poisoning. Vojnosanit Pregl 2000; 57:619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/19/33081/abstract/4\">",
"      Taboulet P, Cariou A, Berdeaux A, Bismuth C. Pathophysiology and management of self-poisoning with beta-blockers. J Toxicol Clin Toxicol 1993; 31:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/19/33081/abstract/5\">",
"      Samuels TL, Uncles DR, Willers JW, et al. Logging the potential for intravenous lipid emulsion in propranolol and other lipophilic drug overdoses. Anaesthesia 2011; 66:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/19/33081/abstract/6\">",
"      Love JN. Acebutolol overdose resulting in fatalities. J Emerg Med 2000; 18:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/19/33081/abstract/7\">",
"      Link MS, Foote CB, Sloan SB, et al. Torsade de pointes and prolonged QT interval from surreptitious use of sotalol: use of drug levels in diagnosis. Chest 1997; 112:556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/19/33081/abstract/8\">",
"      Vlahovic-Palcevski V, Milic S, Hauser G, et al. Toxic epidermal necrolysis associated with carvedilol treatment. Int J Clin Pharmacol Ther 2010; 48:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/19/33081/abstract/9\">",
"      Reith DM, Dawson AH, Epid D, et al. Relative toxicity of beta blockers in overdose. J Toxicol Clin Toxicol 1996; 34:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/19/33081/abstract/10\">",
"      Neuvonen PJ, Elonen E, Vuorenmaa T, Laakso M. Prolonged Q-T interval and severe tachyarrhythmias, common features of sotalol intoxication. Eur J Clin Pharmacol 1981; 20:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/19/33081/abstract/11\">",
"      Love JN, Litovitz TL, Howell JM, Clancy C. Characterization of fatal beta blocker ingestion: a review of the American Association of Poison Control Centers data from 1985 to 1995. J Toxicol Clin Toxicol 1997; 35:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/19/33081/abstract/12\">",
"      Lifshitz M, Zucker N, Zalzstein E. Acute dilated cardiomyopathy and central nervous system toxicity following propranolol intoxication. Pediatr Emerg Care 1999; 15:262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/19/33081/abstract/13\">",
"      M&eacute;garbane B, Deye N, Malissin I, Baud FJ. Usefulness of the serum lactate concentration for predicting mortality in acute beta-blocker poisoning. Clin Toxicol (Phila) 2010; 48:974.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/19/33081/abstract/14\">",
"      Love JN, Enlow B, Howell JM, et al. Electrocardiographic changes associated with beta-blocker toxicity. Ann Emerg Med 2002; 40:603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/19/33081/abstract/15\">",
"      Rennyson SL, Littmann L. Brugada-pattern electrocardiogram in propranolol intoxication. Am J Emerg Med 2010; 28:256.e7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/19/33081/abstract/16\">",
"      Soni N, Baines D, Pearson IY. Cardiovascular collapse and propranolol overdose. Med J Aust 1983; 2:629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/19/33081/abstract/17\">",
"      Hofer CA, Smith JK, Tenholder MF. Verapamil intoxication: a literature review of overdoses and discussion of therapeutic options. Am J Med 1993; 95:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/19/33081/abstract/18\">",
"      Ashraf M, Chaudhary K, Nelson J, Thompson W. Massive overdose of sustained-release verapamil: a case report and review of literature. Am J Med Sci 1995; 310:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/19/33081/abstract/19\">",
"      Bailey B. Glucagon in beta-blocker and calcium channel blocker overdoses: a systematic review. J Toxicol Clin Toxicol 2003; 41:595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/19/33081/abstract/20\">",
"      Boyd R, Ghosh A. Towards evidence based emergency medicine: best BETs from the Manchester Royal Infirmary. Glucagon for the treatment of symptomatic beta blocker overdose. Emerg Med J 2003; 20:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/19/33081/abstract/21\">",
"      Lee J. Glucagon use in symptomatic beta blocker overdose. Emerg Med J 2004; 21:755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/19/33081/abstract/22\">",
"      Holger JS, Engebretsen KM, Obetz CL, et al. A comparison of vasopressin and glucagon in beta-blocker induced toxicity. Clin Toxicol (Phila) 2006; 44:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/19/33081/abstract/23\">",
"      Love JN, Hanfling D, Howell JM. Hemodynamic effects of calcium chloride in a canine model of acute propranolol intoxication. Ann Emerg Med 1996; 28:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/19/33081/abstract/24\">",
"      Sakurai H, Kei M, Matsubara K, et al. Cardiogenic shock triggered by verapamil and atenolol: a case report of therapeutic experience with intravenous calcium. Jpn Circ J 2000; 64:893.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/19/33081/abstract/25\">",
"      Sim MT, Stevenson FT. A fatal case of iatrogenic hypercalcemia after calcium channel blocker overdose. J Med Toxicol 2008; 4:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/19/33081/abstract/26\">",
"      Kerns W 2nd, Schroeder D, Williams C, et al. Insulin improves survival in a canine model of acute beta-blocker toxicity. Ann Emerg Med 1997; 29:748.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/19/33081/abstract/27\">",
"      Holger JS, Engebretsen KM, Fritzlar SJ, et al. Insulin versus vasopressin and epinephrine to treat beta-blocker toxicity. Clin Toxicol (Phila) 2007; 45:396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/19/33081/abstract/28\">",
"      Pertoldi F, D'Orlando L, Mercante WP. Electromechanical dissociation 48 hours after atenolol overdose: usefulness of calcium chloride. Ann Emerg Med 1998; 31:777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/19/33081/abstract/29\">",
"      Avery GJ 2nd, Spotnitz HM, Rose EA, et al. Pharmacologic antagonism of beta-adrenergic blockade in dogs. I. Hemodynamic effects of isoproterenol, dopamine, and epinephrine in acute propranolol administration. J Thorac Cardiovasc Surg 1979; 77:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/19/33081/abstract/30\">",
"      Page C, Hacket LP, Isbister GK. The use of high-dose insulin-glucose euglycemia in beta-blocker overdose: a case report. J Med Toxicol 2009; 5:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/19/33081/abstract/31\">",
"      Burns MJ, Linden CH. Insulin for beta-blocker toxicity. Ann Emerg Med 1997; 30:711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/19/33081/abstract/32\">",
"      Jamaty C, Bailey B, Larocque A, et al. Lipid emulsions in the treatment of acute poisoning: a systematic review of human and animal studies. Clin Toxicol (Phila) 2010; 48:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/19/33081/abstract/33\">",
"      Jovic-Stosic J, Gligic B, Putic V, et al. Severe propranolol and ethanol overdose with wide complex tachycardia treated with intravenous lipid emulsion: a case report. Clin Toxicol (Phila) 2011; 49:426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/19/33081/abstract/34\">",
"      Stellpflug SJ, Harris CR, Engebretsen KM, et al. Intentional overdose with cardiac arrest treated with intravenous fat emulsion and high-dose insulin. Clin Toxicol (Phila) 2010; 48:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/19/33081/abstract/35\">",
"      Kollef MH. Labetalol overdose successfully treated with amrinone and alpha-adrenergic receptor agonists. Chest 1994; 105:626.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/19/33081/abstract/36\">",
"      Hoeper MM, Boeker KH. Overdose of metoprolol treated with enoximone. N Engl J Med 1996; 335:1538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/19/33081/abstract/37\">",
"      Donovan KD, Gerace RV, Dreyer JF. Acebutolol-induced ventricular tachycardia reversed with sodium bicarbonate. J Toxicol Clin Toxicol 1999; 37:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/19/33081/abstract/38\">",
"      Shanker UR, Webb J, Kotze A. Sodium bicarbonate to treat massive beta blocker overdose. Emerg Med J 2003; 20:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/19/33081/abstract/39\">",
"      Snook CP, Sigvaldason K, Kristinsson J. Severe atenolol and diltiazem overdose. J Toxicol Clin Toxicol 2000; 38:661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/19/33081/abstract/40\">",
"      Hurwitz MD, Kallenbach JM, Pincus PS. Massive propranolol overdose. Am J Med 1986; 81:1118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/19/33081/abstract/41\">",
"      Kulling P, Eleborg L, Persson H. Beta-adrenoceptor blocker intoxication: epidemiological data. Prenalterol as an alternative in the treatment of cardiac dysfunction. Hum Toxicol 1983; 2:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/19/33081/abstract/42\">",
"      Lane AS, Woodward AC, Goldman MR. Massive propranolol overdose poorly responsive to pharmacologic therapy: use of the intra-aortic balloon pump. Ann Emerg Med 1987; 16:1381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/19/33081/abstract/43\">",
"      Frierson J, Bailly D, Shultz T, et al. Refractory cardiogenic shock and complete heart block after unsuspected verapamil-SR and atenolol overdose. Clin Cardiol 1991; 14:933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/19/33081/abstract/44\">",
"      DeLima LG, Kharasch ED, Butler S. Successful pharmacologic treatment of massive atenolol overdose: sequential hemodynamics and plasma atenolol concentrations. Anesthesiology 1995; 83:204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/19/33081/abstract/45\">",
"      Love JN, Howell JM, Klein-Schwartz W, Litovitz TL. Lack of toxicity from pediatric beta-blocker exposures. Hum Exp Toxicol 2006; 25:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/19/33081/abstract/46\">",
"      Belson MG, Sullivan K, Geller RJ. Beta-adrenergic antagonist exposures in children. Vet Hum Toxicol 2001; 43:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/19/33081/abstract/47\">",
"      Love JN, Sikka N. Are 1-2 tablets dangerous? Beta-blocker exposure in toddlers. J Emerg Med 2004; 26:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/19/33081/abstract/48\">",
"      Wax PM, Erdman AR, Chyka PA, et al. beta-blocker ingestion: an evidence-based consensus guideline for out-of-hospital management. Clin Toxicol (Phila) 2005; 43:131.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 330 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-122.72.76.133-24348CF07F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_19_33081=[""].join("\n");
var outline_f32_19_33081=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H27\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PHARMACOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Receptor types and general mechanism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CELLULAR TOXICOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      TOXICITY OF SPECIFIC AGENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      PHARMACOKINETICS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      CLINICAL FEATURES OF OVERDOSE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Physical findings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      LABORATORY EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Laboratory studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Electrocardiogram",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H56212731\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Acute stabilization and overview of therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H61484287\">",
"      Approach to the selection of specific therapies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H61484294\">",
"      - Severely symptomatic patients",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H61484301\">",
"      - Mildly symptomatic patients",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H61484308\">",
"      - Asymptomatic patients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Specific therapies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Glucagon",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Calcium",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Vasopressor (catecholamine)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Insulin and glucose",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8781788\">",
"      - Lipid emulsion therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Phosphodiesterase inhibitors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Gastrointestinal (GI) decontamination",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Other therapies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Pediatric considerations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Disposition",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      ADDITIONAL RESOURCES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/330\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/330|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?0/3/53\" title=\"table 1\">",
"      Beta blocker poisoning - Rapid overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?14/26/14766\" title=\"table 2\">",
"      Properties beta blockers",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/55/23418?source=related_link\">",
"      Acquired long QT syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/33/13850?source=related_link\">",
"      Advanced cardiac life support (ACLS) in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/0/8201?source=related_link\">",
"      Approach to hypoglycemia in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/63/31736?source=related_link\">",
"      Calcium channel blocker poisoning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/48/19208?source=related_link\">",
"      Characteristics of antiemetic drugs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/13/25817?source=related_link\">",
"      Digitalis (cardiac glycoside) poisoning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/4/26695?source=related_link\">",
"      Enhanced elimination of poisons",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/58/16297?source=related_link\">",
"      Gastrointestinal decontamination of poisoned adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/6/1129?source=related_link\">",
"      General approach to drug poisoning in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/36/13896?source=related_link\">",
"      Intraaortic balloon pump counterpulsation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/39/3704?source=related_link\">",
"      Major side effects of beta blockers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/55/1912?source=related_link\">",
"      Rapid sequence intubation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/11/19642?source=related_link\">",
"      Status epilepticus in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/61/21465?source=related_link\">",
"      Temporary cardiac pacing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/10/28841?source=related_link\">",
"      Therapeutic use and major side effects of sotalol",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/24/36231?source=related_link\">",
"      Tricyclic antidepressant poisoning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/35/40505?source=related_link\">",
"      Use of vasopressors and inotropes",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_19_33082="Phenytoin: Pediatric drug information";
var content_f32_19_33082=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Phenytoin: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"mobipreview.htm?34/48/35594?source=see_link\">",
"    see \"Phenytoin: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?7/49/7958?source=see_link\">",
"    see \"Phenytoin: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F11284327\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F209593\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Dilantin-125&reg;;",
"     </li>",
"     <li>",
"      Dilantin&reg;;",
"     </li>",
"     <li>",
"      Phenytek&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F209594\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Dilantin&reg;;",
"     </li>",
"     <li>",
"      Novo-Phenytoin;",
"     </li>",
"     <li>",
"      Taro-Phenytoin;",
"     </li>",
"     <li>",
"      Tremytoine Inj",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1054953\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antiarrhythmic Agent, Class I-B",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Anticonvulsant, Hydantoin",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F11444747\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Dosage should be individualized based upon clinical response and serum concentrations. Phenytoin base (eg, oral suspension, chewable tablets) contains ~8% more drug than phenytoin sodium (~92 mg base is equivalent to 100 mg phenytoin sodium). Dosage adjustments and closer serum monitoring may be necessary when switching dosage forms.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Status epilepticus; neonatal seizures:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Manufacturer labeling: I.V.: 15-20 mg/kg in a single or divided dose; then begin maintenance therapy usually 12 hours after dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Alternate dosing: AAP recommendation: I.V.: 10 mg/kg in a single dose; then begin maintenance therapy usually 12 hours after dose.",
"     <b>",
"      Note:",
"     </b>",
"     Phenobarbital is the preferred treatment for treatment of neonatal seizures. Fosphenytoin is preferred over phenytoin if available due to lower risk of cardiac adverse effects (Hegenbarth, 2008).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Seizures; maintenance therapy:",
"     </b>",
"     I.V., Oral: Initial: 5 mg/kg/day in 2 divided doses; usual range: 4-8 mg/kg/day in 2 divided doses; some patients may require dosing every 8 hours",
"    </p>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1054946\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?34/48/35594?source=see_link\">",
"      see \"Phenytoin: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Dosage should be individualized based upon clinical response and serum concentrations; dosage adjustments typically not made more frequently than every 7 days. Phenytoin base (eg, oral suspension, chewable tablets) contains ~8% more drug than phenytoin sodium (~92 mg base is equivalent to 100 mg phenytoin sodium). Dosage adjustments and closer serum monitoring may be necessary when switching dosage forms.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infants, Children and Adolescents:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Status epilepticus:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Manufacturer labeling: Loading dose: I.V.: 15-20 mg/kg in a single or divided dose; then begin maintenance therapy usually 12 hours after dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Alternate dosing: AAP recommendations: Loading dose: I.V.: 20 mg/kg in a single or divided doses; maximum dose: 1000 mg; then begin maintenance therapy usually 12 hours after dose (Hegenbarth, 2008). An additional load of 10 mg/kg if status not resolved has been used (Guerrini, 2006; Shearer, 2011).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Seizures:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Loading dose (if not previously on phenytoin): I.V., Oral: 15-20 mg/kg; if currently on phenytoin, reloading dose should be based upon serum concentrations and recent dosing history; an oral loading dose should be divided into 3 doses and administered every 2-4 hours to decrease GI adverse effects and to ensure complete oral absorption",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Maintenance therapy: Oral: Initial: 5 mg/kg/day in divided doses (based upon dosage form, see below); usual range: 4-8 mg/kg/day; maximum daily dose: 300 mg/",
"     <b>",
"      day",
"     </b>",
"     . Some experts suggest higher maintenance doses (8-10 mg/kg/day) may be necessary in infants and young children (Guerrini, 2006). Dosing should be based upon ideal body weight (IBW).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Dosing interval (product specific):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     Immediate release preparations (including suspension and chewable tablets): Divide daily dose into 2-3 doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     Extended release preparations:  Should be dosed every 12 or 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Seizure prophylaxis, traumatic brain injury:",
"     </b>",
"     Limited data available; efficacy results variable: I.V.: Initial: 18 mg/kg over 20 minutes; followed by 6 mg/kg/day divided every 8 hours for 48 hours was used in a double-blind, placebo-controlled trial of 102 pediatric patients (n=46 treatment group) and showed no significance difference in seizure frequency between groups; however, the trial was stopped early due to a very low seizure frequency among both study groups (Young, 2004). In a retrospective trial, reduced seizure frequency with prophylactic phenytoin use was described (Lewis, 1993).",
"     <b>",
"      Note:",
"     </b>",
"     Current guidelines suggest that prophylactic phenytoin may be considered to reduce the incidence of early post-traumatic seizures in pediatric patients with severe traumatic brain injuries but it does not reduce the risk of long-term seizures or improve neurologic outcome (Kochanek, 2012). Further studies are needed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults:",
"     <b>",
"      Note:",
"     </b>",
"     Phenytoin base (eg, oral suspension, chewable tablets) contains ~8% more drug than phenytoin sodium (~92 mg base is equivalent to 100 mg phenytoin sodium). Dosage adjustments and closer serum monitoring may be necessary when switching dosage forms.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Status epilepticus:",
"     </b>",
"     I.V.: Loading dose: Manufacturer recommends 10-15 mg/kg; however, 15-20 mg/kg at a maximum rate of 50 mg/minute is generally recommended (K&auml;lvi&auml;inen, 2007; Lowenstein, 2005); initial maintenance dose: I.V., Oral: 100 mg every 6-8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Anticonvulsant:",
"     </b>",
"     Oral: Loading dose: 15-20 mg/kg; consider prior phenytoin serum concentrations and/or recent dosing history if available; administer oral loading dose in 3 divided doses given every 2-4 hours to decrease GI adverse effects and to ensure complete oral absorption; initial maintenance dose: 300 mg/day in 3 divided doses; may also administer in 1-2 divided doses using extended release formulation; adjust dosage based on individual requirements; usual maintenance dose range: 300-600 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      Dosage adjustment in obesity:",
"     </i>",
"     Loading dose: Use adjusted body weight (ABW) correction based on a pharmacokinetic study of phenytoin loading doses in obese patients (Abernethy, 1985). The larger correction factor (ie, 1.33) is due to a doubling of V",
"     <sub>",
"      d",
"     </sub>",
"     estimated in these obese patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     ABW = [(Actual body weight &ndash; IBW) x 1.33] + IBW",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Maximum loading dose: I.V.: 2000 mg (Erstad, 2004)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Maintenance doses should be based on ideal body weight, conventional daily doses with adjustments based upon therapeutic drug monitoring, and clinical effectiveness (Abernethy, 1985; Erstad, 2002; Erstad, 2004).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in renal impairment:",
"     </b>",
"     Phenytoin serum concentrations may be difficult to interpret in renal failure. Monitoring of free (unbound) concentrations or adjustment to allow interpretation is recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in hepatic impairment:",
"     </b>",
"     Safe in usual doses in mild liver disease; clearance may be substantially reduced in cirrhosis and plasma concentration monitoring with dose adjustment advisable. Free phenytoin concentrations should be monitored closely.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F209562\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, extended release, oral, as sodium: 100 mg, 200 mg, 300 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dilantin&reg;: 30 mg, 100 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Phenytek&reg;: 200 mg, 300 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as sodium: 50 mg/mL (2 mL, 5 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Suspension, oral: 100 mg/4 mL (4 mL); 125 mg/5 mL (237 mL, 240 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dilantin-125&reg;: 125 mg/5 mL (240 mL) [contains ethanol &le;0.6%, sodium benzoate; orange-vanilla flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, chewable, oral: 50 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dilantin&reg;: 50 mg [scored]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F209547\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F11441305\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Dilantin&reg;:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM241523.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM241523.pdf",
"     </a>",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1054958\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Extended release capsules: May be administered without regard to meals",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Suspension: Shake well prior to use; measure and administer dose using a calibrated oral dosing syringe (or other accurate dose-measuring device). Absorption is impaired when phenytoin suspension is given concurrently to patients who are receiving continuous nasogastric feedings. A method to resolve this interaction is to divide the daily dose of phenytoin and withhold the administration of nutritional supplements for 1-2 hours before and after each phenytoin dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Parenteral: I.V.: Phenytoin should be administered I.V. directly into a large vein through a large gauge needle or I.V. catheter. I.V. injections should be followed by NS flushes through the same needle or I.V. catheter to avoid local irritation of the vein. I.V. intermittent infusion: Dilute with NS to a concentration of 1-10 mg/mL, use an in-line 0.22 micron filter; avoid extravasation. Avoid I.M. use due to erratic absorption, pain on injection, and precipitation of drug at injection site. pH: 10.0-12.3",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neonates: I.V. infusion rate: Usual maximum rate: 0.5-1 mg/kg/minute; FDA-labeled maximum rate: 1-3 mg/kg/minute;",
"     <b>",
"      Note:",
"     </b>",
"     Most clinicians use a lower maximum rate of infusion in neonates of 0.5-1 mg/kg/minute",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Infants, Children, and Adults: Do not exceed I.V. infusion rate of 1-3 mg/kg/minute; maximum rate: 50 mg/minute",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F209651\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Incompatible",
"     </b>",
"     with D",
"     <sub>",
"      5",
"     </sub>",
"     LR, D",
"     <sub>",
"      5",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     W, fat emulsion 10%,",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS;",
"     <b>",
"      variable stability (consult detailed reference)",
"     </b>",
"     in NS.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Esmolol, famotidine, fluconazole, foscarnet.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Amphotericin B cholesteryl sulfate complex, cefepime, ceftazidime, cimetidine, ciprofloxacin, diltiazem, enalaprilat, fenoldopam, fentanyl, heparin, heparin with hydrocortisone sodium succinate, hydromorphone, linezolid, methadone, micafungin, morphine,  potassium chloride, propofol, sufentanil, theophylline, vasopressin, vitamin B complex with C.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Pantoprazole, tacrolimus.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Incompatible:",
"     </b>",
"     Hydromorphone, ondansetron, pantoprazole, sufentanil.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1054949\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Capsule: Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F) in tightly closed container. Protect from light and moisture.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Suspension: Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); do not freeze. Protect from light.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Tablet, chewable: Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F). Protect from moisture.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Parenteral: Solution for injection: Store intact vial at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F). Parenteral solution may be used as long as there is no precipitate and it is not hazy; slightly yellowed solution may be used; refrigeration may cause precipitate, sometimes the precipitate may be resolved by allowing the solution to reach room temperature again; drug may precipitate with pH &le;11.5; do not mix with other medications.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     I.V. intermittent infusion preparations: No consensus exists in the literature regarding phenytoin stability in I.V. solutions; due to a low solubility, phenytoin may precipitate in aqueous solutions; some centers have successfully used dilutions of 1-10 mg/mL in NS or LR; infusions should begin as soon as possible after preparation (eg, within 1 hour); diluted solutions should not be refrigerated; inspect for particulate matter; discard 4 hours after preparation (Gannaway, 1983).",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1054957\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral: Management of generalized tonic-clonic (grand mal) and complex partial seizures and the prevention of seizures following head trauma/neurosurgery [FDA approved in pediatric patients (age not specified) and adults]. Has also been used for simple partial seizures; ventricular arrhythmias, including those associated with digitalis intoxication, prolonged QT interval, and surgical repair of congenital heart diseases in children",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Parenteral: Management of status epilepticus of the grand mal type and prevention and treatment of seizures occurring during neurosurgery [FDA approved in neonatal and pediatric patients (age not specified) and adults]",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F209653\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Phenytoin may be confused with phenelzine, phentermine, PHENobarbital",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Dilantin&reg; may be confused with Dilaudid&reg;, diltiazem, Dipentum&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication (I.V. formulation) among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Dilantin [U.S., Canada, and multiple international markets] may be confused with Dolantine brand name for pethidine [Belgium]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F209650\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     I.V. effects: Bradycardia, cardiac arrhythmia, cardiovascular collapse (especially with rapid I.V. use), hypotension, thrombophlebitis, venous irritation and pain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Effects not related to plasma phenytoin concentrations:",
"     </b>",
"     carbohydrate intolerance, folic acid deficiency, hypertrichosis, gingival hypertrophy, osteomalacia, peripheral neuropathy, systemic lupus erythematosus, thickening of facial features, vitamin D deficiency",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Concentration-related effects:",
"     </b>",
"     ataxia, blurred vision, coma, confusion, diplopia, dizziness, drowsiness, fever, folic acid depletion, gum tenderness, hyperglycemia, lethargy, mood changes, nausea, nystagmus, osteomalacia, rash, slurred speech, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Related to elevated concentrations:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &gt;20 mcg/mL: Far lateral nystagmus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &gt;30 mcg/mL: 45&deg; lateral gaze nystagmus and ataxia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &gt;40 mcg/mL: Decreased mentation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &gt;100 mcg/mL: Death",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Bradycardia, cardiac arrhythmia, cardiovascular collapse, hypotension",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Dizziness, drowsiness, headache, insomnia, psychiatric changes, slurred speech",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Constipation, gingival hyperplasia, enlargement of lips, nausea, taste disturbance, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Peyronie&rsquo;s disease",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Agranulocytosis, granulocytopenia, leukopenia, pancytopenia, thrombocytopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Hepatitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: I.V. administration: Inflammation, irritation, necrosis, sloughing, tenderness, thrombophlebitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Paresthesia, peripheral neuropathy, tremor",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Blurred vision, diplopia, nystagmus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Anaphylaxis, blood dyscrasias, coarsening of facial features, DRESS, dyskinesias, hepatitis, Hodgkin lymphoma, hypertrichosis, immunoglobulin abnormalities, lymphadenopathy, lymphoma, macrocytosis, megaloblastic anemia, periarteritis nodosa,  pseudolymphoma, SLE-like syndrome, Stevens-Johnson syndrome, toxic epidermal necrolysis, venous irritation and pain",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1054961\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to phenytoin, any component, or other hydantoins; concurrent use of delavirdine [due to loss of virologic response and possible resistance to delavirdine or other non-nucleoside reverse transcriptase inhibitors (NNRTIs)]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Injection: Sinus bradycardia, sinoatrial block, second and third degree AV block, Adams-Stokes syndrome",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1054945\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with any condition associated with low serum albumin levels, which will increase the free fraction of phenytoin in the serum and, therefore, the pharmacologic response. Use with caution in renal impairment; serum concentrations may be difficult to interpret; consider monitoring free (unbound) concentrations. Use with caution in hepatic impairment; clearance may be substantially reduced in cirrhosis; frequent monitoring of free (unbound) serum concentrations should be considered. Use with caution in patients with underlying cardiac disease; use is contraindicated in bradycardia, sinoatrial block, second and third degree heart block, or Adam-Stokes. Use with caution in patients with porphyria; may cause exacerbations. Should not be used to treat absence seizures; has been shown to increase frequency. May cause sedation, confusional states, or cerebellar dysfunction (loss of motor coordination) at higher total serum concentrations, or at lower total serum concentrations when the free fraction of phenytoin is increased; effects with other sedative drugs or ethanol may be potentiated; use with caution in patients who are debilitated.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     May cause gingival overgrowth or hyperplasia; reported incidence up to 60%; some data suggest development associated with higher doses and serum concentrations; folic acid supplementation (0.5 mg/day in pediatric patients &ge;6 years) may help to prevent or decrease gingival overgrowth; patients should be counseled regarding the importance of proper dental hygiene (Arya, 2011).",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1054944\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Rapid intravenous administration may cause hypotension",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     and/or cardiac arrhythmias (eg, heart block, ventricular tachycardia, ventricular fibrillation); to reduce these risks, phenytoin must be administered slowly I.V. Intravenous administration should not exceed 50 mg/minute in adult patients. In neonates, the FDA labeled maximum I.V. administration rate is 1-3 mg/kg/minute;",
"     <b>",
"      Note:",
"     </b>",
"     Most clinicians use a lower maximum rate of infusion in neonates: 0.5-1 mg/kg/minute; in infants and children: 1-3 mg/kg/minute. Adverse cardiac events have been reported at or below the recommended infusion rate; cardiac monitoring is necessary during and after administration of intravenous phenytoin; reduction in rate of administration or discontinuation of infusion may be necessary. For nonemergency use, intravenous phenytoin should be administered more slowly; the use of oral phenytoin should be used whenever possible.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Abrupt withdrawal of phenytoin may precipitate status epilepticus in epileptic patients; do not discontinue abruptly; phenytoin should be withdrawn gradually, unless safety concerns (eg, allergic or hypersensitivity reaction) require a more rapid withdrawal.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Acute hepatotoxicity associated with a hypersensitivity syndrome characterized by fever, skin eruptions, and lymphadenopathy has been reported to occur within the first 2 months of treatment; discontinue if skin rash or lymphadenopathy occurs. Serious skin reactions, including toxic epidermal necrolysis (TEN) and Stevens-Johnson syndrome (SJS), although rarely reported, have resulted in fatalities; phenytoin should be discontinued if there are any signs of rash and patient should be evaluated for signs and symptoms of drug reaction with eosinophilia and systemic symptoms (DRESS). Preliminary data suggests that patients testing positive for the human leukocyte antigen (HLA) allele",
"     <i>",
"      HLA-B*1502",
"     </i>",
"     have an increased risk of developing SJS and/or TEN. The risk appears to be highest in the early months of therapy initiation. The presence of this genetic variant exists in up to 15% of people of Asian descent in China, Thailand, Malaysia, Indonesia, Taiwan, and the Philippines, and may vary from &lt;1% in Japanese and Koreans, to 2% to 4% of South Asians and Indians; this variant is virtually absent in those of Caucasian, African-American, Hispanic, or European ancestry; consider avoiding phenytoin use in patients",
"     <i>",
"      HLA-B*1502",
"     </i>",
"     allele positive if other therapeutic options available.",
"     <b>",
"      Note:",
"     </b>",
"     Carbamazepine, another antiepileptic with a chemical structure similar to phenytoin, includes in the manufacturer labeling a recommendation to screen patients of Asian descent for the",
"     <i>",
"      HLA-B*1502",
"     </i>",
"     allele prior to initiating therapy; this is not a current recommendation in the phenytoin manufacturer labeling.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     A spectrum of hematologic effects have been reported with use (eg, agranulocytosis, neutropenia, leukopenia, thrombocytopenia, pancytopenia, and anemias); patients with a previous history of adverse hematologic reaction to any drug may be at increased risk. Early detection of hematologic change is important; advise patients of early signs and symptoms including fever, sore throat, mouth ulcers, infections, easy bruising, petechial or purpuric hemorrhage.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Chronic use of phenytoin has been associated with decreased bone mineral density (osteopenia, osteoporosis, and osteomalacia) and bone fractures. Chronic use may result in decreased vitamin D concentrations due to hepatic enzyme induction and may lead to hypocalcemia and hypophosphatemia; monitor as appropriate and consider implementing vitamin D and calcium supplementation.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     The \"purple glove syndrome\" (ie, discoloration with edema and pain of distal limb) may occur following peripheral I.V. administration of phenytoin. This syndrome may or may not be associated with drug extravasation. Symptoms may resolve spontaneously; however, skin necrosis and limb ischemia may occur; interventions such as fasciotomies, skin grafts, and amputation may be required. To decrease the risk of this syndrome, inject phenytoin slowly and directly into a large vein through a large gauge needle or I.V. catheter. Follow the I.V. injection with NS flushes through the same needle or I.V. catheter.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Antiepileptic drugs (AEDs) increase the risk of suicidal behavior and ideation in patients receiving these medications for any indication. Pooled analyses of placebo-controlled trials involving 11 different AEDs (regardless of indication) showed a twofold increased risk of suicidal thoughts or behavior (estimated incidence rate: 0.43% in AED treated patients compared to 0.24% of patients receiving placebo); increased risk was observed as early as 1 week after initiation of AED and continued through duration of trials (most trials &le;24 weeks); risk did not vary significantly by age (age range: 5&ndash;100 years). Consider risks and benefits of AEDs before prescribing. Monitor all patients receiving an AED for emergence of suicidal thoughts or behavior, thoughts of self-harm, any unusual changes in behavior or mood, or the emergence or worsening of depressive symptoms; notify healthcare provider immediately if symptoms or concerning behavior occur.",
"     <b>",
"      Note:",
"     </b>",
"     The FDA requires a Medication Guide for all antiepileptic drugs informing patients of this risk.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Dilantin&reg; 30 mg capsule and oral suspension contain sodium benzoate; benzoic acid (benzoate) is a metabolite of benzyl alcohol; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates; the &ldquo;gasping syndrome&rdquo; consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension and cardiovascular collapse; use phenytoin products containing sodium benzoate with caution in neonates;",
"     <i>",
"      in vitro",
"     </i>",
"     and animal studies have shown that benzoate displaces bilirubin from protein binding sites. Injection contains 10% alcohol and 40% propylene glycol; in neonates large amounts of propylene glycol delivered orally, intravenously (eg, &gt;3000 mg/day), or topically have been associated with potentially fatal toxicities which can include metabolic acidosis, seizures, renal failure, and CNS depression; use dosage forms containing propylene glycol with caution in neonates.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F209639\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2C19 (major), CYP2C9 (major), CYP3A4 (minor);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Induces",
"     </b>",
"     CYP2B6 (strong), CYP2C19 (strong), CYP2C8 (strong), CYP2C9 (strong), CYP3A4 (strong)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F209556\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetaminophen: Anticonvulsants (Hydantoin) may increase the metabolism of Acetaminophen. This may 1) diminish the effect of acetaminophen; and 2) increase the risk of liver damage.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): May enhance the CNS depressant effect of Phenytoin. Alcohol (Ethyl) may increase the serum concentration of Phenytoin. This may be particularly applicable with acute, heavy alcohol consumption. Alcohol (Ethyl) may decrease the serum concentration of Phenytoin. This may be particularly applicable with chronic, heavy alcohol consumption.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Allopurinol: May increase the serum concentration of Anticonvulsants (Hydantoin).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amiodarone: May increase the serum concentration of Phenytoin. Phenytoin may decrease the serum concentration of Amiodarone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: May decrease the serum concentration of Phenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May decrease the serum concentration of Anticonvulsants (Hydantoin).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antifungal Agents (Azole Derivatives, Systemic): Phenytoin may decrease the serum concentration of Antifungal Agents (Azole Derivatives, Systemic). Antifungal Agents (Azole Derivatives, Systemic) may increase the serum concentration of Phenytoin.  Management: Concomitant therapy with itraconazole, voriconazole, or ketoconazole and phenytoin should probably be avoided, as antifungal failure is likely.  Consider selecting alternative antifungal therapy.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Apixaban: CYP3A4 Inducers (Strong) may decrease the serum concentration of Apixaban.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inducers may decrease the serum concentration of ARIPiprazole.  Management: Double the oral aripiprazole dose and closely monitor clinical response.  Reduce the oral aripiprazole dose to 10-15 mg/day if the inducer is discontinued. Avoid use of CYP3A4 inducers for more than 14 days with extended-release injectable aripiprazole.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Axitinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Axitinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Barbiturates: Phenytoin may enhance the CNS depressant effect of Barbiturates. Barbiturates may decrease the serum concentration of Phenytoin. Phenytoin may increase the serum concentration of Barbiturates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bedaquiline: CYP3A4 Inducers (Strong) may decrease the serum concentration of Bedaquiline.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benzodiazepines: May increase the serum concentration of Phenytoin. Short-term exposure to benzodiazepines may not present as much risk as chronic therapy.",
"     <b>",
"      Exceptions:",
"     </b>",
"     ALPRAZolam.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Boceprevir: Phenytoin may decrease the serum concentration of Boceprevir.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bortezomib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Bortezomib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosutinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Bosutinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Brentuximab Vedotin: CYP3A4 Inducers (Strong) may decrease the serum concentration of Brentuximab Vedotin. Specifically, concentrations of the active monomethyl auristatin E (MMAE) component may be decreased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of CNS depressants used in combination with buprenorphine.  Consider avoiding other CNS depressants in patients thought to be at high risk of buprenorphine overuse or self-injection.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Busulfan: Phenytoin may decrease the serum concentration of Busulfan.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cabozantinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Cabozantinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers: May increase the serum concentration of Phenytoin. Management: Monitor for phenytoin toxicity with concomitant use of a calcium channel blocker (CCB) or decreased phenytoin effects with CCB discontinuation. Monitor for decreased CCB therapeutic effects. Nimodipine Canadian labeling contraindicates use with phenytoin.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Clevidipine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Canagliflozin: Phenytoin may decrease the serum concentration of Canagliflozin.  Management: Consider increasing canagliflozin dose to 300 mg/day in patients with estimated GFR &gt;60 mL/min/1.73 m2 who tolerate canagliflozin 100 mg/day and require greater glycemic control. Consider alternatives in patients with estimated GFR 45-60 mL/min/1.73 m2.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Capecitabine: May increase the serum concentration of Phenytoin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: May decrease the serum concentration of Phenytoin. CarBAMazepine may increase the serum concentration of Phenytoin. Possibly by competitive inhibition at sites of metabolism. Phenytoin may decrease the serum concentration of CarBAMazepine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Carbonic Anhydrase Inhibitors: May enhance the adverse/toxic effect of Anticonvulsants (Hydantoin). Specifically, osteomalacia and rickets.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Brinzolamide; Dorzolamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Caspofungin: Inducers of Drug Clearance may decrease the serum concentration of Caspofungin.  Management: Consider using an increased caspofungin dose of 70 mg daily in adults (or 70 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     , up to a maximum of 70 mg, daily in pediatric patients) when coadministered with known inducers of drug clearance.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CeFAZolin: May decrease the protein binding of Phenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Chloramphenicol: May decrease the metabolism of Anticonvulsants (Hydantoin). Anticonvulsants (Hydantoin) may decrease the serum concentration of Chloramphenicol. Increased chloramphenicol concentrations have also been seen.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cimetidine: May enhance the adverse/toxic effect of Anticonvulsants (Hydantoin). Cimetidine may increase the serum concentration of Anticonvulsants (Hydantoin). Management: Consider using an alternative H",
"     <sub>",
"      2",
"     </sub>",
"     -antagonist to avoid this interaction. Monitor for toxic effects of hydantoin anticonvulsants if cimetidine is initiated/dose increased.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ciprofloxacin (Systemic): May decrease the serum concentration of Phenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CISplatin: May decrease the serum concentration of Phenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Clarithromycin: CYP3A4 Inducers (Strong) may increase serum concentrations of the active metabolite(s) of Clarithromycin. Clarithromycin may increase the serum concentration of CYP3A4 Inducers (Strong). CYP3A4 Inducers (Strong) may decrease the serum concentration of Clarithromycin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloZAPine: Phenytoin may decrease the serum concentration of CloZAPine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cobicistat: Fosphenytoin-Phenytoin may decrease the serum concentration of Cobicistat.  Management: Consider using an alternative antiepileptic when possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Colesevelam: May decrease the serum concentration of Phenytoin. Management: Administer phenytoin at least 4 hours prior to colesevelam.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Contraceptives (Estrogens): Phenytoin may diminish the therapeutic effect of Contraceptives (Estrogens). Contraceptive failure is possible.  Management: Use of an alternative, nonhormonal means of contraception is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Contraceptives (Progestins): Phenytoin may diminish the therapeutic effect of Contraceptives (Progestins). Contraceptive failure is possible.  Management: Contraceptive failure is possible.  Use of an alternative, nonhormonal contraceptive is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cosyntropin: May enhance the hepatotoxic effect of Phenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Crizotinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Crizotinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): Phenytoin may increase the metabolism of CycloSPORINE (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2B6 Substrates: CYP2B6 Inducers (Strong) may increase the metabolism of CYP2B6 Substrates.  Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C19 Inducers (Strong): May increase the metabolism of CYP2C19 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C19 Inhibitors (Moderate): May decrease the metabolism of CYP2C19 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C19 Inhibitors (Strong): May decrease the metabolism of CYP2C19 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C19 Substrates: CYP2C19 Inducers (Strong) may increase the metabolism of CYP2C19 Substrates.  Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C8 Substrates: CYP2C8 Inducers (Strong) may increase the metabolism of CYP2C8 Substrates.  Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Inducers (Strong): May increase the metabolism of CYP2C9 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Inhibitors (Moderate): May decrease the metabolism of CYP2C9 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Inhibitors (Strong): May decrease the metabolism of CYP2C9 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Substrates: CYP2C9 Inducers (Strong) may increase the metabolism of CYP2C9 Substrates.  Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Substrates: CYP3A4 Inducers (Strong) may increase the metabolism of CYP3A4 Substrates.  Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Darunavir: Phenytoin may decrease the serum concentration of Darunavir.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Dasatinib.  Management: Avoid when possible. If such a combination cannot be avoided, consider increasing dasatinib dose and monitor clinical response and toxicity closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: Phenytoin may decrease the serum concentration of Deferasirox.  Management: Avoid combination when possible; if the combination must be used, consider a 50% increase in initial deferasirox dose, with monitoring of serum ferritin concentrations and clinical responses to guide further dosing.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Delavirdine: May increase the serum concentration of Phenytoin. Phenytoin may decrease the serum concentration of Delavirdine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dexmethylphenidate: May increase the serum concentration of Phenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Diazoxide: May decrease the serum concentration of Phenytoin. Total phenytoin concentrations may be affected more than free phenytoin concentrations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Diclofenac (Systemic): CYP2C9 Inducers (Strong) may decrease the serum concentration of Diclofenac (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Disopyramide: Phenytoin may decrease the serum concentration of Disopyramide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Disulfiram: May increase the serum concentration of Phenytoin. Management: Avoid concomitant use of disulfiram and phenytoin when possible.  Phenytoin dose adjustment will likely be necessary when starting and/or stopping concurrent disulfiram.  Monitor phenytoin response and concentrations closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Divalproex: May decrease the serum concentration of Phenytoin. Phenytoin may decrease the serum concentration of Divalproex.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Doxycycline: Phenytoin may decrease the serum concentration of Doxycycline.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dronedarone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Dronedarone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Efavirenz: May increase the serum concentration of Phenytoin. Phenytoin may decrease the serum concentration of Efavirenz.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Elvitegravir: Fosphenytoin-Phenytoin may decrease the serum concentration of Elvitegravir.  Management: Consider using an alternative antiepileptic when possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Enzalutamide: May decrease the serum concentration of Fosphenytoin-Phenytoin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ethosuximide: May enhance the CNS depressant effect of Phenytoin. Ethosuximide may increase the serum concentration of Phenytoin. Phenytoin may decrease the serum concentration of Ethosuximide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Etoposide: Phenytoin may decrease the serum concentration of Etoposide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Etoposide Phosphate: Phenytoin may decrease the serum concentration of Etoposide Phosphate. Phenytoin may increase the metabolism, via CYP isoenzymes, of etoposide phosphate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Etravirine: Phenytoin may decrease the serum concentration of Etravirine.  Management: The manufacturer of etravirine states these drugs should not be used in combination",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Everolimus: CYP3A4 Inducers (Strong) may decrease the serum concentration of Everolimus.  Management: Avoid concurrent use of strong CYP3A4 inducers, but if strong CYP3A4 inducers cannot be avoided, consider gradually (in 5 mg increments) increasing the everolimus dose from 10 mg/day to 20 mg/day (adult doses).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Exemestane: CYP3A4 Inducers (Strong) may decrease the serum concentration of Exemestane.  Management: Exemestane U.S. product labeling recommends using an increased dose (50 mg/day) in patients receiving concurrent strong CYP3A4 inducers. The Canadian product labeling does not recommend a dose adjustment  with concurrent use of strong CYP3A4 inducers.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Felbamate: May increase the serum concentration of Phenytoin. Phenytoin may decrease the serum concentration of Felbamate. Management: Decreased phenytoin dose will likely be needed when adding felbamate; some reports suggest an empiric 20% decrease in phenytoin dose. Additional reductions may be needed if felbamate dose is increased or as otherwise guided by monitoring.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Floxuridine: May increase the serum concentration of Phenytoin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluconazole: May increase the serum concentration of Phenytoin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Flunarizine: Phenytoin may decrease the serum concentration of Flunarizine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluorouracil (Systemic): May increase the serum concentration of Phenytoin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluorouracil (Topical): May increase the serum concentration of Phenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     FLUoxetine: May increase the serum concentration of Phenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     FluvoxaMINE: May increase the serum concentration of Phenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Folic Acid: May decrease the serum concentration of Phenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosamprenavir: May decrease the serum concentration of Phenytoin. The active amprenavir metabolite is likely responsible for this effect. Phenytoin may increase the serum concentration of Fosamprenavir. Specifically, phenytoin may increase the concentration of the active metabolite amprenavir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gefitinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Gefitinib.  Management: In the absence of severe adverse drug reactions, consider increasing gefitinib dose to 500 mg daily in patients receiving strong CYP3A4 inducers.  Carefully monitor clinical response and development of adverse reactions.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     GuanFACINE: CYP3A4 Inducers (Strong) may decrease the serum concentration of GuanFACINE.  Management: Consider increasing the guanfacine dose by 2-fold when adding a strong CYP3A4 inducer.  Titrate the guanfacine dose up to a max of 8 mg/day when starting guanfacine in a patient who is taking a strong CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Halothane: May increase the serum concentration of Phenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HMG-CoA Reductase Inhibitors: Phenytoin may decrease the serum concentration of HMG-CoA Reductase Inhibitors.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Pitavastatin; Rosuvastatin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ifosfamide: CYP3A4 Inducers (Strong) may increase serum concentrations of the active metabolite(s) of Ifosfamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Imatinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Imatinib.  Management: Avoid concurrent use of imatinib with strong CYP3A4 inducers when possible.  If such a combination must be used, increase imatinib dose by at least 50% and monitor the patient's clinical response closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Irinotecan: Phenytoin may decrease the serum concentration of Irinotecan. Concentrations of the active metabolite SN-38 may also be reduced.  Management: Change to a non-enzyme inducing anticonvulsant, when clinically possible, at least 2 weeks prior to beginning irinotecan.  Dosage increases for irinotecan may be needed when used with phenytoin, but specific dosing guidelines are not available.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Isoniazid: May increase the serum concentration of Phenytoin. Management: Consider alternatives. If concomitant therapy cannot be avoided, monitor for increased phenytoin concentrations/effects with isoniazid initiation/dose increase, or decreased concentrations/effects with isoniazid discontinuation/dose decrease.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ivacaftor.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ixabepilone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ixabepilone.  Management: Avoid this combination whenever possible.  If this combination must be used, a gradual increase in ixabepilone dose from 40 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     to 60 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     (given as a 4-hour infusion), as tolerated, should be considered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketorolac (Nasal): May diminish the therapeutic effect of Anticonvulsants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketorolac (Systemic): May diminish the therapeutic effect of Anticonvulsants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lacosamide: Phenytoin may decrease the serum concentration of Lacosamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     LamoTRIgine: Phenytoin may decrease the serum concentration of LamoTRIgine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lapatinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Lapatinib.  Management: If therapy overlap cannot be avoided, consider titrating lapatinib gradually from 1,250 mg/day up to 4,500 mg/day (HER2 positive metastatic breast cancer) or 1,500 mg/day up to 5,500 mg/day (hormone receptor/HER2 positive breast cancer) as tolerated.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leucovorin Calcium-Levoleucovorin: May decrease the serum concentration of Phenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Levodopa: Phenytoin may diminish the therapeutic effect of Levodopa.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Levomefolate: May decrease the serum concentration of Phenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Linagliptin: CYP3A4 Inducers (Strong) may decrease the serum concentration of Linagliptin.  Management: Strongly consider using an alternative to any strong CYP3A4 inducer in patients who are being treated with linagliptin. If this combination is used, monitor patients closely for evidence of reduced linagliptin effectiveness.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: Phenytoin may enhance the adverse/toxic effect of Lithium.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: Phenytoin may diminish the diuretic effect of Loop Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lopinavir: May decrease the serum concentration of Phenytoin. Phenytoin may decrease the serum concentration of Lopinavir. Management: The manufacturer of lopinavir/ritonavir recommends avoiding once-daily administration if used together with phenytoin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lurasidone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Lurasidone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Maraviroc: CYP3A4 Inducers (Strong) may decrease the serum concentration of Maraviroc.  Management: Increase maraviroc adult dose to 600 mg twice daily when used with strong CYP3A4 inducers. This does not apply to patients also receiving strong CYP3A4 inhibitors. Do not use maraviroc with strong CYP3A4 inducers in patients with Clcr less than 30 mL/min.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mebendazole: Phenytoin may decrease the serum concentration of Mebendazole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mefloquine: May diminish the therapeutic effect of Anticonvulsants. Mefloquine may decrease the serum concentration of Anticonvulsants. Management: Mefloquine is contraindicated for malaria prophylaxis in persons with a history of convulsions.  Monitor anticonvulsant concentrations and treatment response closely with concurrent use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Meperidine: Phenytoin may decrease the serum concentration of Meperidine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methadone: Phenytoin may decrease the serum concentration of Methadone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylfolate: May decrease the serum concentration of Phenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: May increase the serum concentration of Phenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MethylPREDNISolone: Phenytoin may decrease the serum concentration of MethylPREDNISolone.  Management: Consider an alternative corticosteroid. If this combination cannot be avoided, monitor for diminished methylprednisolone effects during phenytoin treatment, and increased methylprednisolone effects following phenytoin discontinuation.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MetroNIDAZOLE (Systemic): May increase the serum concentration of Phenytoin. Phenytoin may decrease the serum concentration of MetroNIDAZOLE (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrapone: Phenytoin may decrease the serum concentration of Metyrapone. The oral metyrapone test would thus be unreliable unless the metapyrone dosage was substantially increased (e.g., 750 mg every 2 hours).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mexiletine: Phenytoin may decrease the serum concentration of Mexiletine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Mifepristone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP2C9 Substrates. Management: Use CYP2C9 substrates at the lowest recommended dose, and monitor closely for adverse effects, during and in the 2 weeks following mifepristone treatment.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): May decrease the serum concentration of Fosphenytoin-Phenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nelfinavir: May decrease the serum concentration of Phenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nilotinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Nilotinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     OXcarbazepine: Fosphenytoin-Phenytoin may decrease serum concentrations of the active metabolite(s) of OXcarbazepine. Specifically, concentrations of the major active 10-monohydroxy metabolite may be reduced. OXcarbazepine may increase the serum concentration of Fosphenytoin-Phenytoin.  Management: Consider increasing the initial adult oxcarbazepine extended release tablet (Oxtellar XR) dose to 900 mg/day. No specific recommendations are available for other oxcarbazepine formulations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pazopanib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Pazopanib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2C9 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: Fosphenytoin-Phenytoin may decrease the serum concentration of Perampanel.  Management: Increase the perampanel starting dose to 4 mg/day when perampanel is used with phenytoin/fosphenytoin.  Patients receiving this combination should be followed closely for response, especially with any changes to phenytoin/fosphenytoin therapy.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pomalidomide: CYP3A4 Inducers (Strong) may decrease the serum concentration of Pomalidomide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ponatinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ponatinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Praziquantel: CYP3A4 Inducers (Strong) may decrease the serum concentration of Praziquantel.  Management: Avoid concomitant use of praziquantel with strong CYP3A4 inducers. Discontinue rifampin 4 weeks prior to initiation of praziquantel therapy. Rifampin may be resumed the day following praziquantel completion.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PrednisoLONE (Systemic): Phenytoin may decrease the serum concentration of PrednisoLONE (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PredniSONE: Phenytoin may decrease serum concentrations of the active metabolite(s) of PredniSONE.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prilocaine: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Prilocaine. Combinations of these agents may increase the likelihood of significant methemoglobinemia.  Management: Monitor patients for signs of methemoglobinemia (e.g., hypoxia, cyanosis) when prilocaine is used in combination with other agents associated with development of methemoglobinemia.  Avoid lidocaine/prilocaine in infants receiving such agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Primidone: Phenytoin may increase the metabolism of Primidone. The ratio of primidone:phenobarbital is thus changed.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Proton Pump Inhibitors: May increase the serum concentration of Phenytoin.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Dexlansoprazole; Esomeprazole; Lansoprazole; Pantoprazole; RABEprazole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pyridoxine: May increase the metabolism of Phenytoin. This is most apparent in high pyridoxine doses (e.g., 80 mg to 200 mg daily)",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QUEtiapine: Phenytoin may decrease the serum concentration of QUEtiapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNIDine: Phenytoin may decrease the serum concentration of QuiNIDine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNINE: Phenytoin may decrease the serum concentration of QuiNINE.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ranolazine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ranolazine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Regorafenib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Regorafenib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: May decrease the serum concentration of Phenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rilpivirine: Phenytoin may decrease the serum concentration of Rilpivirine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ritonavir: Phenytoin may decrease the serum concentration of Ritonavir. Ritonavir may decrease the serum concentration of Phenytoin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rivaroxaban: CYP3A4 Inducers (Strong) may decrease the serum concentration of Rivaroxaban.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Roflumilast: CYP3A4 Inducers (Strong) may decrease the serum concentration of Roflumilast.  Management: Roflumilast U.S. prescribing information recommends against combining strong CYP3A4 inducers with roflumilast.  The Canadian product monograph makes no such recommendation but notes that such agents may reduce roflumilast therapeutic effects.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RomiDEPsin: CYP3A4 Inducers (Strong) may decrease the serum concentration of RomiDEPsin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rufinamide: Phenytoin may decrease the serum concentration of Rufinamide. Rufinamide may increase the serum concentration of Phenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saxagliptin: CYP3A4 Inducers may decrease the serum concentration of Saxagliptin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sertraline: Phenytoin may decrease the serum concentration of Sertraline. Sertraline may increase the serum concentration of Phenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sirolimus: Phenytoin may decrease the serum concentration of Sirolimus.  Management: Monitor for decreased sirolimus serum concentrations if phenytoin is initiated/dose increased. Monitor for increased sirolimus concentrations with phenytoin discontinuation/dose decrease. Sirolimus dose adjustments may be necessary.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     SORAfenib: CYP3A4 Inducers (Strong) may decrease the serum concentration of SORAfenib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sulfonamide Derivatives: May increase the serum concentration of Phenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     SUNItinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of SUNItinib.  Management: Avoid when possible. If such a combination cannot be avoided, consider increasing sunitinib dose and monitor clinical response and toxicity closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Systemic): Phenytoin may decrease the serum concentration of Tacrolimus (Systemic). Tacrolimus (Systemic) may increase the serum concentration of Phenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tadalafil: CYP3A4 Inducers (Strong) may decrease the serum concentration of Tadalafil.  Management: Erectile dysfunction: monitor for decreased effectiveness - no standard dose adjustments recommended.  Avoid use of tadalafil for pulmonary arterial hypertension in patients receiving a strong CYP3A4 inducer.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: Phenytoin may decrease the serum concentration of Telaprevir. Telaprevir may decrease the serum concentration of Phenytoin. Telaprevir may increase the serum concentration of Phenytoin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Temsirolimus: Phenytoin may decrease the serum concentration of Temsirolimus. Concentrations of the active metabolite, sirolimus, are also likely to be decreased (and maybe to an even greater degree).  Management: Temsirolimus prescribing information recommends against coadministration with strong CYP3A4 inducers such as phenytoin; however, if concurrent therapy is necessary, an increase in temsirolimus adult dose to 50 mg/week should be considered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Teniposide: Phenytoin may decrease the serum concentration of Teniposide.  Management: Consider alternatives to combined treatment with phenytoin and teniposide due to the potential for decreased teniposide concentrations.  If the combination cannot be avoided, monitor teniposide response closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Theophylline Derivatives: May decrease the serum concentration of Phenytoin. Phenytoin may decrease the serum concentration of Theophylline Derivatives.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Dyphylline.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thyroid Products: Phenytoin may decrease the serum concentration of Thyroid Products. Phenytoin may also displace thyroid hormones from protein binding sites.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ticagrelor: CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of Ticagrelor. CYP3A4 Inducers (Strong) may decrease the serum concentration of Ticagrelor.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ticlopidine: May increase the serum concentration of Phenytoin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tipranavir: Phenytoin may decrease the serum concentration of Tipranavir. Tipranavir may decrease the serum concentration of Phenytoin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Tofacitinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolvaptan: CYP3A4 Inducers (Strong) may decrease the serum concentration of Tolvaptan.  Management: If concurrent use is necessary, increased doses of tolvaptan (with close monitoring for toxicity and clinical response) may be needed.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topiramate: Phenytoin may decrease the serum concentration of Topiramate. Topiramate may increase the serum concentration of Phenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Toremifene: CYP3A4 Inducers (Strong) may decrease the serum concentration of Toremifene.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     TraZODone: Phenytoin may decrease the serum concentration of TraZODone. TraZODone may increase the serum concentration of Phenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Treprostinil: CYP2C8 Inducers (Strong) may decrease the serum concentration of Treprostinil.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trimethoprim: May increase the serum concentration of Phenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ulipristal: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ulipristal.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Valproic Acid: Phenytoin may increase the metabolism of Valproic Acid. A hepatotoxic metabolite of valproic acid may result. Valproic Acid may decrease the serum concentration of Phenytoin. Continued therapy usually yields a normalization (or slight increase) of serum phenytoin concentrations.  Free phenytoin concentrations, however, tend to remain relatively stable (possibly increased with continued therapy).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vandetanib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Vandetanib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vecuronium: Phenytoin may enhance the therapeutic effect of Vecuronium. Phenytoin may diminish the therapeutic effect of Vecuronium. Phenytoin may decrease the serum concentration of Vecuronium.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vemurafenib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Vemurafenib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vigabatrin: May decrease the serum concentration of Phenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     VinCRIStine: Phenytoin may decrease the serum concentration of VinCRIStine. VinCRIStine may decrease the serum concentration of Phenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     VinCRIStine (Liposomal): CYP3A4 Inducers (Strong) may decrease the serum concentration of VinCRIStine (Liposomal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Phenytoin may enhance the anticoagulant effect of Vitamin K Antagonists. Vitamin K Antagonists may increase the serum concentration of Phenytoin.  Management: Anticoagulant dose adjustment will likely be necessary when phenytoin is initiated or discontinued.  Monitor patients extra closely (INR and signs/symptoms of bleeding) when using this combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zonisamide: Phenytoin may decrease the serum concentration of Zonisamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zuclopenthixol: CYP3A4 Inducers (Strong) may decrease the serum concentration of Zuclopenthixol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1054964\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Food may effect absorption of phenytoin, depending on product formulation; a high fat meal decreases the rate, but not the extent of absorption of 100 mg Dilantin&reg; Kapseals (Cook, 2001); a high fat meal decreased the bioavailability of a generic extended phenytoin sodium capsule (Mylan) by 13% compared to Dilantin&reg; Kapseals; when taken with a high fat meal, substituting the generic product for Dilantin&reg; could result in a 37% decrease in serum phenytoin concentrations; substituting Dilantin&reg; for the generic could result in a 102% increase in plasma phenytoin concentrations; thus, when taking phenytoin sodium with food, switching products may result in decreased efficacy or increased toxicity (Wilder, 2001)",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Tube feedings decrease phenytoin bioavailability; to avoid decreased serum levels with continuous NG feeds, hold feedings for 2 hours prior to and 2 hours after phenytoin administration, if possible; phenytoin may increase the metabolism of vitamins D and K; dietary requirements of vitamins D, K, B",
"     <sub>",
"      12",
"     </sub>",
"     , folate, and calcium may be increased with long-term use; high doses of folate may decrease bioavailability of phenytoin; avoid giving calcium or magnesium supplements at the same time as phenytoin, space administration by &ge;2 hours",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F209558\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F209573\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Phenytoin crosses the placenta. Congenital malformations (including a pattern of malformations termed the &ldquo;fetal hydantoin syndrome&rdquo; or &ldquo;fetal anticonvulsant syndrome&rdquo;) have been reported in infants. Isolated cases of malignancies (including neuroblastoma) and coagulation defects in the neonate following delivery have also been reported. Epilepsy itself, the number of medications, genetic factors, or a combination of these probably influence the teratogenicity of anticonvulsant therapy.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Total plasma concentrations of phenytoin are decreased by 56% in the mother during pregnancy; unbound plasma (free) concentrations are decreased by 31%. Because protein binding is decreased, monitoring of unbound plasma concentrations is recommended. Concentrations should be monitored through the 8th week postpartum. The use of folic acid throughout pregnancy and vitamin K during the last month of pregnancy is recommended.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Patients exposed to phenytoin during pregnancy are encouraged to enroll themselves into the AED Pregnancy Registry by calling 1-888-233-2334. Additional information is available at www.aedpregnancyregistry.org.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1054952\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     CBC with differential, liver function, suicidality (eg, suicidal thoughts, depression, behavioral changes), bone growth or BMD",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Serum phenytoin concentrations: If available, free phenytoin concentrations should be obtained in patients with hyperbilirubinemia, renal impairment, uremia, or hypoalbuminemia; in adult patients, if free phenytoin concentrations are unavailable, the adjusted total concentration may be determined based upon equations. Trough serum concentrations are generally recommended for routine monitoring. To ensure therapeutic concentration is attained, peak serum concentrations may be measured 1 hour after the end of an I.V. infusion (particularly after a loading dose).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Additional monitoring with I.V. use: Continuous cardiac monitoring (rate, rhythm, blood pressure) and clinical observation during administration is recommended; blood pressure and pulse should be monitored every 15 minutes for 1 hour after administration with nonemergency use (Meek, 1999); emergency use may require more frequent monitoring and for a longer time after administration; infusion site reactions",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F1054956\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Timing of serum samples: Because it is slowly absorbed, peak blood levels may occur 4-8 hours after ingestion of an oral dose. The serum half-life varies with the dosage and the drug follows Michaelis-Menten kinetics. In adults, the average half-life is about 24 hours; in pediatric patients, the half-life is age-dependent (longer in neonates). Steady-state concentrations are reached in 5-10 days.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Toxicity is measured clinically, and some patients may require levels outside the suggested therapeutic range.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Therapeutic range:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Total phenytoin:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Neonates: 8-15 mcg/mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Pediatric patients &ge;1 month and Adults: 10-20 mcg/mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Concentrations of 5-10 mcg/mL may be therapeutic for some patients, but concentrations &lt;5 mcg/mL are not likely to be effective",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50% of patients show decreased frequency of seizures at concentrations &gt;10 mcg/mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     86% of patients show decreased frequency of seizures at concentrations &gt;15 mcg/mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Add another anticonvulsant if satisfactory therapeutic response is not achieved with a phenytoin concentration of 20 mcg/mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Free phenytoin: 1-2.5 mcg/mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Total phenytoin:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Toxic:",
"     </i>",
"     &gt;30 mcg/mL (SI: &gt;119 micromole/L)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Lethal:",
"     </i>",
"     &gt;100 mcg/mL (SI: &gt;400 micromole/L)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      When to draw levels:",
"     </b>",
"     This is dependent on the disease state being treated and the clinical condition of the patient.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Key points:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Slow absorption of extended capsules and prolonged half-life minimize fluctuations between peak and trough concentrations, timing of sampling not crucial.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Trough concentrations are generally recommended for routine monitoring. Daily levels are not necessary and may result in incorrect dosage adjustments. If it is determined essential to monitor free phenytoin concentrations, concomitant monitoring of total phenytoin concentrations is not necessary and expensive.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     After a loading dose: If rapid therapeutic levels are needed, initial levels may be drawn after 1 hour (I.V. loading dose) or within 24 hours (oral loading dose) to aid in determining maintenance dose or need to reload.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Rapid achievement: Draw within 2-3 days of therapy initiation to ensure that the patient's metabolism is not remarkably different from that which would be predicted by average literature-derived pharmacokinetic parameters; early levels should be used cautiously in design of new dosing regimens.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Second concentration: Draw within 6-7 days with subsequent doses of phenytoin adjusted accordingly.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     If plasma concentrations have not changed over a 3- to 5-day period, monitoring interval may be increased to once weekly in the acute clinical setting.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     In stable patients requiring long-term therapy, generally monitor levels at 3- to 12-month intervals.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Adjustment of serum concentration:",
"     </b>",
"     See tables.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Although it is ideal to obtain free phenytoin concentrations to assess serum concentrations in patients with hypoalbuminemia or renal failure (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &le;10 mL/minute), it may not always be possible. If free phenytoin concentrations are unavailable, the following equations may be utilized in adult patients.",
"    </p>",
"    <table border=\"1\" frame=\"border\" rules=\"all\">",
"     <caption style=\"text-align:center;\">",
"      Adjustment of Serum Concentration in Adults With Low Serum Albumin",
"     </caption>",
"     <col align=\"center\" width=\"120\">",
"     </col>",
"     <col align=\"center\" width=\"87\">",
"     </col>",
"     <col align=\"center\" width=\"87\">",
"     </col>",
"     <col align=\"center\" width=\"88\">",
"     </col>",
"     <col align=\"center\" width=\"88\">",
"     </col>",
"     <thead valign=\"middle\">",
"      <tr>",
"       <th align=\"center\" rowspan=\"3\">",
"        <p style=\"text-indent:0em;\">",
"         Measured Total Phenytoin Concentration",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         (mcg/mL)",
"        </p>",
"       </th>",
"       <th align=\"center\" colspan=\"4\">",
"        <p style=\"text-indent:0em;\">",
"         Adult Patient's Serum Albumin (g/dL)",
"        </p>",
"       </th>",
"      </tr>",
"      <tr>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         3.5",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         3",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         2.5",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         2",
"        </p>",
"       </th>",
"      </tr>",
"      <tr>",
"       <th align=\"center\" colspan=\"4\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         Adjusted Total Phenytoin Concentration (mcg/mL)",
"         <sup>",
"          1",
"         </sup>",
"        </p>",
"       </th>",
"      </tr>",
"     </thead>",
"     <tbody valign=\"middle\">",
"      <tr>",
"       <td align=\"center\" colspan=\"5\">",
"        <p style=\"text-indent:0em;\">",
"         <sup>",
"          1",
"         </sup>",
"         Adjusted concentration = measured total concentration divided by [(0.2 x albumin) + 0.1].",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         5",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         6",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         7",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         8",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         10",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         10",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         13",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         14",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         17",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         20",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         15",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         19",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         21",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         25",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         30",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"    <table border=\"1\" frame=\"border\" rules=\"all\">",
"     <caption style=\"text-align:center;\">",
"      Adjustment of Serum Concentration in Adults With Renal Failure (Cl",
"      <sub>",
"       cr",
"      </sub>",
"      &le;10 mL/min)",
"     </caption>",
"     <col align=\"center\" width=\"120\">",
"     </col>",
"     <col align=\"center\" width=\"70\">",
"     </col>",
"     <col align=\"center\" width=\"70\">",
"     </col>",
"     <col align=\"center\" width=\"70\">",
"     </col>",
"     <col align=\"center\" width=\"70\">",
"     </col>",
"     <col align=\"center\" width=\"70\">",
"     </col>",
"     <thead valign=\"middle\">",
"      <tr>",
"       <th align=\"center\" rowspan=\"3\">",
"        <p style=\"text-indent:0em;\">",
"         Measured Total Phenytoin Concentration",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         (mcg/mL)",
"        </p>",
"       </th>",
"       <th align=\"center\" colspan=\"5\">",
"        <p style=\"text-indent:0em;\">",
"         Adult Patient's Serum Albumin (g/dL)",
"        </p>",
"       </th>",
"      </tr>",
"      <tr>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         4",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         3.5",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         3",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         2.5",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         2",
"        </p>",
"       </th>",
"      </tr>",
"      <tr>",
"       <th align=\"center\" colspan=\"5\">",
"        <p style=\"text-indent:0em;\">",
"         Adjusted Total Phenytoin Concentration (mcg/mL)",
"         <sup>",
"          1",
"         </sup>",
"        </p>",
"       </th>",
"      </tr>",
"      <tr>",
"       <th align=\"center\" colspan=\"6\">",
"        <p style=\"text-indent:0em;\">",
"         <sup>",
"          1",
"         </sup>",
"         Adjusted concentration = measured total concentration divided by [(0.1 x albumin) + 0.1].",
"        </p>",
"       </th>",
"      </tr>",
"     </thead>",
"     <tbody valign=\"middle\">",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         5",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         10",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         11",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         13",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         14",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         17",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         10",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         20",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         22",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         25",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         29",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         33",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         15",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         30",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         33",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         38",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         43",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         50",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1054943\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stabilizes neuronal membranes and decreases seizure activity by increasing efflux or decreasing influx of sodium ions across cell membranes in the motor cortex during generation of nerve impulses; prolongs effective refractory period and suppresses ventricular pacemaker automaticity, shortens action potential in the heart",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1054960\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Oral: Slow, variable; dependent on product formulation; decreased in neonates",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     :",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neonates:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Premature: 1-1.2 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Full-term: 0.8-0.9 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Infants: 0.7-0.8 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children: 0.7 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: 0.6-0.7 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: Adults: 90% to 95%; Neonates: Increased free fraction of phenytoin (up to 20%) and decreased protein binding; Infants: Increased free fraction of phenytoin (up to 15%) and decreased protein binding; also increased free fraction in patients with hyperbilirubinemia, hypoalbuminemia, renal dysfunction, or uremia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Follows dose-dependent (Michaelis-Menten) pharmacokinetics; &ldquo;apparent&rdquo; or calculated half-life is dependent upon serum concentration, therefore, metabolism is best described in terms of K",
"     <sub>",
"      m",
"     </sub>",
"     and V",
"     <sub>",
"      max",
"     </sub>",
"     ; V",
"     <sub>",
"      max",
"     </sub>",
"     is increased in infants &gt;6 months and children compared to adults; major metabolite (via oxidation) HPPA undergoes enterohepatic recycling and elimination in urine as glucuronides",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Formulation dependent",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 7-42 hours; in newborns (PNA &lt;7 days): Half-life greatly increased (clearance decreased) and then rapidly accelerates to infant levels by 5 weeks of life;",
"     <b>",
"      Note:",
"     </b>",
"     Elimination is not first-order and follows Michaelis-Menten pharmacokinetics; half-life increases with increasing phenytoin concentrations",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: Oral: Dependent upon formulation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Extended release capsule: Within 4-12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Immediate release preparation: Within 2-3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: &lt;5% excreted unchanged in urine; increased clearance and decreased serum concentrations with febrile illness; highly variable clearance, dependent upon intrinsic hepatic function and dose administered",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1054951\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?7/49/7958?source=see_link\">",
"      see \"Phenytoin: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Avoid alcohol. May cause drowsiness and impair ability to perform activities requiring mental alertness or physical coordination. Do not change brand or dosage without consulting physician. Do not abruptly discontinue (an increase in seizure activity may result). Maintain good oral hygiene. Antiepileptic agents may increase the risk of suicidal thoughts and behavior; notify physician if you feel more depressed or have thoughts of suicide or self harm. Report chest pain, irregular heartbeat, or palpitations; slurred speech, unsteady gait, coordination difficulties, or change in mentation; skin rash; unresolved nausea, vomiting, or constipation; swollen glands; swollen, sore, or bleeding gums; unusual bruising or bleeding; acute persistent fatigue; vision changes; or other persistent adverse effects. Report worsening of seizure activity or loss of seizure control.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Abernethy DR and Greenblatt DJ, \"Phenytoin Disposition in Obesity. Determination of Loading Dose,\"",
"      <i>",
"       Arch Neurol",
"      </i>",
"      , 1985, 42(5):468-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/19/33082/abstract-text/3994563/pubmed\" id=\"3994563\" target=\"_blank\">",
"        3994563",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Drugs, \"'Inactive\" Ingredients in Pharmaceutical Products: Update (Subject Review),\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1997, 99(2):268-78.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/19/33082/abstract-text/9024461/pubmed\" id=\"9024461\" target=\"_blank\">",
"        9024461",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Arya R, Gulati S, Kabra M, et al, \"Folic Acid Supplementation Prevents Phenytoin-Induced Gingival Overgrowth in Children,\"",
"      <i>",
"       Neurology",
"      </i>",
"      , 76(15):1338-43.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/19/33082/abstract-text/21482950/pubmed\" id=\"21482950\" target=\"_blank\">",
"        21482950",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Au Yeung SC and Ensom MH, \"Phenytoin and Enteral Feedings: Does Evidence Support an Interaction?\"",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 2000, 34(7-8):896-905.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/19/33082/abstract-text/10928402/pubmed\" id=\"10928402\" target=\"_blank\">",
"        10928402",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bauer LA and Blouin RA, &ldquo;Phenytoin Michaelis-Menten Pharmacokinetics in Caucasian Pediatric Patients,&rdquo;",
"      <i>",
"       Clin Pharmacokinet",
"      </i>",
"      , 1983, 8(6):545-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/19/33082/abstract-text/6653035/pubmed\" id=\"6653035\" target=\"_blank\">",
"        6653035",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Black J, Hannaman T, and Malone C, \"The Relationship of Serum Albumin Level to Phenytoin Toxicity,\"",
"      <i>",
"       J Clin Pharmacol",
"      </i>",
"      , 1987, 27(3):249-50.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/19/33082/abstract-text/3680582/pubmed\" id=\"3680582\" target=\"_blank\">",
"        3680582",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chiba K, Ishizaki T, Miura H, et al, &ldquo;Michaelis-Menten Pharmacokinetics of Diphenylhydantoin and Application in the Pediatric Age Patient,&rdquo;",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 1980, 96(3 Pt 1):479-84.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/19/33082/abstract-text/7359247/pubmed\" id=\"7359247\" target=\"_blank\">",
"        7359247",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cook J, Randinitis E, and Wilder BJ, &ldquo;Effect of Food on the Bioavailability of 100-mg Dilantin&reg; Kapseals,&rdquo;",
"      <i>",
"       Neurology",
"      </i>",
"      , 2001, 57(4):698-700.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/19/33082/abstract-text/11524482/pubmed\" id=\"11524482\" target=\"_blank\">",
"        11524482",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Erstad BL, \"Dosing of Medications in Morbidly Obese Patients in the Intensive Care Unit Setting,\"",
"      <i>",
"       Intensive Care Med",
"      </i>",
"      , 2004, 30(1):18-32.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/19/33082/abstract-text/14625670/pubmed\" id=\"14625670\" target=\"_blank\">",
"        14625670",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Erstad BL, \"Which Weight for Weight-Based Dosage Regimens in Obese Patients?\"",
"      <i>",
"       Am J Health Syst Pharm",
"      </i>",
"      , 2002, 59(21):2105-10.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/19/33082/abstract-text/12434728/pubmed\" id=\"12434728\" target=\"_blank\">",
"        12434728",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Guerrini R, \"Epilepsy in Children,\"",
"      <i>",
"       Lancet",
"      </i>",
"      , 2006, 367(9509):499-524.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/19/33082/abstract-text/16473127/pubmed\" id=\"16473127\" target=\"_blank\">",
"        16473127",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      H&auml;gg S and Spigset O, \"Anticonvulsant Use During Lactation,\"",
"      <i>",
"       Drug Saf",
"      </i>",
"      , 2000, 22(6):425-40.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/19/33082/abstract-text/10877037/pubmed\" id=\"10877037\" target=\"_blank\">",
"        10877037",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hegenbarth MA and American Academy of Pediatrics Committee on Drugs, \"Preparing for Pediatric Emergencies: Drugs to Consider,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2008, 121(2):433-43.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/19/33082/abstract-text/18245435/pubmed\" id=\"18245435\" target=\"_blank\">",
"        18245435",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      K&auml;lvi&auml;inen R, \"Status Epilepticus Treatment Guidelines,\"",
"      <i>",
"       Epilepsia",
"      </i>",
"      , 2007, 48(Suppl 8):99-102.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/19/33082/abstract-text/18330014/pubmed\" id=\"18330014\" target=\"_blank\">",
"        18330014",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kerrick JM, Wolff DL, and Graves NM, \"Predicting Unbound Phenytoin Concentrations in Patients Receiving Valproic Acid: A Comparison of Two Prediction Methods,\"",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 1995, 29(5):470-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/19/33082/abstract-text/7655129/pubmed\" id=\"7655129\" target=\"_blank\">",
"        7655129",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kochanek PM, Carney N, Adelson PD, et al, \"Guidelines for the Acute Medical Management of Severe Traumatic Brain Injury in Infants, Children, and Adolescents-Second Edition,\"",
"      <i>",
"       Pediatr Crit Care Med",
"      </i>",
"      , 2012, 13(Suppl 1):S1-82.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/19/33082/abstract-text/22217782/pubmed\" id=\"22217782\" target=\"_blank\">",
"        22217782",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lewis RJ, Yee L, Inkelis SH, et al, \"Clinical Predictors of Post-Traumatic Seizures in Children With Head Trauma,\"",
"      <i>",
"       Ann Emerg Med",
"      </i>",
"      , 1993, 22(7):1114-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/19/33082/abstract-text/8517559/pubmed\" id=\"8517559\" target=\"_blank\">",
"        8517559",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lowenstein DH, &ldquo;Treatment Options for Status Epilepticus,&rdquo;",
"      <i>",
"       Curr Opin Pharmacol",
"      </i>",
"      , 2005, 5(3):334-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/19/33082/abstract-text/15907922/pubmed\" id=\"15907922\" target=\"_blank\">",
"        15907922",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mansur LI, Murrow RW, Garrelts JC, et al, \"Rebound of Plasma Free Phenytoin Concentration Following Plasmapheresis in a Patient With Thrombotic Thrombocytopenic Purpura,\"",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 1995, 29(6):592-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/19/33082/abstract-text/7663032/pubmed\" id=\"7663032\" target=\"_blank\">",
"        7663032",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      McAuley JW and Anderson GD, \"Treatment of Epilepsy in Women of Reproductive Age: Pharmacokinetic Considerations,\"",
"      <i>",
"       Clin Pharmacokinet",
"      </i>",
"      , 2002, 41(8):559-79.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/19/33082/abstract-text/12102641/pubmed\" id=\"12102641\" target=\"_blank\">",
"        12102641",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Meek PD, Davis SN, Collins DM, et al, \"Guidelines for Nonemergency Use of Parenteral Phenytoin Products: Proceedings of an Expert Panel Consensus Process. Panel on Nonemergency Use of Parenteral Phenytoin Products,\"",
"      <i>",
"       Arch Intern Med",
"      </i>",
"      , 1999, 159(22):2639-44.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/19/33082/abstract-text/10597754/pubmed\" id=\"10597754\" target=\"_blank\">",
"        10597754",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pfeifle CE, Adler DS, and Gannaway WL, \"Phenytoin Sodium Solubility in Three Intravenous Solutions,\"",
"      <i>",
"       Am J Hosp Pharm",
"      </i>",
"      , 1981, 38(3):358-62.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/19/33082/abstract-text/7223749/pubmed\" id=\"7223749\" target=\"_blank\">",
"        7223749",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Relling MV, Pui CH, Sandlund JT, et al, &ldquo;Adverse Effect of Anticonvulsants on Efficacy of Chemotherapy for Acute Lymphoblastic Leukaemia,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2000, 356(9226):285-90.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/19/33082/abstract-text/11071183/pubmed\" id=\"11071183\" target=\"_blank\">",
"        11071183",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Shearer P and Riviello J, \"Generalized Convulsive Status Epilepticus in Adults and Children: Treatment Guidelines and Protocols,\"",
"      <i>",
"       Emerg Med Clin North Am",
"      </i>",
"      , 2011, 29(1):51-64.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/19/33082/abstract-text/21109102/pubmed\" id=\"21109102\" target=\"_blank\">",
"        21109102",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Suzuki Y, Mimaki T, Cox S, et al, &ldquo;Phenytoin Age-Dose-Concentration Relationship in Children,&rdquo;",
"      <i>",
"       Ther Drug Monit",
"      </i>",
"      , 1994, 16(2):145-50.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/19/33082/abstract-text/8009561/pubmed\" id=\"8009561\" target=\"_blank\">",
"        8009561",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wilder BJ, Leppik I, Hietpas TJ, et al, &ldquo;Effect of Food on Absorption of Dilantin&reg; Kapseals and Mylan Extended Phenytoin Sodium Capsules,&rdquo;",
"      <i>",
"       Neurology",
"      </i>",
"      , 2001, 57(4):582-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/19/33082/abstract-text/ 11524464 /pubmed\" id=\" 11524464 \" target=\"_blank\">",
"        11524464",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Young KD, Okada PJ, Sokolove PE, et al, \"A Randomized, Double-Blinded, Placebo-Controlled Trial of Phenytoin for the Prevention of Early Posttraumatic Seizures in Children With Moderate to Severe Blunt Head Injury,\"",
"      <i>",
"       Ann Emerg Med",
"      </i>",
"      , 2004, 43(4):435-46.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/19/33082/abstract-text/15039684/pubmed\" id=\"15039684\" target=\"_blank\">",
"        15039684",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12702 Version 47.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-200.131.240.2-13CD9D8202-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_19_33082=[""].join("\n");
var outline_f32_19_33082=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11284327\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F209593\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F209594\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054953\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11444747\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054946\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F209562\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F209547\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11441305\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054958\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F209651\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054949\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054957\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F209653\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F209650\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054961\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054945\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054944\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F209639\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F209556\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054964\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F209558\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F209573\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054952\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054956\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054943\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054960\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054951\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12702\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12702|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?34/48/35594?source=related_link\">",
"      Phenytoin: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?7/49/7958?source=related_link\">",
"      Phenytoin: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_19_33083="Colorectal CA risk factors";
var content_f32_19_33083=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F72216&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F72216&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Factors associated with an increased and decreased risk of colorectal cancer",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tbody>",
"      <tr>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Increased risk",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Lack of physical activity",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Consumption of red meat",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Obesity",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Cigarette smoking",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Alcohol use",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Decreased risk",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Multivitamins containing folic acid",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Aspirin and other NSAIDs",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Postmenopausal hormone use",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Calcium supplementation",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Selenium",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Consumption of vegetables, fruits, and fiber",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Harvard Report on Cancer Prevention, Cancer Causes and Control 1999; 10:167.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_19_33083=[""].join("\n");
var outline_f32_19_33083=null;
var title_f32_19_33084="Differential dx of ITP";
var content_f32_19_33084=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F67855&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F67855&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Differential diagnosis of idiopathic thrombocytopenia purpura",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Falsely low platelet counts",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        In vitro platelet clumping caused by EDTA-dependent agglutinins",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Insufficiently anticoagulated specimen",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Presence of giant platelets (may be counted as white blood cells)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &nbsp;Following administration of abciximab",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Common causes of thrombocytopenia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Pregnancy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Gestational thrombocytopenia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Preeclampsia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Drug-induced thrombocytopenia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Heparin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Quinine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Sulfonamides",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Antibiotics",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Viral infections",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        HIV",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        infectious mononucleosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Hepatitis C virus infection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypersplenism due to chronic liver disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &nbsp;Foods and beverages (eg, certain tree nuts, quinine-containing beverages)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Other causes of thrombocytopenia that may mimic ITP",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Myelodysplasia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Acquired pure megakaryocytic aplasia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Congenital thrombocytopenias",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        von Willebrand disease type 2B",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Wiskott-Aldrich syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Alport syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        May-Hegglin anomaly",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Fanconi syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Bernard-Soulier syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Thrombocytopenia-absent radius (TAR) syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chronic disseminated intravascular coagulation",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_19_33084=[""].join("\n");
var outline_f32_19_33084=null;
var title_f32_19_33085="Food records standard";
var content_f32_19_33085=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PSYCH%2F67548&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PSYCH%2F67548&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Food records standard",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"6\">",
"        Instructions for monitoring",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"6\">",
"        <strong>",
"         Column 1 (Time):",
"        </strong>",
"        Note the time when you had anything to eat or drink. Do your best to be accurate.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"6\">",
"        <p>",
"         <strong>",
"          Column 2 (Food/drink consumed):",
"         </strong>",
"         Record exactly what you eat and drink, including any binge eating. Don't leave anything out. Instead of recording calories, write down a simple description of what you eat and drink. Write down each item you eat or drink as soon as possible after you eat it. Trying to remember what it was that you ate or drank later is not a good idea, because it can be unreliable and won't help you change.",
"        </p>",
"        <p>",
"         Monitoring at the time of eating is extremely important. For example, if you are eating out, it can be helpful to record what you are eating during the meal by monitoring in private, like in the restaurant's bathroom.",
"        </p>",
"        <p>",
"         Episodes of eating that you consider to be meals should be bracketed. Do not bracket snacks or other episodes of overeating.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"6\">",
"        <strong>",
"         Column 3 (Place):",
"        </strong>",
"        Write down where you consumed the food or drink. If you are eating or drinking at home, specify the room.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"6\">",
"        <strong>",
"         Column 4 (Loss of control?):",
"        </strong>",
"        Place an asterisk (*) in this column if you feel like you were out of control (like you couldn't stop eating or control what, or how much you were eating).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"6\">",
"        <strong>",
"         Column 5 (V/L/D):",
"        </strong>",
"        Record if and when you vomit or use laxatives or diuretics.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"6\">",
"        <strong>",
"         Column 6 (Context/comments):",
"        </strong>",
"        Use this column like a diary. You should note anything that is going on while you are eating, or anything that is influencing your eating. For example, if you note in column 4 that you felt out of control, record in column 6 the circumstances at the time you were eating. This will help to identify triggers of any times you feel like you overate.",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td colspan=\"5\">",
"        &nbsp;",
"       </td>",
"       <td>",
"        <p>",
"         <strong>",
"          Day:",
"         </strong>",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Time",
"       </td>",
"       <td class=\"subtitle1\">",
"        Food/drink consumed",
"       </td>",
"       <td class=\"subtitle1\">",
"        &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Place&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Loss of control?",
"       </td>",
"       <td class=\"subtitle1\">",
"        V/L/D",
"       </td>",
"       <td class=\"subtitle1\">",
"        Context/comments",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <br/>",
"        <br/>",
"        <br/>",
"        <br/>",
"        <br/>",
"        <br/>",
"        <br/>",
"        <br/>",
"        <br/>",
"        <br/>",
"        <br/>",
"        <br/>",
"        <br/>",
"        <br/>",
"        <br/>",
"        <br/>",
"        <br/>",
"        <br/>",
"        <br/>",
"        <br/>",
"        <br/>",
"        <br/>",
"        <br/>",
"        <br/>",
"        <br/>",
"        <br/>",
"        <br/>",
"        <br/>",
"        <br/>",
"        <br/>",
"        <br/>",
"        <br/>",
"        <br/>",
"        <br/>",
"        <br/>",
"        <br/>",
"        <br/>",
"       </td>",
"       <td>",
"        <br/>",
"        <br/>",
"        <br/>",
"        <br/>",
"        <br/>",
"        <br/>",
"        <br/>",
"        <br/>",
"        <br/>",
"        <br/>",
"        <br/>",
"        <br/>",
"        <br/>",
"        <br/>",
"        <br/>",
"        <br/>",
"        <br/>",
"        <br/>",
"        <br/>",
"        <br/>",
"        <br/>",
"        <br/>",
"        <br/>",
"        <br/>",
"        <br/>",
"        <br/>",
"        <br/>",
"        <br/>",
"        <br/>",
"        <br/>",
"        <br/>",
"        <br/>",
"        <br/>",
"        <br/>",
"        <br/>",
"        <br/>",
"        <br/>",
"       </td>",
"       <td>",
"        <br/>",
"        <br/>",
"        <br/>",
"        <br/>",
"        <br/>",
"        <br/>",
"        <br/>",
"        <br/>",
"        <br/>",
"        <br/>",
"        <br/>",
"        <br/>",
"        <br/>",
"        <br/>",
"        <br/>",
"        <br/>",
"        <br/>",
"        <br/>",
"        <br/>",
"        <br/>",
"        <br/>",
"        <br/>",
"        <br/>",
"        <br/>",
"        <br/>",
"        <br/>",
"        <br/>",
"        <br/>",
"        <br/>",
"        <br/>",
"        <br/>",
"        <br/>",
"        <br/>",
"        <br/>",
"        <br/>",
"        <br/>",
"        <br/>",
"       </td>",
"       <td>",
"        <br/>",
"        <br/>",
"        <br/>",
"        <br/>",
"        <br/>",
"        <br/>",
"        <br/>",
"        <br/>",
"        <br/>",
"        <br/>",
"        <br/>",
"        <br/>",
"        <br/>",
"        <br/>",
"        <br/>",
"        <br/>",
"        <br/>",
"        <br/>",
"        <br/>",
"        <br/>",
"        <br/>",
"        <br/>",
"        <br/>",
"        <br/>",
"        <br/>",
"        <br/>",
"        <br/>",
"        <br/>",
"        <br/>",
"        <br/>",
"        <br/>",
"        <br/>",
"        <br/>",
"        <br/>",
"        <br/>",
"        <br/>",
"        <br/>",
"       </td>",
"       <td>",
"        <br/>",
"        <br/>",
"        <br/>",
"        <br/>",
"        <br/>",
"        <br/>",
"        <br/>",
"        <br/>",
"        <br/>",
"        <br/>",
"        <br/>",
"        <br/>",
"        <br/>",
"        <br/>",
"        <br/>",
"        <br/>",
"        <br/>",
"        <br/>",
"        <br/>",
"        <br/>",
"        <br/>",
"        <br/>",
"        <br/>",
"        <br/>",
"        <br/>",
"        <br/>",
"        <br/>",
"        <br/>",
"        <br/>",
"        <br/>",
"        <br/>",
"        <br/>",
"        <br/>",
"        <br/>",
"        <br/>",
"        <br/>",
"        <br/>",
"       </td>",
"       <td>",
"        <br/>",
"        <br/>",
"        <br/>",
"        <br/>",
"        <br/>",
"        <br/>",
"        <br/>",
"        <br/>",
"        <br/>",
"        <br/>",
"        <br/>",
"        <br/>",
"        <br/>",
"        <br/>",
"        <br/>",
"        <br/>",
"        <br/>",
"        <br/>",
"        <br/>",
"        <br/>",
"        <br/>",
"        <br/>",
"        <br/>",
"        <br/>",
"        <br/>",
"        <br/>",
"        <br/>",
"        <br/>",
"        <br/>",
"        <br/>",
"        <br/>",
"        <br/>",
"        <br/>",
"        <br/>",
"        <br/>",
"        <br/>",
"        <br/>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Fairburn (2008).",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_19_33085=[""].join("\n");
var outline_f32_19_33085=null;
var title_f32_19_33086="STARI rash";
var content_f32_19_33086=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F60256&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F60256&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Erythema migrans-like rash of STARI",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 324px; height: 243px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCADzAUQDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5eRSzBRWosYVQMVDZQZYuc47VoBKbGyuYh3FRG3Xd0q6U+ualhsppjhI2OfahXEUGhBGMUgj2jAFdJa6BLJjzWCD0HJrYtNCtIcEoXPq1UoslzSOIhtJpziONmPsK2bLw7dy8y4jU+vWuyit0jXCIFX0AxVhYxmrUCXUMG08O28WPNLSH8hWvb2MMIxHEo/CriR+tSqoq1FGbmyFYgB0qVUx0FSBaeBxV2Ichipx0p4WngU4CgVxgXBpwXmngU4CmK4wLzmlx+VP2mlxigQ3bzTgpNPAp6g0BYjVOKcEGfepFWpAlOwyIJTvL4zipQtKaYEWB6UhWpcZpCOaAItlGypdvtS7aAItlMZBVjbSbaBFVk46VQv4A8TZ9K12UGq0yZU0WDY4aaPbIwPYmoWQH1rW1OHZNnHB5qg2OfeuSas7HbF3RUZOfbtTNnOOxq2yjFNKZ/wD1VIymygdqjdc9qu7M59ajaPn3pgUyuaidMfSrpTJ9q09B8O3utzslpHiJTh5G+6v/ANeiwHOFFzyOaK9PX4dQAfPeTMf9mMAUVVieY8mt7KWTGxCBWpBo5Y5kbHsK1o0xirKr6VSppGbm+hTt9Nt4yDsBPq1aEcYUcKAPanqvFSotUkRdsRE4GOKlVcnBpVFSKKpILgq881Kq+1CqTUgU07EtgB2pyjFKo9aeFoEIBzTgtOAp4FMVxqrT1FKBTwtAhoWnAU4CnKtFgG4pQvrTwtOAqgGhaeopwXinAUDEApR1NLRQAUUUuKAEoxTgKcFzQK4wClxxTwlOxxQBA3FVnlbNWJeM1UYc1nOTWxcUSLJnrTmXcMAZJ6YqDpWx4XiFzq0Sv0QF/wAqSqWWo+S7NHTvh5DqMSS6nczxEhj5cIHGPUnP8qwfHHw+OkRSXulyvPZoN0iSY3xjOM5/iH8q9osgFj2jgYcfrmkv4VkiYbQcrzkcEd/0rJScn7xsvd2Pldk9ulIU9q9I8U+AblLia50WISwE5+zL99M9hnqKl0D4bvMyvq82zkfuoz6+rf4UmrFcx5iIxnGD7VPFpd5NKiRWszM/CjYRk19HaP4a0rTUQWdnZoQoy4UMx4I5bk96vXYt/s/lyNuPYH1wOf0p6C5meN6R4FhEC/blLzMBuVWwFNdnomnwafbvZW8QUI2cLx1HUmt1YUBJQFuMcDGPf1qO5tvKljnIO3BR8Dgeh+lJaibKgtQRljg0VrC1LcxsB65U8n1orTlRnzI+boh0zVhFpkYxj6VOgxVEocoqUA0KPSplXmmgYKvFSIvqKVBUiiqJbBRUgGaACaeoxQK4gFPApyrzTgKBCAe1PxQBzT1FCARRTwKAKfiqAQDmlApwFKB60AIB6U8CgCngUAIBS4pwGKKBDcGlAp2OlOAoGMxTgpNO2inAUCGqDmnAU4LSgUAIBQR7VIBQQKAKE1ViOTxV6bbniqpXnisZ7m0diMKO4ro/AlsZtYcJjPlEcnp71hxW8kxIiRnI7KM10/gaT+yddKaiGtoruExiSQbQrZBGT74I/EVD1Viloz0eOMIvdmJJz0AyBnisHUta13TdSjDaDb32mOMGW1nYSR8fxBhjGPQY966wQEDDLjGR/KmTW6urYIHJ/lVWjsF2c9Hquk35Z2eaylBAxKmR09VyMfXFT/ZpgivFiaLGRJCdw6U9dNjg1V2wEjkAbI4wRxn+VakOnwtIriMq6E4K8Eeozjt19OaXKlux37GUqxtGvzfKexP8+34UC1GcqMg8Z/rW29ntcmXDqOfmj56Y9qUIkY+ZRjjd06/XtU2HcwlgZJQdh29Dx61NNAZEMZUYIwQec1pyEbcxDDDodvOajiZpYg5xuPUiqUSXI5t/JtT5NwruycKwU8r26UV0JT160VpoZnzImnzZHAqVLGYc7RXRw2uRkA469KmW3PQJn3rz1WqHp/VoHNpZzgfc/WnrbSjjyzXTLbgnpUot16FTmq+sVBPCwOXWGQdUb8qeY3UDKN+VdP8AZAe2f50/7Gp6pgVX1mfYl4SHc5dQeeDTuK6g2KleAKjNjGeijHemsU+qI+pLuc8BT1FdAunRn+EE0r6XFjJUD6VSxXdEvBPpIwAKetbY0pCOEoGkr/dP51f1pdifqcu5jgUqitX+ygOMH86Bpfrup/Wo9hfU5mYOlPxWh/ZTdmP5UHS5B/Efyp/WYCeEmUAKXbV3+zpB3o/s6bJ+YD8Kf1iHcn6pU7FQD1pwWrX2CUcbh+VH2KUHgin7en3F9VqdivinBanW0mBzkelKbWbqAKft4dxfVqnYgxzS4qdbWckjaM1HJYXJ4GBT9vDuH1ep2KsspUcVWEz561fOk3bD+E/jWvoei2GS+rSyA5wsaKcfUmsZVU9blqjJdDHsfNuZ0iiUszcAV6Ho3hO08iNr2NpZm6rknj6D+pq9plho8UW6wSIS8gf3iBznmt3TXSS34OF4LkHliealzbGqaiYV94M0yVSvlrbkjAYPkj6gZrCsvAiB2S7uGZlbA8sZDfT8K9PjBVB5aogzwx6/n+Ham3FuzYOVaQcbgMMR3+tLmHynNabpEOnwrHDHGqA8uMbsj+vatSTSobuForqNGjcHKMoPB9SavpGrggLwOQNvJ98/56VPEuMKfvYwTjt/XpRewJHLfYb/AEeWKK3vGksecR3AEnlj+6D1x6DNXkmuzdBZLWKSErkMuQ5PpjkGt2WMyR7TlgezUiwK0KZH3SOCxHHpT5l2E4u5hy+VPb206IyuWI8t8Zx35+oq9bDgNjjGOQcEep46dj6mq11EkcZQYCpMQAOm3npn0z+lS27dlC5PHBXBI68+neq6CLBG1c9COfmGPx9cn0qvKrEcYU9ATzjuPx7VayByGPIzuAGfrz7/AM6hkO0EZCFRnBPQZ59uvNJCZXkUCNgQyqeRnjv0yR2PvUVkPmmjPruH8j+H41bB24b7h5GSCuT0IyMg565qrEAuoxspG1/lJyCDxwMjrV30JZIyDNFWWXDHiio5hHhMCEnA9KsxxfL71JHHySRUyrg4xXKj2CAJ7flUsUQHbnqKlVD0wM1MsfzLkCnYCJI+TkYI705kHYcVZjTDEnvTjHnORxSAqrCCB3qVIgOo/SphHj0596VFPY8djQFyJ4toHGee1KYwB05q0VJGaRY+4pWFcrLGdop6oc/dxVlAfTr6VNGBgMRj0osJyM9oS1OWIdDjIq+YywIFL5QA6VIcxR8o54p3knvV1YsCpPJB54PrTsF2ZxtwR05qP7MAQMVrGHI64+lQsvAwAaOUqN2Z7xAHBwfpTBECOnFWnUq2Oo/lQqZHXitFA15SAQDP3cjtmpEgB6AZqYLx0yRT0JY45AFHIJwI0sx3FSi1UdRwTVqEbsA9qsCLJBzkd6aiZOLKJtV7c0otVP8ADg+lXxbnqOtTLDkD171fKSZwtAQMjHNXtGmbTbhUkb/RiSQSfun/AAP9asLEOi0rQiSIqy5BGKaVjOSTVjrLc7lBY5yOuP0FWFU7cgH6VgaBdSMrxzP80J2g9Mjsa6GMHHp6cYoZztW0KoTErKy5XIwB0Oe9WFzxtwQfSmXAOVOeOhH+fxqRDlQRxntSAXaozkLz69aSLjcOPankBT6CmEgOSenBoAy9UBMxIOcvn2+6KjQllZQxduFA3gk91GCO/Oal1blxxnkYH4HrVaFyQGBPGRnG7jqOOuSQwrVbGT3LKNuUZGR7pjdxzj2x/KlY/KduSeSR0BPrz6ioo2G7BxgY6HoOoUA09eQBk59DjqP/AK1AELjy2ZuAcD5+evbkd/wqs0aTXkCB2TJx8pBIHXGR3yKtum1lCkDI4JyCB1BzUWlfvr+ST5gIo+M88t15/Cqvpcm1yxPaySOCt5dRgDGEZcfqDRVwjniisudj5UeJqoUZB4qYqcdj9aaNpxxzViKMEE5rA9USNOenap9hAANEalW55qwqho8jnFBLZEqcnIqREPOeDUiqqquT1pwU4IXhu2aBXGNGcZ6A05UwcVMiEqN2N3fFOZORjoaVhEWzHb9KFjyRt4HpUxGOM9aXZkHNOw0II12Hj3oCDBxT1GfypyAEZxTsFhAnpxQyjn0NS7TxkYxSsmQfpT5SrEa+mKk2FvTHtTokKgA9+9TADHB68dKLBcrEDbk4+tRSA9AOKsygYxgAVD1ppGkUUZVz14obaFGOatMoxgjNR+Xg8EYrRI0bIyg6559KVVI6GlKZl55HtUgQtnkUxKQ6NuccE1Yi3k9sVWVCG7nNXYQOh6YpWCVi0iLtVTn61IF9CDREyhQAQanAGOlM45EarjORTwADn9Kdt7UscZUAA5HvTsSQf8e17DPu2ryjnsAen611lq29MnPTBz3rlr5N1pKDjO01vaPKs1tG6K4VlBw455FTIzmupeny0TDnOM0y3xtOcce9Scbuc4PaoLfILqO1SQWRwuf1qOQgMoJ6gjn6U8Dg1HIdoUk8A0AUtUAZDxn5Nw98EZ/TNZO8gnBXf2JPRhyMHtjGPxrauow8SsMnaSuR/dPXisCRzGeSQw4JH+fWtYbGUtyaSTIBBZY8kLuG7g8g5Hep7V8nAGRwRht3bgfzqkM8hcbxypztyRzn06ZH4VKrbSDkgdAXTGF6g5Hc81ViS/cZ+ZVIz1HGBnqD9BTtET/RJJicmaRm/Acf41BIWaMbAOBnJbI47Yx0q5pmBptuoIIC4J98nNTLSJS3L0akr8qqR6mimxuVBGR19KKzuOyPFUQbh6VbiQAHFVI2OQV9KtIxxWVmejqTKqkA4wRU6Dv0qvHzkHpViMAEClYhiD72AKmAIHIoHJzUwGDTsCdxq8+9Lznjmn7eCQKcFyOmKdh2IwhOAevWpkT5fpSBMdDTlJK44zTGN8sDOOtSrEpHHfmjJIpUYgAkYHTFOwxwQADP0oAGQBThxwVPrSgdjwPWnYQgjIJ75NOwRHgnJHen4OMZx70h3bePpRYEVX6kHnNRkVOy4OAajYjcM9KdjoQ0jaMDvSCIA44NPYbjgdqTbzkHn0qrCY0KAM804KOtPVSTkEYxzTtuXwpHTpTsRciI557GpkYYxjJodMMSRimNHtP3qdik7ksbYIyOnYVegIZMqc1mqcgcc1ct3AJAGOKbRFSN1ctjkYzUg7k1GeQCaC2OmT3pHMwnJwRxuxjmrvhuQGzjUK/ykofTIOPyrPJDYI61a8NuB50RVvkkJBxwcnP9aT2JlsdC55HUVAuFu2wQQf0qY4z0OPeopxsnVg2BjsOlZmTJgeeABUc/3DxyOfypx5cZ/WmzrmJwRnjjnvQMEZSrgYbB3Vk6tbr5qjgNKTsIGOcfdP64P4Vpwuu8AEMzLUWpKJrKRRtCjgnnn6VcHZkPWJzis8LAMpBUgkY4POQP8+tSxSeWSYWzjkEPgnHOcemMioF3v5cNyD5uP3U2G+YDsfeod5SRQwz0yCODjoPpiuiximbsThIVJ4UnILpnI+o/lUthMQ8sLkE/fU+uev61kpPtwobOOQd+M4/iwfbgVY3PHtljVyyHPOORjn36VDjoVc2C57ZNFQbwwVkOVYZBBorHlFdnkqoQcD61bhXuajRR1x1qeJSv0rI9VssIgI5qVE9ajj64zxUynjmhIxbHgYOcZFOXP4ULTwmOKdioip07mnjOeOneiFOuetPb6DB9KLFJjcEnjFKFORTVGCcfhUwOMVVh3G7eeenrUsYBU59aGOecjA60iMFJx064ppCuSA4wD9KQgc5zihnGOxz0pFO7JB+bvTSAcrAKcnI7+1KSpVWVuO1INp4Ax6mpQqqhAAxTsFynKNrMep71Djcv41PMvzbug7VXViM9s+tNI6Y7FiJBgjr2oKBTtB5zTIpNrktj061PLyFLHp1PrVWM5aPURIyNxwCOlKikMDn2OaiklkWLI5HtUdtdMx5Q7M8bjzSFyu1yaTHGR3xUTsGJzzipZ8bQQeKpMxLnrimOCuWFYgcdqljcjoeaoxyEyHB4qYN2FUmW0aiSb+AeRTi3P0qnbu29fSp2fuKTOSasx4OSexq54cYh7vChl83I46HAzVAHjNXvDAb/AEiRfmR5T8vYYxk1MtjKWx0bHp1ptwAWUg47YFDttUYXjtio7gfKGBYE+vSsiB0+SnG4H0xTpOIj16Z4NMmDmNguQ2DwBjNMZNtsAM5C5GCPT3pktiQkIkJ3ZY+o4qVzgv0JPOSKrL8sEJUsTkEf5xU7uVkJYcY6d6b3JTMyW1NzZvCyHIYlWBA2nrnB/wAax2DTboZkIvIRySQNyjnj1roMH7U5Y8HH3lrL1+ARol3Cyh04fB6j9a2jLUyaMqGUhgRywx2BBI/oKvQSKw2kKR1yUPPoTj16VSv41JSdVISTqMdG9B/OmwSfd3EZzg8Hk/8A1q0auK5q2t3LBHsWIMCSRuGMe1FVMq4B+0rCe4Ib5vf8aKnlQrnIx4xjNWExtGetU4xkY9KsI3ODXGes1csLjIqUdRUCD5sGpk6c07GbJ1PaplwVz3qBTxT1fH0pjTJkOD15p+PQ1ATTg5A65ppFCHGcipAxxwKiY805DyfWmUThcrkfjSMCGBxmkDZAGPqae5yPeqsAnGRinjGcZ5qPOOMe+aYJcHkZ96AsWFJA57+tSdTtDdOSPSoQ4OPSpBgMWJHPemS2MlHzEkdP1qs3JyKllOTg8ccVWclSaDojsRhsMR7881cEh8sc5BFVDtbG7rUhB42/doFNkqlipGefSkGCvygBge1VyxUk9uhpwfAyMdKVyLkjNgfMSSKqykfw85705pBu3Ek9sVXlnXBA+X0FNDjd7EpO0A55FSRuckn61SE4bn+I1NHJlfeqsVJ2WppQHjJNShwAPSqKP8o9acZPxqro5ZSTZb8w7Tn7tbHhNGW0eaM53ysSmO44/l/OucMgCsfauo8OCMabblCUkKAuucbs9T+tRMzm9DYZjzhVOO+cGmSlGGPuyDuO9EjSAn5jx/eH+FNmbKqkikZ+62aysZXHvnyjyfTIA5H1qOUNHZAA5+X2H86R/ukKxx0JyP8A9dQyDNuioV7Aep9R/wDrqkiGyUECCMIpBJGMHjP51ISRNuDDJGCM5PUVBKSCgO1ASNx7j36UgZTOxjcjA79/wp2EmJJ/x8ksC3Hr0/Km3ixy20ivu5UjGM9arSOpn2JJhycdOtSXMxjt3YlcqCScdqu2xFznLZjJpTK7EFcMABz6HmqyttORgY4OOw9KtWwMdoQecxk8f5/zis8kBs59+fT1rdbErc0FcsM/Z1l/2mz+XWis/djj5sdgO1FGhRkxgcHvVhMYqmrcDByKljlzx3rhSPU3LIfnBqWLBzVVT83NWEPFOxEkWM8e9KucVEG+bg1KG5xRYgcT6/pSoeaZnI60u4YplJk3vQrc81GG/SjcCKCrkqvg5HSpGk4FVmOFI60CT1NND5kTHkcCmgfKaj8zBwKSN+eO/aqDmJ16CpVIZeDx6VUL9ccGnJJgZ70BzE7bsnPSom9c59KPMGMdM1BPIQOBxSLjIY0gz1pwuF5B4I5rNlnPOBzmqxmOQcmqsb8nMjZM2VHI574qGS5ySoI6Vm+a2M7+M9PSmvP6fSixKpFma5IXGfyqu8m4ZB/M1B5ueB+fpTlI+pqrFq0SaN+eODVuFyD1zmqAbLHninpMFGPSqMas00aokAHWgSc+1Zv2g59BSifnmp5TksaEr7ovLH3nOwduTx/Wu7sykNqsU5AkiAUNjg4HBrgNMAu9UtomBaFTvkx2A4B/MivQI98UeXiMy44YHBx9amxlUdtCR2TcCrnH1zU5bbEM/PE3I46VnhyzAxQEH/b6mrSvlQ1uPlOd0Z5wfb/Ck4mSYsxi8okOAp4PQ/1qrG6SPGiMyhQCCT0ouJ0KEbTnkbQ2PzotMhSZlU7u6gY/SrUbIhu7sTTGRZIw4VyM/KvOeKUMw3l4vmzwB9faqM8sbSSFXIwNvygZJp9y6w2+1JcjHtmny7BciQ+ZeDzFUKvI28gc96j1qT/RxGGJMjBBz2PX9M1JpQZY2nAGHOcEE4qnO5uLt3BHlwDaCf7xHP6fzqupJVlzGkhUE4GOP5GsxmAbPUHrn+dXb6QfZsHALNxwcnHv6VUuArIJVzz1ODg+5/l1qwTGeYqDBmZM8gBc5HqeaKiM3lnbvx36bs+9FKw7mEkhUAYzUkTEtz0qnG/ODVqJulcp6uxfTpzzT95FVkfHepGb86QizG2QM+tSliDxmqauMDJ5qTzST7UCaLQY9qDKMdDVQzDJ4NI0wxzTSEolsScdaeJO9ZwnOcAg0+OUkc8U7D5S8ZBmgEHvVMyEkY605pDnoKdhcpb+tIzBcZqqbgAfMeKQS5HXIpWDlZaD5zj8zSGQDhqqPKB06fWojMB/F0phyl4zbR14qJ5mJ7Y+tUHnyfameZ05yRTsUrIWdvnx3qqz5b0xTpJBk7jVWVwOAaZsqw95yuQBlajaQt6ioTJ7UxpQBk4/OqQOsXVl4xiniTHJrL+2AHk4qM34C9QadrmMqrZsmUZ6jFMNwAOv5VivqA654qM3zc7cnNUot7HPKrFbs3WuMHqMVG12IwxJ4Fcdd668NysckThc/Mw9PWu38PWlleJHc+Z568EDOf09aUlYlVU9jrvBNu0ULTyLm6l5Eb8Bo/QepBGa6R5YlG2IXER/uCM5BrEgliEA5TA52tlcH1VgD+VObU1XaoeWRjwqG4OD/n60oxMJybZrxMpl/eCUf9NC4O09sj0q15g+9IPLcDiVOVb8Kx7aZUyU2qem/Zgf7rj+tWFmSPglUBOTHJ9w/wC6aGrkp2LN1NI+A9ysmeCEJJI759BUvmeRbEqUePHR2wR7VnQzCSU/PCmwEjnhvxNQTXSTyEIoAR/nCfN+PpVcvQi5ct3edgVeHgk7QMZOOlQXEjT3QiVUUJywXnPtUUt0BGkMXlzH7qt0Iz60sMkVnBmV2DqST8vLfTvVCLGpXS2tsxQZZyAqDux4AFMhjFvbIrHnq7Hrk85x6ZzWTp7y6rqBvJA4tYCVhHZn5BP4dPzrUkclsKSPXBH5Gla4Nkfl21xGdyg7jnK8EfQ/0qt9j2kiOaNlI58xdpPtkA8flRMNrbkBxjLdBiqsl2AnLceua0sTqJ9lvFJEbFFz0Eqc+/LUVWe6G4/MT9DRT5R3OSDHOKtwH1NUBIevWnrKT3rhPaNNW561JvOKz45CKk80jGDRYRf3ZHJ6Uok9DVAXHbvQZRg4NFgLpk57U0scHJ/CqRl45wRQZuME8UwRZ83aeR+NSicY9qzGmA4LcUizDbxTsM1ftGDxQZ8r8xIrK83jrik+0hTgkUWEaZmUjrmmCbbn5sjtWVJdgE88VEbzngmixLZryXAx9KrvcnFZUt56nn2qrNf4HBNVYlzSNz7VgY61E17hTzisA3rEDFRvLIx+9WsaMn0MJ4qEepsyXq85P51We/UcA557VmhWPXNPVPatVh31OeWN7ItPeyE8AY+tQvLI+MnFKEp4StFRgtzCWKqPZkW1ieWJpRCCOcmrATjpT1X2rRRitkYupKW7K6wAdBT1i56YFThfpUgTk07kFC406C5H7xOncdadpti2nSFrW5njB5wrcGr6ripAvPTilyp9ClJrZk02oahLAYxduh/vgDJ/Ssu0m1qyuC6XCXSsclZf8a0FXIx/SlC9sUOlFjVSS6mtbeK7q3tmee0IdRz5UvJHpz1Hsc1u+HdTk17TlubZxDE2coBnGDg5Hb8K40qCCCOMY6U7wNqR0PVJ9OuuLeYmWByMgHv9M8c1jUpqOqNIVHLRnpS6V5kXlvPLtyTjj9KU6Wyw7YpnDLjaf8SK0La7R8EHuD6/+PUrzKAOn1/z1rG7LMiPT5owwcx/MNpJyeR3rDuI57nVGtmnYxIMu5POPQV1M90oBOQOev8AniuNnv1h1WUqwSSQ8Irbs/Qj+VN3sEX3OpWWGCJbeFVRQNoUcbec5PtUhdcHbz3JHeuNk1h0BJ2cEjI9qrJqFzfXDW0DHzdu/AP601FIGrnXXM64PQmsG/mEWWiyOMbFHaqF5cSaZB5d/DcvM3RySAPyrFM93OC6JJj/AGQSKsSRfkutzZVsg0VkNdncQ4+YccjmigdhVmwOvFOW4weDWOk59akE4OMda4D2jbW4GO9O84Z461kic44PSgzk/WmLQ1jPj6+1Ma4OKyzcYOGpr3IPUjihAaTXR/vZNNN0x71ltc8daja6A6tj6VQnKxrG4z94jFRm6AORWLLfouec1Vkv2b7tVGEpbIylXjHdnQyX2M81Xa/A53Vg+dK5+ZqcgJPXNaxoN7nNLGLoar6gCDhs1Cbp2HHGarKntUqrW0aMUc8sRN7aChmP8Rp6gHv0pVWpFWtUktjnlJy3YgGBUqjigLxUirTJBVqRRShakC0CsNA5qRRTlX8qkUcdqBjVXjrTgKeAPwpQoNAmNAxT1X1604L6U8LxQIb/ACpVyDyM88U4Lz0H86djkccmqTAaOuSOvrSgc8ipMZyR0ApdmD29cU7gRgccVFcW8c8eyVVZT+Y/wNWgh7cgfrRsPAOT7Emi6ALC9v7JAkF7JsAwPMAfHPqetXJdb1GRNrSjOOSFGT71UaPsRzT1iHbpU8sexXNLuUZmnkOZJpX56sxNRWg8m/tpPSVf1OP61fkiOB05rPuwYY944CMG5PTBFU7NMlXuWNV1NdN125trsEWk5V45D0ViMEH0BxVjRba10qS4u49onuOXYH+EdAKg8ZRL9ujYgFXj6EcGudCiKPZHlU/ug8Vj7LmSdzb2lrposeM/Et35yizkAEfzMCMhvauWk8fauI2ji8mI9NyrzVvVE3L9RXEXilJ3HoajEJwScTWg1Pc2U8Uahg7/ACZWzy7ryaK5xpNpwP50Vxc0jq5T0KK44+Y1NHcjocfUVzf2/j72KVtRAHB5qNTsczpnuNv3WFRm8PPzdPeua/tCQ9Pzpv2iVzya0jSkzGVeK6nQvfgEbmqCTUAc4NY4G4nOTU6LwK2VDuznni39lFtruVvu8CmBpGHzMaaq8VOi8VtGnFbI5pVZy3YirnrzUqJnpTkXp61PGnrWhncREqdVpUWpVX0oEIi1IFpVXmpdvtQJjVWpFWnKp9KlCcUCGBalRc05F9amRcGgLEax/XH0qVU7inhaeBz60AMC08LTgP8AOaeF4oEMA/GnhcdaUL+dPVc0IBnpTwOKcqnFPC1VwsNC5qRV5zjHpTgp64qUKOmevWlcViEqfX8qeE4xjntxT8Y604Lx079KLjsMC4AG3HrTljPbHSpMdM5A9KkUAnHbNFwsQhD/APrqTy9owenWpgvPcmnbMZOAQfrSApSoMEnrms3U4jJZTqoyShA+tbbj1OOMVTuEBU4IOe/ammBU8QTwXtpYtExaVI8SAgjacCudlT0rZuIgoIXGKzJ1xVw0VhS1dzIvow0Z9q4nWo9lxu9a76dcgg/rXHeIYxtzj7pqKyvBmtB2kc421Tg8mil+X+LrRXmHo2J0JJBJqxGKrx9qspXZFJbHNJt7k6Yq1HnFV0xgVZiOaZmyZBng1NGvA4qJKnTpVIlkyrUyLUUfQetWE607iJEUdcCpkX/9VMTH5VOnHagTHquKlUU1BUy0XEOC+1SKvrSKOgFTKue1O4gC9OKkRacq9M1IoFK4xFQ4qVV9qcvOcCnLwaLgAFOCilHtTh06UxAB14pQOKcOeo4pyimIaBzTwv0pQKcB+VAAFpyjHpRjnvT8c0CFAxTx0GKaOtOzz7UDF4OKf7UgAxS+nvQITripPmx1ye3NGODx3p5x04GTQAYOeuPTPrUyAEZP400AheOOOgpw5KjIx19MfWgCORQM9APYVUmACkg/0q+QCM+nUCqNwAM4PGM5oGjLuB96su5xk1rXOBxnt271kXJAzjmrQihOK5rW49yOOPWujmasTVBuDeuKcldDi7anBv8AeOQMjiinXyMty4Xp1orzXGztY9OMtCePqKsRUUVvE5nuWU6VYh6CiiqI6liOrC96KKZCJ0qxH2ooqiolhe1Tp0FFFBJKlTp92iiggmSpl+6D3oooAmHVR61IOAMUUUDH5x+VOU5PNFFAEtSADiiimgFXoKePumiimJCpzT05BoooEtxf4aVehoooESUEcUUUAOB5Ap0fPXnmiigB3QjH+eacxIkIBxgZFFFAE4Ubenb+maRWK4Ix2PSiigAldllQKcAqKrXoATPfJ/rRRQNGXdfdT361jXX9KKKpCMybqayb/oaKKphHc5C9H+kNxRRRXM9zqR//2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Circular erythema migrans-like lesion with central clearing on the lower leg of a patient with STARI. The central papule was the site of a recent tick bite.",
"    <div class=\"footnotes\">",
"     STARI: Southern tick-associated rash illness.",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Edwin Masters, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_19_33086=[""].join("\n");
var outline_f32_19_33086=null;
var title_f32_19_33087="Pterygium PI";
var content_f32_19_33087=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F86731&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F86731&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pterygium",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 402px; height: 255px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A pterygium is a triangle-shaped area of tissue that grows from the corner of the eye towards the center.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Deborah S Jacobs, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_19_33087=[""].join("\n");
var outline_f32_19_33087=null;
